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ABSTRACT 
 
Introduction: 
The co-incidence of thyroid auto-immunity and neuro-psychiatric disorders is well-documented.  
However, the prevailing school of thought implicating auto-immune thyroid disease (AITD) in bipolar 
disorder is neither well-understood nor universally accepted.  Thus, the lack of recent plausible data 
linking these two disorders provides the rationale for the present study and lends novelty to our results.  
We investigated the association between Hashimoto’s disease (the most common cause of auto-immune 
hypo-thyroidism) and bipolar disorder through the extra-thyroidal localisation of  
thyroid-specific proteins, thyroid-stimulating hormone receptor (TSH-R) and thyroglobulin (TG) in 
major limbic regions of bipolar human brain.  The limbic system represents the cerebral control centres 
for human emotional behaviour responses. Interestingly, the extra-thyroidal localisation of TSH-R and 
TG has been well-documented.  Thyroid-stimulating hormone receptors have been identified in 
mammalian heart, kidneys, bone, lymphocytes, thymus, pituitary, adipose, skin, hair follicles, fish testes 
and astrocyte culture.  Thyroglobulin has been identified in mammalian skin, hair follicles, thymus and 
kidney.  With particular reference to central nervous system (CNS) localisation, the most relevant to 
the present study are reports of immuno-reactive TSH-R in human anterior pituitary tissue and cultured 
astrocytes, as well as in rat brain tissue and cultured astrocytes.  However, no previous studies have 
specifically detected TSH-R and TG in other human cerebral cortical regions.  Recently, in a pilot study 
to the present project, we immuno-localised TSH-R and TG to cortical neurons and cerebral vasculature, 
respectively, within various human non-limbic brain regions including occipital lobe, parieto-occipito-
temporal, primary motor cortex and primary sensory cortex.  The present study extends this 
investigation into the distribution of thyroid-specific proteins, specifically in limbic regions of normal 
and bipolar human brain at both protein and molecular levels.  We postulated that changes in thyroid 
protein expression in bipolar limbic regions may contribute to mood dysregulation associated with 
bipolar disorder, thereby implying a significant role for the thyroid system in the pathophysiology of 
xx 
 
bipolar disorder.  Thus, we chose to compare the distribution of thyroid-specific mRNA and proteins in 
major limbic regions between normal and bipolar human adult brain and then use this data to infer 
whether any regulation of limbic thyroid protein expression could be related to the pathophysiology of 
bipolar disorder.   
 
Methods: 
Ethical approval for the present study was granted by the University of KwaZulu-Natal (UKZN), 
Biomedical Research Ethics Committee (Reference EXPO42/06).  Forensic human brain limbic tissue 
samples (frontal cortices, amygdalae, cingulate gyrii, thalamii, hippocampi and hypothalamii) were 
obtained from five individuals whom had succumbed to causes unrelated to head injury and who had 
demonstrated no evidence of brain disease or psychological abnormality.  Bipolar brain limbic tissue 
samples of frontal cortices, amygdalae and cingulate gyri were obtained from five confirmed cases of 
bipolar disorder from a commercial brain bank.  In addition, normal thyroid gland tissue was collected 
for use as a control tissue.  Three experimental techniques were used to fulfil the objectives of this 
project:  (i) Commercial polyclonal antibodies raised in rabbit against human thyroid-specific proteins, 
TSH-R and TG, were used to immuno-localise TSH-R and TG proteins in the major limbic regions of 
normal and bipolar human brain by standard immuno-histochemical techniques.  Quantification of 
TSH-R and TG immuno-staining was determined by image analysis digitalisation followed by  
inter- and intra-group statistical comparisons.  (ii) Using specific oligonucleotide primers, TSH-R 
mRNA in normal and bipolar limbic regions was detected by in-situ reverse-transcriptase polymerase 
chain reaction (in-situ RT-PCR).  This cellular distribution of TSH-R mRNA was then graded according 
to visual intensity of labelling as well as the extent of cellular distribution.  (iii) Solution-type  
reverse-transcriptase quantitative polymerase chain reaction (RTqPCR) was then used to determine 
fold-change in TSH-R gene expression in the bipolar limbic group, relative to normal controls, and 
normalised to the endogenous reference gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  
The comparative threshold cycle (CT) method was used to calculate gene expression fold-differences 
between normal and bipolar groups.  
xxi 
 
Results: 
There were a number of novel results that were demonstrated in this study: 
(i) Immuno-reactive TSH-R and TG was demonstrated within the neurons and vasculature, respectively, 
of normal and bipolar limbic regions.  Specifically, we immuno-localised TSH-R to large motor neurons 
whilst TG was evident in smooth muscle cells of the tunica media and tunica adventitia of limbic 
vasculature.  Other results included the presence of TG in limbic neurons of cingulate gyrus and frontal 
cortex in both normal and bipolar limbic regions.  Thyroglobulin was also evident in bipolar amygdala 
neurons but not in the normal neurons.  Further, TSH-R and TG proteins were not detected in any limbic 
neuronal support cells examined, such as astrocytes, neuroglia, oligodendrocytes and satellite cells.  
Image analysis intra-group statistical comparisons indicated a significant reduction of TSH-R and TG 
proteins in the bipolar limbic groups when compared to matched normal groups.  In addition, we 
obtained inter-group statistical comparisons for TSH-R and TG proteins in all limbic regions examined.  
Inter-regional comparisons for TSH-R in normal limbic regions showed significant differences in the 
hypothalamus and thalamus groups when compared to the other four limbic regions but not when 
compared to each other.  No appreciable difference was noted amongst the remaining four normal 
limbic groups.  Inter-regional comparisons in all bipolar limbic regions examined, indicated no 
appreciable difference between any of these categories.  Inter-regional comparisons for TG in normal 
limbic vasculature demonstrated that when compared to the amygdala, there was a significant difference 
in the cingulate gyrus, frontal cortex and thalamus.  None of the other inter-regional comparisons 
showed statistical differences in these normal groups.  Inter-regional comparisons for TG in bipolar 
limbic vasculature demonstrated that when compared to the frontal cortex, significant differences were 
noted in the cingulate gyrus and amygdala.   
(ii) The cellular localisation of TSH-R mRNA by in-situ RT-PCR demonstrated evident labelling for 
TSH-R mRNA in neurons within all matched normal and bipolar limbic regions.  However,  
semi-quantitative comparisons indicated a down-regulated expression of TSH-R mRNA in all bipolar 
limbic regions when compared to normal controls.  In other normal limbic regions examined, TSH-R 
mRNA was found exclusive to hypothalamic neurons, whilst the thalamus and hippocampus were 
xxii 
 
devoid of labelling.  Further, TSH-R mRNA was not detected in cerebral vasculature or any neuronal 
support cells.   
(iii) RTqPCR determinations of TSH-R gene expression between normal and bipolar groups confirmed 
the down-regulated expression of TSH-R mRNA in the bipolar limbic regions.  Bipolar inter-group 
statistical comparisons demonstrated TSH-R expression to be significantly reduced in the cingulate 
gyrus when compared to the amygdala.  None of the other comparisons showed appreciable statistical 
differences.   
 
Discussion and Conclusion: 
The main study findings that demonstrate the extra-thyroidal expression of TSH-R and TG in limbic 
regions of normal and bipolar human brain are unique, and are suggestive of the translocation of  
thyroid-like proteins via the seemingly-impervious blood-brain barrier (BBB).  Interestingly, multiple 
modes of egress beyond the BBB have been previously described, whereby the integrity of the BBB 
may be altered during neuro-pathological diseases including HIV-associated dementia, multiple 
sclerosis, Alzheimer’s disease and bipolar disorder.  Alteration of the protective BBB increases its 
permeability to leukocytes and other circulating compounds and triggers signal transduction 
mechanisms that facilitate the loss of tight junction proteins that constitute the highly specialised 
cerebral endothelium. Thus, those reports indicating an altered BBB during neuro-pathological 
conditions, lends support to our findings of TSH-R and TG proteins in the bipolar brain.  
 
Further to these novel discoveries is the demonstration of reduced thyroid protein expression in major 
limbic regions of the bipolar brain.  In particular, our findings of reduced TSH-R expression in limbic 
regions correlate with previous neuro-imaging reports that describe reduced physiological  
cortico-limbic tissue volumes and neuro-physiological activity during bipolar disorder.  In addition, the 
presence of TG-like proteins, exclusive to bipolar amygdala neurons, may be associated with other 
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neuro-imaging findings of amygdala neuro-physiological hyperactivity and enhanced emotional 
sensitivity in bipolar disorder.   
 
The importance of the thyroid hormones, T3 and T4, in mammalian CNS during various life stages has 
been reported.  It is therefore reasonable to speculate that our findings of thyroid-related proteins,  
TSH-R and TG, in normal limbic neurons may also exhibit an alternate neuro-physiological role, 
specifically related to mood control.  Further, the reduced expression of TSH-R/TG will likely result in 
reduced localised thyroid function in limbic neurons with consequent altered neuronal functioning and 
this may predispose or exhibit some involvement in the pathophysiology of mood dysregulation often 
observed in bipolar disorder.  Interestingly, in the present study, we report the reduced expression of 
TSH-R and TG in limbic neurons of bipolar brain.  Alternatively, we may attribute symptoms of mood 
dysregulation due to limbic-derived TSH-R providing potential targets for thyroid auto-immunity 
during Hashimoto’s disease.  We speculate that inhibitory-type auto-antibodies associated with 
Hashimoto’s disease, may agonise TSH-R expressed in limbic neurons.  This abnormal interaction may 
lead to the inactivation or cell-mediated atrophy of limbic neurons with consequential reduction in the 
levels of expressed TSH-R.  Thus, the loss of limbic neurons or diminished neuronal activity may 
contribute towards mood dysregulation.   
 
The neuro-pathology of diminished neuronal functioning or neuronal atrophy, is suggestive of a  
neuro-degenerative aetiology in bipolar disorder.  This is particularly controversial, since current 
evidence implicating neuronal structural and functional changes in the pathophysiology of bipolar 
disorder is limited and does not provide enough support to classify bipolar disorder as a  
neuro-degenerative type disorder.  However, our study suggests that neuronal alterations may be due to 
changes in thyroidal status in bipolar disorder.  Moreover, our correlation of reduced thyroid protein 
expression levels in bipolar limbic regions with previous neuro-imaging findings of reduced  
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cortico-limbic volumes and activity during bipolar disorder, provides further supporting evidence 
indicating neuro-degeneration of mood-controlling limbic structures in bipolar disorder.  
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1.1  THYROID SYSTEM 
The thyroid gland is responsible for producing the thyroid hormones, thyroxine (T4) and 
triiodothyronine (T3), both of which play significant roles in cell differentiation, growth and metabolism 
(Yen, 2001, Landek and Caturegli, 2009). 
In order to fully understand the structures and functions of the thyroid system in relation to the research 
objective of the current study and to integrate the results later at an anatomical level, a short description 
of the physiology, structure and function of the thyroid axis participants is required. 
 
1.1.1  Structure of the thyroid gland 
The thyroid gland is one of the largest endocrine glands in the body, weighing ~2 g at birth and 15 g in 
adults, (Landek and Caturegli, 2009) and is situated on the anterior side of the neck, inferior to thyroid 
cartilage (Adam’s apple) and in close proximity to the larynx and trachea (Figure. 1.1).  It originates at 
the base of the tongue and continues downward along the midline before terminating at the trachea. It 
is a butterfly-shaped organ comprising two lobes connected by the isthmus (Landek and Caturegli, 
2009).  The thyroid gland has an extensive blood flow of approximately 5 ml/g/min, and is supplied by 
the superior, inferior and lowest accessory thyroid arteries (Landek and Caturegli, 2009). 
 
The thyroid gland is encased by a fibrous capsule from which septae extend into the gland dividing it 
into lobules.  Each lobule contains about thirty follicles which represents the functional units of the 
gland (Landek and Caturegli, 2009) (Figure 1.2).  Thyroid follicles are filled with a secretory substance 
called colloid and lined with a single layer of simple cuboidal epithelial cells (Landek and Caturegli, 
2009).  The size of the follicles and their epithelial cells tends to vary with the activity of the gland.  In 
the hypo-thyroid state, where activity is reduced, the follicles appear large, containing increased 
amounts of colloid and lined by thin, flattened epithelial cells (Young and Heath, 2000).  In the  
hyper-thyroid state, where activity of the gland is increased, follicles appear smaller and are lined with 
tall, cuboidal/columnar epithelial cells (Young and Heath, 2000). 
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Figure 1.1:  Gross anatomy of the human thyroid gland, anterior view Adapted from Antranik 
(2011), http://antranik.org/the-endocrine-system/ 
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Figure 1.1 legend:  Gross anatomy of the human thyroid gland, anterior view 
Figure illustrates the anatomy of the human thyroid gland which is situated on the anterior side of the 
neck, inferior to thyroid cartilage and around the larynx and trachea.  It is composed of two lobes that 
borders the right and left sides of the trachea and is connected by the isthmus.  The thyroid gland has a 
rich blood flow and is supplied by the superior, inferior and lowest accessory thyroid arteries. 
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Figure 1.2:  Histology of the human thyroid gland.  Adapted from Barron (2010) 
http://jonbarron.org/article/endocrine-system-thyroid-and-parathyroid-gland 
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Figure 1.2 legend:  Histology of the human thyroid gland 
The thyroid gland is primarily composed of follicles that are lined by cuboidal epithelial cells which is 
responsible for the synthesis and secretion of thyroid hormones, T3 and T4.  Thyroid follicles are filled 
with a secretory substance called colloid that contains TG which stores thyroid hormones prior to 
secretion.  A surrounding lumen separates the colloid from the follicular epithelium.  Parafollicular cells 
(clear cells) are single cells with extensive unstained cytoplasm that are scattered among follicular cells.  
These cells produce calcitonin in response to raised blood calcium levels.  
  
7 
 
In addition to the thyroid follicular cells, the thyroid gland also contains parafollicular cells also known 
as clear (C) cells, scattered around the follicular cells (Figure 1.2).  Clear (C) cells synthesize and secrete 
the hormone calcitonin in response to increased blood calcium levels (Young and Health, 2000).    
 
1.1.2  Synthesis of thyroid hormones 
Thyroglobulin (TG) is a glycoprotein homodimer that is manufactured by the thyroid follicular cells 
and released into the colloid by exocytosis (Taurog, 2005, Landek and Caturegli, 2009), (Figure 1.3).  
Within the colloid, selected tyrosyl residues of the TG polypeptide become iodinated with the aid of the 
enzyme thyroid peroxidase (TPO), following active uptake of iodine from plasma.  This results in the 
generation of mono-iodotyrosines (MITs) and di-iodotyrosines (DITs), which are inactive hormone 
precursors.  A coupling reaction then leads to the formation of thyroxine (T4) from two DIT residues, 
or triiodothyronine (T3) from one DIT and one MIT (Taurog, 2005, Landek and Caturegli, 2009).  
Iodinated TG, carrying T3, T4, DIT and MIT, is stored as colloid in the lumen.   
 
Following TSH stimulation, the thyroid follicular cells reabsorb TG by macro- and micropinocytosis 
(Figure 1.3), where hormone release occurs by enzymatic splitting of T3 and T4 from TG  
(Taurog, 2005, Landek and Caturegli, 2009).  Within the follicular cell, TG gets digested in lysosomes, 
whilst T4 and T3 are released into the bloodstream through unidentified channels  
(Landek and Caturegli, 2009).  Therefore, TG acts as a substrate for thyroid hormone synthesis as well 
as storage of the inactive forms of thyroid hormone.   
 
The thyroid gland produces primarily T4 and only 20% of T3 (Davis et al., 2003, Kopp, 2005,  
Bauer et al., 2008).  Additionally, site-specific T3 is produced by deiodination of T4 at peripheral tissues, 
by enzymes called deiodinases. The local conversion of T4 to T3 varies among tissues, with greater 
conversion occurring in the cerebral cortex (Larsen et al., 1981, Bauer et al., 2008).  
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Figure 1.3:  Synthesis of thyroid hormones.  Adapted from 
http://www.slideshare.net/roger961/thyroid-gland-5514388 
 
 
9 
 
Figure 1.3 legend:  Synthesis of thyroid hormones  
(1) Synthesis of TG and enzymes within follicular cell and release into colloid, (2) active uptake of 
iodine from plasma along with Na+ into cell, and colloid, (3) incorporation of iodine on selected tyrosyl 
residues of TG to produce T3 and T4, (4) following TSH stimulation, the cell reabsorbs TG, mainly by 
micropinocytosis, (5) T3 and T4 release by enzymatic splitting from TG, (6) Free T3 and T4 enter the 
bloodstream. 
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1.1.3  Human thyroid-stimulating hormone receptor (TSH-R) 
The structural and functional properties of human TSH-R as well as its location within the thyroid gland 
are listed in Table 1.1. 
 
1.1.4  Human thyroglobulin (TG) 
The structural and functional properties of human TG as well as its location within the thyroid gland 
are listed in Table 1.2. 
 
1.1.5  Extra-thyroidal expression of TSH-R and TG 
During auto-immune thyroid disorders (AITD), patients express immuno-reactivity directed towards 
thyroid-specific proteins including TSH-R and TG (Davies et al., 2002, Ai et al., 2003, Parvathaneni  
et al., 2012).  However, anti-TSH-R and anti-TG auto-antibodies are not limited to binding thyroid 
proteins located in thyroid tissue only. Several studies have demonstrated the expression and 
localisation of functional TSH-R in mammalian extra-thyroidal tissues and cells (Table 1.3) including 
the heart, kidneys, bone, lymphocytes, thymus, pituitary, adipose, skin, hair follicles, astrocyte culture 
and fish testes (Chabaud and Lissitzky, 1977, Perkonen and Weintraub, 1978, Drvota et al., 1995,  
Endo et al., 1995, Murakami et al., 1996, Inoue et al., 1998, Valyasevi et al., 1999, Kumar et al., 2000, 
Prummel et al., 2000, Sellitti, 2000, Crisanti et al., 2001, Davies et al., 2002, Szkudlinski et al., 2002, 
Bodo et al., 2009, Cianfarani et al., 2010).  Of these studies, the most relevant to our present study is 
that conducted by Prummel (2000) and Crisanti (2001). The Crisanti group demonstrated  
immuno-reactive TSH-R in cultured rat and human astrocytes and rat brain whilst the Prummel group 
reported TSH-R in human anterior pituitary tissue.  However, TSH-R has not been reported in other 
human cerebral cortical regions.  Thyroglobulin has also been identified in non-thyroid tissue  
(Table 1.3) such as human skin, hair follicles, thymus and kidney (Spitzweg et al., 1999, Sellitti, 2000, 
Bodo et al., 2009, Cianfarani et al., 2010). 
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Table 1.1:  Biological properties of human TSH-R 
Human TSH-R  
 
Structural properties of human TSH-R 
 
Reference 
 Belongs to family of guanine-nucleotide 
binding (G) protein-coupled receptor       
Patibandla and Prabhakar, 1996, Ando et al., 
2005, de Lloyd et al., 2010,  
 Encoded by the TSH-R gene located on 
chromosome 14q31 
Rousseau-Merck et al., 1990, Haraguchi et al., 
1996,  
 Full-length TSH-R gene is 
approximately 4 kb long, consists of 
764 amino acid residues, including a 21 
amino acid signal peptide 
 TSH-R protein comprises: 
- A large extracellular domain or 
ectodomain (A-subunit) 
- 7 transmembrane domains (B-
subunit) 
- A short cytoplasmic tail in the C-
terminus (B-subunit) 
Nagayama et al., 1989, Patibandla and 
Prabhakar, 1996, Porcellini et al., 1997 
 Glycoprotein A-subunit is linked to the 
membrane-spanning B-subunit by 
disulphide bridges 
Chistiakov, 2003 
 Has an unglycosylated molecular 
weight of approximately 84 kDa & a 
glycosylated molecular weight of 95-
100 kDa  
 
Davies et al., 2002 
Location of human TSH-R on thyroid gland Reference 
 Primarily expressed on the basolateral 
surface of thyroid follicular cells 
Ando et al., 2005 
Biological functions of human TSH-R Reference 
 A-subunit represents TSH binding site 
on external surface of thyroid cell 
membrane 
 B-subunit is involved in signal 
transduction 
Ando et al., 2005 
 
 Regulation of the synthesis and 
secretion of thyroid hormones from 
thyroid follicular cells 
 Controls growth and development of the 
thyroid gland 
Vassart and Dumont, 1992, de Lloyd et al., 
2010,  
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Table 1.2:  Biological properties of human TG 
Human TG 
 
Structural properties of human TG 
 
Reference 
 Encoded by human TG gene 8q24.2-
8q24.3 
Baas et al., 1985, Berge-Lefranc et al., 1985, 
Rabin et al., 1985, Vono-Toniolo and Kopp, 
2004 
 Full-length TG mRNA sequence is 8.5 
kb long & contains an 8307 nucleotide 
segment 
Malthiery and Lissitzky, 1987, van de Graaf et 
al., 1997, Vono-Toniolo and Kopp, 2004 
 Mature TG exists as a 19S glycosylated 
dimer  
Dunn and Dunn, 2000, Vono-Toniolo and 
Kopp, 2004 
 Has a molecular weight of 660 kDa 
 
 
Dunn and Dunn, 2000, Vono-Toniolo and 
Kopp, 2004 
 Sites for thyroid hormone synthesis are 
clustered at both ends of the TG gene 
 
Malthiery and Lissitzky, 1987 
 TG constitutes up to 75% of protein 
content in the thyroid gland 
 
Malthiery et al., 1989 
        Location of human TG in thyroid gland 
 
Reference 
 Synthesised in thyroid follicular cells & 
exported to the thyroid lumen 
 Exported to the colloid space for 
iodination of its tyrosine residues 
 
Taurog, 2005, Landek and Caturegli, 2009 
Biological functions of human TG 
 
Reference 
 It serves as a backbone for the synthesis 
of thyroid hormones 
 Acts as a storage vehicle for iodine in 
the form of tyrosyl residues, i.e. MIT 
and DIT, the inactive  hormone 
precursors 
Taurog, 2005, Landek and Caturegli, 2009  
 A recognised auto-antigen in the 
implication of Hashimoto’s thyroiditis 
Vali et al., 2000 
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Table 1.3:  Tissue distribution of thyroid-specific genes.  Adapted and modified from Davies et al 
(2002)  
Tissue/Cells 
 
Gene expressed mRNAa Proteinb References 
Lymphocytes TSH-R + + Chabaud and Lissitzky, 1977, Davies 
et al., 1978a, Perkonen and 
Weintraub, 1978, Bagriacik and 
Klein, 2000,  
Thymus TSH-R, TG + + Murakami et al., 1996, Spitzweg et 
al., 1999 
Pituitary TSH-R + + Prummel et al., 2000 
Testis TSH-R + + Davies et al.,1978b, Kumar et al., 
2000 
Kidney TSH-R, TG + + Sellitti et al., 2000 
Brain TSH-R + + Crisanti et al., 2001 
Adipose/ 
Fibroblast 
TSH-R + + Roselli-Rehfuss et al., 1992, 
Cornelius et al., 1994, Endo et 
al.,1995, Haraguchi et al., 1996, 
Bahn et al., 1998, Valyasevi et al., 
1999 
Heart TSH-R + + Drvota et al., 1995, Sellitti et al., 
1997 
Bone TSH-R + NR Inoue, et al., 1998, Marians, 2001 
Skin TSH-R, TG + + Cianfarani et al., 2010 
Hair Follicles TSH-R, TG + + Bodo et al., 2009 
aRT-PCR/in situ hybridization;  bImmuno-histochemistry/ligand binding assay;  NR, not reported 
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Upon initiation of the current project, our group conducted a pilot study to determine whether AITD 
antibodies may immuno-localise in normal, human adult cerebral cortex (Moodley et al., 2011).  Brain 
tissues were obtained post mortem from five patients, all of whom had died of unnatural causes 
unrelated to head injury and had no indication of psychological abnormality.  Various human  
non-limbic cortical regions were investigated in all five brains, viz. parieto-occipito-temporal lobe, 
primary motor cortex and primary sensory cortex and the occipital lobe.  In that study, we reported the 
immuno-localisation of anti-TSH-R IgG in normal human cortical neurons of the above regions.  Our 
group also investigated the presence of TG in normal human brain tissue, where we immuno-localised 
anti-TG IgG to the cerebral vasculature of all brain regions, in all five different human brains examined.  
Specifically, TG was detected in the smooth muscle cells of the tunica media and tunica adventitia of 
cerebral blood vessels as well as in some perivascular structures (Moodley et al., 2011).   
 
1.1.6  Regulation of thyroid hormones 
Thyroid hormone production is regulated by the hypothalamic-pituitary-thyroid (HPT) axis  
(Shupnik et al., 1989, Taurog, 2005, Landek and Caturegli, 2009).  In response to low circulating thyroid 
hormone levels, the basal medial hypothalamus releases thyrotropin-releasing hormone (TRH) which 
then stimulates production of thyroid-stimulating hormone (TSH) from the thyrotropes of the anterior 
pituitary gland (Figure 1.4).  Thyroid-stimulating hormone then binds to TSH-Rs located on the 
basolateral plasma membrane of the thyroid follicular cell, causing an increase in intracellular cyclic 
adenosine monophosphate (cAMP) and stimulation of second messenger systems, for the production of 
thyroid hormones, T3 and T4, in order to restore a euthyroid state.  Thyroid hormones form long negative 
feedback loops at the hypothalamic and pituitary levels:  TSH production is suppressed when the levels 
of T3 and T4 are high, and TSH is increased when thyroid hormone levels are low (Yen, 2001, 
Szkudlinski et al., 2002, Bauer et al., 2008).  A short negative feedback loop refers to the negative action 
of TSH on the hypothalamic secretion of TRH. 
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Figure 1.4: Thyroid hormone production as regulated by the hypothalamic-pituitary-thyroid 
axis.  Adapted from  
http://teachmephysiology.com/endocrine-system/pituitary-gland/anterior-pituitary-gland/ 
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Figure 1.4 legend:  Thyroid hormone production as regulated by the hypothalamic-pituitary-
thyroid axis  
This figure schematically illustrates thyroid hormone production as regulated by the HPT axis. Short 
and long negative feedback loops along the HPT axis are depicted.  The rate of synthesis of thyroid 
hormones is regulated by anterior pituitary TSH, which is stimulated by hypothalamic TRH.  Thyroid 
hormones exert a negative feedback on thyroid hormone release at the hypothalamic and pituitary levels 
in order to restore a euthyroid state.  A short negative feedback loop refers to the negative action of 
TSH on the hypothalamic TRH, thus decreasing high levels of pituitary TSH and consequently overall 
thyroid hormone production from the thyroid gland.     
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Thus, following an increase in TSH secretion from the anterior pituitary, it causes a corresponding 
decrease in the amount of TRH released by the hypothalamus.  This leads to consequential decreases in 
pituitary TSH and thyroid hormones from the thyroid gland, thus, restoring a euthyroid state  
(Yen, 2001, Szkudlinski et al., 2002, Bauer et al., 2008).   
 
1.1.7  Function of thyroid hormones in cognitive development 
Thyroid hormones play critical roles in cell differentiation, growth, metabolism, energy and oxygen 
consumption, and physiological functions of all human tissues (Yen, 2001, Landek and Caturegli, 
2009).  To achieve this, the thyroid hormones, T3 and T4, must bind to thyroid hormone receptors which 
are expressed in all tissues.  There are two major isoforms of human thyroid hormone receptors viz. 
TRα1 and TRβ-1 (Yen, 2001, Landek and Caturegli, 2009).  However, the relative expression of the 
thyroid receptor isoforms can vary among the tissues.   Both T3 and T4 can bind to α and β thyroid 
hormone receptors.  However, T3 has higher binding affinity for both receptors when compared to T4 
(Jameson and Weetman, 2005).  In humans, both TRα-1 and TRβ-1 are present in most adult tissues.  
TRβ-1 is also highly expressed in liver, whilst TRβ-2 is mostly expressed in the anterior pituitary and 
hypothalamus brain regions.  Thus, the expression of thyroid hormone receptor isoforms in different 
tissue types suggests additional specific functions of the thyroid hormones in the various tissues 
throughout the body, namely: 
 
1.1.7.1  In the developing brain 
Thyroid hormone receptors are expressed in oligodendrocytes, astrocytes and neurons (Mellstrom  
et al., 1991, Strait et al., 1991, Bradley et al., 1992, Carlson et al., 1994, Carlson et al., 1996,  
Strait et al., 1997, Carre et al., 1998, Ahmed et al., 2008).  TRα is expressed at high levels during early 
brain development whilst expression of TRβ dramatically increases during later brain development 
(Anderson, 2001). Thyroid hormones have critical roles in the developing brain in utero and during the 
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neonatal period.  Thyroid hormone deficiency during this period could result in permanent brain 
dysfunction that consequently affects intellectual development as well.  Providing thyroid hormone 
replacement therapy to the newborn infant during this period will result in recovery of intellectual 
development.  However, treatment delay beyond 3 months of age can have permanent deficits in 
intellectual development where “thyroid hormone exerts most of its effects on the maturation of the 
developing mammalian brain” (Anderson, 2001).   
 
1.1.7.2  In the mature brain 
Thyroid hormones appear to have a critical role in the mental and psychological stability in adults where 
an association between low thyroid hormone levels in hypo-thyroid patients and depression/mood 
disorders has been reported (Henley and Koehnle, 1997, Anderson, 2001).  Further, the mental status 
of the individual may be improved/reversed following administration of thyroid hormone replacement 
therapy either solely or as combination therapy with other drugs such as lithium whilst treating for 
bipolar disorder (Jackson and Asamoah, 1999).  In addition, the cognitive deficits observed in  
hypo-thyroid patients, such as memory impairment, learning, attentiveness and psychomotor slowing 
can be treated with thyroid hormone (Boyages, 2000, Whybrow and Bauer, 2000).  Neuro-psychiatric 
changes such as dysphoria, anxiety, restlessness, irritability, emotional lability, impaired concentration, 
intellectual dysfunction, insomnia and behaviour that may mimic mania, have also been reported in 
hyper-thyroidism (Bennett and Cambor, 1961, Whybrow et al., 1969, Whybrow and Bauer, 2005b, 
Hage and Azar, 2012). 
 
1.2   THYROID-ASSOCIATED DISEASE 
1.2.1  Auto-immune thyroid disease (AITD) 
Dysregulation of thyroid hormone production may occur as a consequence of auto-immune thyroid 
disease (AITD).  Patients with AITD have immuno-reactivity directed to thyroid factors such as the 
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TSH-R, TG, TPO and sodium-iodine symporter (NIS) and can present as either hyper-thyroidism or 
hypo-thyroidism (Davies et al., 2002, Ai et al., 2003, Parvathaneni et al., 2012). 
 
1.2.1.1  Pathological basis for hyper-thyroidism 
Hyper-thyroidism refers to increased circulating levels of thyroid hormones.  Grave’s disease, an  
auto-immune genetic abnormality is the most common cause of excess thyroid function  
(Jameson and Weetman, 2005).  The hyper-thyroidism in Grave’s disease is caused by  
thyroid-stimulating immunoglobulins (TSI) which are synthesized in the thyroid gland, bone marrow 
and lymph nodes (Jameson and Weetman, 2005).  These auto-antibodies bind to and stimulate the  
TSH-R causing over-activity of the thyroid gland (Davies et al., 2002, Szkudlinski et al., 2002,  
Ai et al., 2003). 
 
1.2.1.2 Pathological basis for hypo-thyroidism 
Hypo-thyroidism refers to a deficiency in the circulating levels of thyroid hormones.  Clinical features 
include fatigue, cold intolerance, poor appetite coupled with an increase in body weight, constipation, 
cool dry skin, hair loss, menstrual irregularities, bradycardia and numerous neuro-psychiatric 
manifestations (Jameson and Weetman, 2005).  Hashimoto’s disease is the most common cause of  
auto-immune hypo-thyroidism.  It is caused by auto-antibodies to TG, TSH-R, TPO and follicular 
microsomes (Jameson and Weetman, 2005).  These auto-immune anti-thyroid antibodies fix 
complement and cause cell-mediated destruction of thyroid follicular cells.  The resulting outcome is 
lymphocytic infiltration, thyroid follicle atrophy, glandular fibrosis and hypofunction (Ai et al., 2003).  
This leads to reduced TG, TSH-R, TPO and thyroid hormone production and a compensatory rise in 
TSH, all of which serve as diagnostic markers for clinical hypo-thyroidism (Ai et al., 2003,  
Jameson and Weetman, 2005). 
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1.2.1.3  Anti-TG antibodies 
Anti-TG antibodies were the first type of circulating thyroid antibodies to be recognised in patients with 
AITDs.  These antibodies act against the protein TG, which is manufactured by the thyroid follicular 
cells of the thyroid gland and serves as a substrate for thyroid hormone synthesis  
(Landek and Caturegli, 2009).  Hence, this auto-immune antigen-antibody binding may result in 
destruction of the thyroid tissue.   
 
1.2.1.4  Anti-TSH-R antibodies 
Anti-TSH-R antibodies are directed against epitopes on the ectodomain of the TSH-R, located on the 
thyroid gland.  Two classes of TSH-R antibodies can be associated with auto-immune thyroid disorders:  
(a) thyroid-stimulating auto-antibodies that mimic the actions of TSH and causes Graves’  
hyper-thyroidism and (b) thyroid-inhibitory auto-antibodies which blocks the receptor binding of TSH, 
thus, preventing TSH stimulation of the thyroid gland to cause hypo-thyroidism (Hashimoto’s disease), 
(Spencer, 2013).   
 
1.2.1.5  Anti-TPO antibodies 
Anti-TPO antibodies are directed against TPO, the enzyme that is manufactured within the thyroid 
gland and catalyses the oxidation of iodide to iodine on tyrosine residues of the TG polypeptide, for 
thyroid hormone synthesis (Brix et al., 2004).  Hence, this auto-immune antigen-antibody binding will 
prevent the synthesis of thyroid hormones resulting in lower circulating levels of thyroid factors.   
Anti-TPO antibodies have also been recognised to be a heritable marker, and thus may serve as an  
endo-phenotype since family studies have demonstrated aggregation of this type of antibody in healthy 
first-degree relatives of those with auto-immune thyroiditis. 
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1.2.1.6  Anti-microsomal antibodies 
Recently, the microsomal antigen which was previously mis-identified as TPO due to their antigenic 
similarities, was found to be expressed on the thyroid cell surface and within the cytoplasm and may 
represent the cell-surface antigen involved in complement-mediated cytotoxicity (Labodia, 2005).  
Thyroid microsomal antibodies are directed against the microsomal antigen. Anti-thyroid antibodies 
provide useful measures for identifying subclinical hypo-thyroidism and for investigating the 
association between mood and thyroid disorders (Gold et al., 1982, Nemeroff et al., 1985,  
Reus et al., 1986, Haggerty et al., 1990, Haggerty et al., 1997, Carta et al., 2004). 
 
1.3  MAJOR COMPONENTS OF THE HUMAN LIMBIC SYSTEM 
In 1878, Paul Broca applied the term “limbic” (meaning border in Latin) to describe the curved rim of 
the cortex (later referred to as the limbic lobe), which included the cingulate gyrus and parahippocampal 
gyri (Fuchs and Flugge, 2003).  In 1937, James Papez associated emotions, including consciousness, to 
these specific brain areas (Papez, 1937).  Later, in 1952, Paul D. MacLean was the first to coin the 
phrase “limbic system” in order to describe the limbic lobe along with associated subcortical nuclei as 
the collective neural substrate for emotion, thereby characterising a functional system (MacLean, 1952). 
Functionally, the limbic system is responsible for providing most of the emotional drives for setting the 
other areas of the brain into action.  The activities of the body that are governed by the limbic system 
are those relating with self-preservation (e.g. the search for food or fighting), preservation of species 
(e.g. reproduction and nurturing the offspring), expression of rage, fear and pleasure as well as the 
establishment of memory patterns.  In addition, it provides the motivational drive for the process of 
learning (Guyton and Hall, 2000).  The major areas of the limbic system includes the amygdala, 
cingulate gyrus, frontal cortex, hippocampus, hypothalamus and thalamus (Figure 1.5).  The limbic 
areas along with their numerous interconnections forms a complex network for the overall control of 
emotion.  Table 1.4 outlines the location, structure and function of the major human limbic areas.   
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Figure 1.5:  Major limbic structures of human brain.  Adapted from 
http://gabispsychology.blogspot.co.za/2014/01/regions-of-brain-involving-emotion.html 
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Figure 1.5 legend: Major limbic structures of human brain   
Figure illustrates the major brain limbic structures namely: amygdala, cingulate gyrus, hippocampus, 
hypothalamus and thalamus.  Together these structures support the limbic system to control human 
emotion, behaviour, motivation and memory. 
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Table 1.4:   Major components of the limbic system 
Brain Limbic 
Region 
Location, Structure & 
Connections 
Function Reference 
Amygdala  Located near the 
temporal pole 
 Almond-shaped 
structure 
 Comprises multiple 
small nuclei  
 Has several 
bidirectional 
connections with the 
hypothalamus & other 
limbic areas 
 
 Several connections with 
hypothalamus & other 
limbic areas 
 Receives neuronal signals 
from limbic cortex 
 Assists the limbic system 
to pattern the individuals 
behavioural response 
 Emotional response to 
olfactory stimuli & smell 
 Choice of food & 
modulation of food intake 
 Role in consolidation & 
retrieval of memories 
 Fear responses & fear 
learning 
 Addiction, motivation & 
social cognition 
 
Guyton and 
Hall, 2000,  
Ganong, 2003a,  
Ganong, 2003b,  
LaBar and 
Cabeza, 2006, 
Rajmohan and 
Mohandas, 
2007,  
Barr, 2009 
 
 
 
  
 
 
Cingulate 
gyrus 
 Connected to the  
parahippocampal gyrus 
by an isthmus around 
the splenium of the 
corpus callosum 
 Connected gyri forms 
the limbic cortex   
 Stimulation elicits 
autonomic responses that 
includes:  
 Regulation of heart rate & 
blood pressure 
 Cognitive, attentional & 
emotional processing 
 
Rajmohan and 
Mohandas, 
2007, 
Barr, 2009 
 
Hippocampus  Trilaminate structure 
 Comprises 3 layers: (a) 
outer molecular layer; 
(b) middle pyramidal 
layer; (c) inner 
polymorphic layer 
 Layer of fibres adjacent 
to the polymorphic 
layer, coalesces to form 
the fornix. 
 Fornix is the main 
efferent pathway of the 
hippocampal formation 
 Hippocampus, dentate 
gyrus & subicular 
complex form the 
hippocampal formation 
 Most sensory experiences 
activate certain parts of 
hippocampus 
 Distributes out-going 
signals to the limbic areas 
 Stimulation of different 
areas of hippocampus, 
initiates various 
behavioural patterns of 
pleasure, rage, passivity 
& sex drive 
 Long-term declarative 
memory storage 
Mark et al., 
1993, Guyton 
and Hall, 2000, 
Pierri and 
Lewis, 2004, 
LaBar and 
Cabeza, 2006, 
Rajmohan and 
Mohandas, 
2007,  
 
Hypothalamus  Less than 1% of brain 
mass 
 Located at the centre of 
the limbic system; part 
of the diencephalon 
 Controls most vegetative 
& endocrine functions 
 Controls emotional 
behaviour 
Guyton and 
Hall, 2000,  
Pierri and 
Lewis, 2004,  
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 Is at the confluence of 
many neural pathways 
 Divided into 3 regions: 
              (a) supraoptic region; 
              (b) tuberal region 
              (c) mammillary region 
 Regulates arterial 
pressure, heart rate, body 
temperature & body 
water 
 Controls hunger & satiety 
 Endocrine hormone 
secretion by the anterior 
pituitary gland 
 Uterine contractility at 
termination of pregnancy 
& during milk ejection 
 Behavioural functions 
such as: (a) control of 
rage & tranquillity; (b) 
fear & punishment 
reactions; (c) sexual drive 
Rajmohan and 
Mohandas, 2007 
 
Thalamus  Egg-shaped structure 
 Largest component of 
diencephalon 
 Divided into 3 principle 
nuclear masses, by the 
internal medullary 
lamina: (a) anterior; (b) 
medial; (c) lateral 
 Sensory perception & 
regulation of motor 
functions 
Barr, 2009 
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1.4  LIMBIC-ASSOCIATED DISEASE 
1.4.1  Bipolar disorder 
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts 
in mood, ranging from extreme elation and hyperactivity (mania) to severe depression, with periods of 
normal mood in between (Figure 1.6), (Emilien et al., 2007, NIMH, 2012).  Sometimes during an 
episode, patients may experience symptoms of both mania and depression, referred to as “mixed state”.  
Further, the individual’s sleep pattern, energy, activity levels and overall ability to function is affected.  
The symptoms of bipolar disorder are much more severe than the normal highs and lows that people 
experience, and can result in damaged relationships, poor job or school performance, impulsive and 
reckless behaviour, substance abuse and, sadly, even suicide.  Bipolar disorder typically develops 
during late adolescent or early adult years.  Some individuals may experience initial symptoms during 
childhood, whilst others may develop symptoms later in life (Emilien et al., 2007, NIMH, 2012).   
 
1.4.2  The limbic system and bipolar disorder 
The limbic system plays a critical role in emotional and behavioural responses.  This is supported by 
Jaak Panksepp’s theory of emotional systems, based on neuronal mechanisms of emotions, to describe 
“integrated neurobiology of affect, behavioural biology, evolutionary psychology and psychoanalysis” 
(Zechowski, 2017).   Dysfunction of the emotional systems will result in different variants of excitation, 
which may then predispose to mental disorders (Panksepp, 2005, Panksepp and Biven, 2012).  
 
The limbic system’s intricate functional neuro-anatomy along with its diverse circuits may explain some 
of the manifestations of neuro-psychiatric disorders (Rajmohan and Mohandas, 2007).  Functional 
neuro-imaging studies have shown decreased prefrontal and anterior cingulate activity in affective 
disorders (Rajkowska, 2006, Rajmohan and Mohandas, 2007).   The anterior cingulate represents a 
functional centre for the integration of attentional and emotional output and facilitates control of  
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Figure 1.6: Scale showing varying range of moods associated with bipolar disorder.  Adapted 
and modified from NIMH (2012) 
 
 
    Severe mania 
  
    Hypomania (mild to moderate mania) 
  
   Normal/balanced mood 
  
 Mild to moderate depression 
 
 Severe depression 
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Figure 1.6 legend:  Scale showing varying range of moods associated with bipolar disorder   
Figure illustrates the various mood states reported in bipolar disorder.  The upper half of the scale  
(pink-red) indicates hypomania and severe mania; whilst the bottom half of the scale  
(light blue-dark blue) indicates mild-to-moderate depression with severe depression at its extreme end.  
The centre of the scale (black bar) indicates a normal or balanced state of mood.   
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emotional arousal.  It has been suggested that the spectrum of affective and cognitive symptoms is as a 
result of dysfunction within the anterior limbic network.  This network includes the prefrontal regions 
and subcortical structures such as the thalamus, striatum, amygdala and the midline cerebellum.  Neuro-
imaging studies provide evidence that dysfunction of the anterior limbic system may be responsible for 
the symptoms of bipolar disorder (Strakowski et al., 1999, Strakowski et al., 2005).  These studies have 
shown that neuro-anatomic abnormalities do exist in the network of bipolar patients and include 
decreased gray matter volumes of prefrontal sub-regions, enlargement of the amygdala and striatum 
and midline cerebellar atrophy (Strakowski et al., 2005). The neuro-anatomic abnormalities in the 
prefrontal cortex are consistent with prefrontal histological abnormalities that have also been reported 
in bipolar patients, and include decreased glial and neuronal density with glial hypertrophy in prefrontal 
regions of bipolar patients (Rajkowska et al., 2001, Strakowski et al., 2005).  Interestingly, it was noted 
that some of these abnormalities, specifically the reduced volumes of gray matter in the left inferior 
prefrontal cortex, the reduced size of the cerebellar vermis as well as ventriculomegaly appear to 
influence the number of affective psychiatric episodes.  This suggests that brain changes occur in 
response to illness course; however, the underlying mechanisms are unclear (Strakowski et al., 2005).  
Such brain changes may increase the vulnerability of the patient to further affective episodes or even 
disability (Strakowski et al., 2005).  Enlargement of the amygdala and striatum, on the other hand, has 
not been associated with clinical course, but rather appears to be present at the clinical onset of affective 
disorders (Strakowski et al., 2005).   
 
The amygdala and hippocampus project into the prefrontal-striatal-thalamic networks and have roles in 
modulation of emotional and cognitive behaviour (Strakowski et al., 2005).  Interestingly, findings of 
normal hippocampal volumes together with increased amygdala volumes have been reported as a 
specific neuro-anatomic abnormality dyad in bipolar patients when compared to healthy individuals 
(Strakowski et al., 1999, Altshuler et al., 2000, Brambilla et al., 2003, Strakowski et al., 2005).  In 
contrast, DelBello and co-workers (2004), reported decreased amygdala volumes in bipolar adolescents, 
(DelBello et al., 2004).  “These findings suggest that amygdala enlargement may therefore be a 
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consequence of abnormal development of this structure during adolescence and early adulthood” 
(Strakowski et al., 2005).   
 
Differences in thalamic volumes between bipolar versus healthy subjects have also been reported 
(Strakowski et al., 1999).  Three groups have reported enlargement of the thalamus in bipolar patients 
compared with healthy subjects (Swayze et al., 1992, Dupont et al., 1995, Strakowski et al, 1999).  
However, Strakowski and colleagues (1999) found that the effects due to differences in thalamic 
volumes were considered minimal as opposed to the significant/larger effect exhibited by differences 
in amygdala volumes (Strakowski et al, 1999). 
 
The midline cerebellum, also referred to as the cerebellar vermis, was initially thought to be solely 
involved in motor control (Strakowski et al., 2005); however, it has recently been recognised to have 
strong interconnections with limbic regions (Schmahmann and Sherman, 1998, Strakowski et al., 2005).  
Several past computed X-ray tomography (CT) studies have reported decreased cerebellar volumes in 
bipolar disorder (Nasrallah et al., 1981, Lippmann et al., 1982, Nasrallah et al., 1982, Yates et al., 1987).  
However, this work had not been extended for years until DelBello and co-workers (1999) conducted a 
study that aimed to determine the size of the cerebellar vermis in bipolar patients afflicted with repeated 
affective episodes in comparison to first-episode patients and healthy control subjects  
(DelBello et al., 1999).  The DelBello group found that the multiple-episode patients displayed reduced 
vermis size, compared to the two control groups (i.e. first-episode patients and healthy subjects).  Hence, 
there appears to be an association between vermal size and the number of repeated affective episodes 
(or recurrent mood episodes), where increasing number of episodes predicts a smaller vermis.  
 
Lateral ventriculomegaly is another well-established neuro-anatomic finding in bipolar disorder 
(Strakowski et al., 2002a, Strakowski et al., 2005).  However, it is unclear as to whether ventricular 
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enlargement is present at the onset of the disorder or develops during illness. To investigate this, 
Strakowski and co-workers compared the ventricular volumes among first- and multiple-episode 
bipolar patients, and healthy subjects (Strakowski et al., 2002b, Strakowski et al., 2005).  They found 
that the lateral ventricles were significantly larger in the patients presenting with multiple-episode 
bipolar disorder than in the first-episode and healthy subjects.  No differences were observed in the 
latter two groups.  In addition, enlarged lateral ventricles correlated strongly with a higher number of 
prior manic episodes.  This finding was supported by the work of Brambilla and co-workers (2001) who 
also found a correlation between ventricular volume and number of prior episodes in bipolar disorder 
(Brambilla et al., 2001).  These results suggest that brain ventricles increase in size during the course 
of bipolar disorder and may present as a consequence of prior affective episodes.  
 
1.5  ASSOCIATION BETWEEN AITD AND NEURO-PSYCHIATRIC DISEASES 
Neurological conditions associated with thyroid auto-immunity have been widely reported, but not 
conclusively defined (Krishnan, 2005, Whybrow and Bauer, 2005a, Whybrow and Bauer, 2005b).  
Suggested potential mechanisms include: (a) A blunted TSH response to TRH, observed in some 
patients with depression (Jackson, IM, 1998, Larsen et al., 2004); (b) the interactions of the thyroid 
system with neurotransmitters: Norepinephrine (Whybrow and Bauer, 2005a), serotonin  
(Bauer et al., 2002) and dopamine (Mano et al., 1998); and (c) the presence of thyroid hormone receptors 
in limbic structures that influences mood (Whybrow and Bauer, 2005a).   
 
1.5.1  Neuro-psychiatric manifestations in thyroid disorders 
There appears to be a neuro-immunological link between AITD and psychiatric disorders, particularly 
bipolar disease.  Hyper-thyroidism or thyrotoxicosis is also accompanied by psychiatric symptoms such 
as dysphoria, anxiety, restlessness, irritability, emotional lability, impaired concentration, intellectual 
dysfunction, insomnia and behaviour that may mimic mania (Whybrow and Bauer, 2005b,  
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Hage and Azar, 2012).  In hyper-thyroid elderly patients, depressive symptoms such as apathy, lethargy, 
pseudo-dementia and depressed mood may also occur (Taylor, 1975, Hage and Azar, 2012).  
 
In hypo-thyroid patients, depression-like symptoms include, psychomotor retardation, insomnia, 
decreased appetite, irritability, anger, fatigue and lethargy (Whybrow and Bauer, 2005a).  This may be 
accompanied by neuro-cognitive dysfunction and depression as well as impaired perception with 
paranoia and visual hallucinations (Whybrow and Bauer, 2005a).  It appears that severe  
hypo-thyroidism may mimic melancholic depression and dementia (Whybrow et al., 1969,  
Hage and Azar, 2012). 
 
1.5.2 Relationship between mood changes and TSH release in response to TRH stimulation 
Mood disorders have often been associated with Hashimoto’s disease, following a closely-established 
link between the mood changes (depression and mania), characteristic of bipolar disorder and TSH 
release in response to TRH.  It is well known that the TSH response to TRH stimulation is reduced in 
overt depression or mania (Kirkegaard, 1981, Loosen, 1985), but this has not been previously 
demonstrated in milder mood disturbances.  In order to determine whether these mild fluctuations in 
mood are also accompanied by changes in the HPT axis, Larsen and co-workers (2004) conducted a 
study to investigate a possible relationship between mild mood changes and the TSH response to TRH 
stimulation in patients with bipolar disorder (Larsen et al., 2004).  Their findings were that minor 
fluctuations in mood, as assessed using mania and depression rating scales, in bipolar patients, actually 
did correlate with changes in the TSH response to TRH stimulation and, hence, changes in the  
HPT axis.  As mood symptoms become more severe, the TSH release in response to TRH stimulation 
is reduced.  Therefore, these changes mimic those observed in overt depression and mania  
(Kirkegaard, 1981, Loosen, 1985).  Further, observations made in major depressed patients are 
consistently normal or increased serum T4 levels, both total and non-protein-bound (free) whereas 
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serum T3 levels are normal (Kirkegaard, 1981, Baumgartner et al., 1988).  In addition, tracer studies 
showed a 30% increase in daily production of T4 and normal production of T3 in depressed patients 
(Kirkegaard et al., 1990).  These findings suggest some degree of centrally-mediated hyperactivity of 
the HPT axis during depression.  In contrast, Larsen and co-workers (2004) demonstrated a negative 
correlation between serum T3 and mood symptom rating scores i.e. the greater the severity of the 
symptoms, the lower their serum T3 concentration (Larsen et al., 2004).  However, it has long been 
known that levels of T3 are reduced in somatic illness and during fasting (Doctor et al., 1993).  
Therefore, Larsen’s findings could be attributed to the possibility that increasing symptom severity is 
associated with a state that is similar to stress caused by somatic disease, as well as reduced caloric and 
carbohydrate intake (Doctor et al., 1993, Larsen et al., 2004).  
  
1.5.3  Thyroid disorders as a risk factor for rapid-cycling bipolar disorder 
Hypo-thyroidism has been reported to be a probable risk factor for the rapid-cycling type of bipolar 
disease (Heinrich and Grahm, 2003).  Rapid-cycling bipolar disorder occurs when patients experience 
four or more episodes within a twelve-month period (Heinrich and Grahm, 2003).  An episode can 
consist of depression, mania, hypomania or even a mixed state.  Anti-thyroid antibody titres were found 
in 50% of rapid-cycling bipolar patients (Hennesey and Jackson, 1996, Heinrich and Grahm, 2003).  In 
a study using lithium concurrently, those authors reported overt hypo-thyroidism in 50% of the  
rapid-cycling bipolar patients and zero in the non-rapid-cycling patients (Heinrich and Grahm, 2003).  
 
1.5.4  Cerebral perfusion abnormalities in thyroid and mood disorders 
Functional imaging studies have shown an association between thyroid dysfunction and cerebral  
hypo-perfusion. These studies included hypo-thyroid patients of varying levels of severity from  
auto-immunity or thyroid cancer (Bauer et al., 2008).  Cerebral hypo-perfusion has been notably 
observed in the posterior brain regions (Krausz et al., 2004, Nagamachi et al., 2004,  
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Krausz et al, 2007, Bauer et al., 2008), the parietal lobe (Constant et al., 2001, Bauer et al., 2008) as 
well as in limbic regions such as the amygdala and hippocampus (Bauer et al., 2006,  
Bauer et al., 2008).  Nevertheless, several studies indicate that perfusion abnormalities are reversible 
following treatment or when patients achieved a euthyroid state; however, the mechanism remains 
unclear (Forchetti et al., 1997, Kinuya et al., 1999, Bauer et al., 2006, Schraml et al., 2006,  
Bauer et al., 2008).  A study involving depressed bipolar patients, revealed that receiving  
supra-physiological dosages of T4 (300µg/day), resulted in significant improvement in mood which was 
accompanied by normalisation of cerebral metabolic perfusion in frontal, limbic and subcortical regions 
(Bauer et al., 2005, Bauer et al., 2008).  Associations between thyroid and neuro-psychiatric disorders 
have, therefore, long been established.  This work later prompted investigators including our group to 
investigate further the link between the thyroid disorders, particularly hypo-thyroidism and bipolar 
disorder. 
 
1.5.5  Thyroid factors and the acute phases of bipolar disorder 
1.5.5.1  Depression 
The following alterations in the HPT axis have been reported in patients having experienced depressive 
episodes: 
(a) an altered (blunted) TSH response to TRH, 
(b) abnormally elevated levels of anti-thyroid antibodies, 
(c) elevated levels of TRH in cerebrospinal fluid (CSF), 
(d) increased serum T4 levels 
Cole and colleagues (2002) investigated pre-treatment thyroid values in bipolar depressed patients, as 
a predictor for response to anti-depressant treatment (Cole et al., 2002).  They reported that low levels 
of free T4 and high levels of TSH, both within the normal ranges, were significantly associated with a 
slower treatment response during early phase treatment for bipolar depression.  These patients had a 
median time to remission of nearly a year.  Conversely, high levels of free T4 and low levels of TSH 
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were associated with more rapid remission of depression.  “Patients with this optimal thyroid profile 
experienced remission an average of at least 4 months earlier than the remainder of the study group” 
(Cole et al., 2002).  Two earlier studies by Prange (1990) and Frye (1999) also found a similar 
association between pre-treatment thyroid values and poorer treatment response to anti-depressants 
(Prange et al., 1990, Frye et al., 1999).  In addition, Frye (1999) associated low levels of free T4 with 
an increase in the number of affective episodes and greater severity of depression during lithium 
treatment for bipolar disorder.  Similar results were obtained for T3 levels by Hatterer and colleagues 
(Hatterer et al., 1988).  In addition, it has been shown conclusively for T3 to augment the efficacy of a 
variety of anti-depressants (Musselman and Nemeroff, 1996).  Some studies have suggested that local 
hypo-thyroidism in the brain may contribute to depression, especially bipolar depression.  Interestingly, 
this occurs despite the presence of a euthyroid state as indicated by routine peripheral blood thyroid 
hormone results (Bauer et al., 1990a, Sullivan et al., 1999, Fountoulakis et al., 2004).  Lastly, treatment 
for alleviating symptoms of depression has been shown to reverse alterations in thyroid function in most 
depressed patients (Jackson, 1998, Konig et al., 2000, Sagud et al., 2002, Fountoulakis et al., 2004).   
 
1.5.5.2  Manic and mixed states 
Studies conducted by Zarate (1997) and Chang (1998) compared two states of bipolar disorder:  Manic 
versus mixed states, but lacking a control group (Zarate et al., 1997, Chang et al., 1998).  In both those 
studies, the authors reported significantly elevated TSH levels in their mixed groups compared to the 
pure manic group.  However, they identified differences in the T4 levels, where Chang (1998) reported 
a significantly lower T4 concentration in the mixed group compared to the manics.  No significant 
differences were noted with regards to the T3 concentration or with previous lithium exposure.  Due to 
their findings, Chang and colleagues, concluded that thyroid axis dysfunction was a common 
occurrence in the bipolar mixed state rather than the bipolar manic state.  In contrast, Cassidy and 
colleagues (Cassidy et al., 2002) reported no differences in the thyroid profiles between their mixed and 
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manic groups.  It is possible that the differences between the Chang (1998) and Cassidy (2002) studies 
were due to study design and were influenced by sample number, age, gender or even ethnicity. 
 
1.5.5.3  Rapid-cycling variant of bipolar disorder 
Considered as the more severe form of the illness, rapid-cycling occurs when a patient experiences four 
or more episodes of major depression, mania, hypomania, or mixed symptoms within a twelve-month 
period.  Rapid-cycling usually affects about 9% to 20% of all bipolar patients, with women being more 
susceptible than men (Ahmed and Morriss, 1997, Kilzieh and Akiskal, 1999, Schneck, 2006,  
Azorin et al., 2008).  
 
All categories of HPT axis dysfunctions have been reported in rapid-cycling bipolar disorder.  These 
include overt hypo-thyroidism (Wehr and Goodwin, 1979, Cowdry et al., 1983, Khouzam et al., 1991, 
Szabadi, 1991, Chakrabarti, 2011), increased TSH levels (O’Shancik and Ellinwood, 1982,  
Cowdry et al., 1983, Bauer et al., 1990, Kusalic, 1992, Chakrabarti, 2011), an exaggerated TSH 
response to TRH stimulation (Kusalic, 1992), and increased antibody titres (Oomen, et al., 1996).  
 
However, there have also been inconsistent findings with some studies suggesting no association 
between thyroid dysfunctions and rapid-cycling (Joffe et al., 1988, Wehr et al., 1988,  
Bartalena et al., 1990, Maj et al., 1994, Post et al., 1997, Valle et al., 1999, Kupka et al., 2002).  This 
could be attributed to “methodological problems such as retrospective designs, lack of controls, 
predominance of female subjects and varying definitions of hypo-thyroidism” (Chakrabarti, 2011).  
More importantly, it should be noted that the studies that suggest a positive association, recruited  
rapid-cycling bipolar patients who were being treated with long-term lithium prophylaxis.  Lithium is 
an agent that has demonstrated anti-thyroid properties (Lazarus, 1998), and thereby contributing to  
hypo-thyroidism in rapid-cyclers (Cho et al., 1979, Gyulai et al., 2003).   
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1.5.6  Thyroid auto-immunity as a genetic vulnerability for bipolar disorder 
Bipolar disorder and genetics:  
It is long known that bipolar disorder occurs within families.  Results from family-studies and, in 
particular, twin-studies suggest that there is a genetic basis for bipolar disorder  
(Craddock and Jones, 1999).  That study reported that the approximate lifetime risk of bipolar disorder 
in relatives of a bipolar patient is 40-70% for a monozygotic co-twin; first-degree relative  
5-10%; and 0.5-1.5% for unrelated individual.    
 
Studies investigating monozygotic (identical) twins who share common genetic makeup have shown 
that if one of the twins is bipolar, the other twin is more vulnerable (60 to 80%) to develop the illness 
as compared to another sibling (NIMH, 1998).  In contrast, a dizygotic twin of one affected stands only 
an 8% chance of getting the disorder.  Therefore, bipolar disorder is not the result of abnormal genes 
only (NIMH, 1998).  Instead, bipolar disorder is the result of the roles, of both, genes along with other 
factors including environmental factors. Similarly to other mental illnesses, bipolar disorder is not 
necessarily the result of a single gene but of multiple genes acting together, and in combination with 
other factors of the individual or the individual’s environment to produce the illness (Hyman, 1999). 
 
Some studies have also considered a genetic relationship between bipolar disorder and biological factors 
relating to thyroid auto-immunity (Hillegers et al., 2007, Vonk et al., 2007, Holtmann et al., 2010).  
Thyroid factors have been suggested as state and/or trait related to the development of bipolar disorder 
and as mentioned earlier, changes in the HPT axis are evident in patients with mood disorders 
(Kirkegaard and Faber, 1998). 
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Auto-immune thyroiditis with accompanying increased levels of TPO antibodies has been linked with 
bipolar disorder.  Vonk and co-workers (2007) “compared the prevalence of TPO antibodies among 22 
monozygotic twins and 29 dizygotic twins with bipolar disorder, with 35 healthy control twins.”  
(Vonk et al., 2007).  They found that TPO antibody titres were positive in 27% of the bipolar twins and 
only 16% in the control twins.  Those authors, therefore, suggest that auto-immune thyroiditis with 
increased TPO antibody titres as markers, could serve as an endo-phenotype for bipolar disorder and 
could be related to the genetic vulnerability to develop the disease as well (Vonk et al., 2007).   
 
Another study by Hillegers and co-workers (2007) investigated the prevalence of auto-immune 
thyroiditis in adolescent offspring of parents with bipolar disorder (Hillegers et al., 2007).  Those 
authors examined serum TSH levels and the presence of TPO antibodies in the investigative group.  
They found that female offspring, in particular, exhibited a higher prevalence of auto-immune 
thyroiditis as indicated by increased positive TPO antibody titres as compared to control groups.  
Further, in TPO antibody positive offspring, an increased prevalence of thyroid failure was evident by 
the raised serum TSH levels or T4 treatment.  Therefore, children of bipolar parents appear more 
vulnerable to develop thyroid auto-immunity independently from their vulnerability to develop 
psychiatric disorders (Hillegers et al., 2007).  A more recent study suggests that altered thyroid function 
among children presenting with severe affective, behavioural and cognitive impairments may form part 
of a broad behavioural phenotypic expression of bipolar disorder (Holtmann et al., 2010).   
 
1.5.7  The influence of lithium on the thyroid status of bipolar patients 
Lithium continues to remain the most effective long-term preventative treatment for manic - depressive 
bipolar disorder, as well as unipolar depression in some cases.  Further, it is the only drug approved by 
FDA for treating acute mania and bipolar disorder in adolescents between the ages of 12 to 18 years 
(Emilien et al., 2007).  However, a negative aspect to patients receiving lithium treatment, is that their 
renal and thyroid function and lithium levels require regular monitoring since lithium therapy is 
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associated with hypo-thyroidism, goitre and increased anti-thyroid antibody titres, as discussed in 
greater detail below (Bocchetta and Loviselli, 2006, Emilien et al., 2007, Chakrabarti, 2011).   
 
Interestingly, significantly higher rates of overt and subclinical hypo-thyroidism, goitre and a rise in 
anti-thyroid antibody titres have been reported among patients receiving lithium treatment when 
compared to the general population and non-bipolar controls (Bocchetta and Loviselli, 2006, 
Chakrabarti, 2011).  This has been attributed to the known anti-thyroid effects of lithium therapy.  
Lithium has inhibitory actions on normal cell functioning.  It inhibits adenosine triphosphatase 
(ATPase) activity, cAMP and intracellular enzymes.  It was shown to alter the response of cultured cells 
to TRH and to stimulate DNA synthesis (Lazarus, 1998).  In the thyroid gland, where lithium is 
concentrated, it inhibits iodine uptake, iodothyrosine coupling and alters TG structure, thus, further 
inhibiting thyroid hormone secretion by the thyroid gland.  In addition, it inhibits the conversion of T4 
to T3.  The resulting effect is, therefore, hypo-thyroidism as well as goiter due to subsequent increase 
in TSH levels following the decreased release of T3 and T4 (Lazarus, 1998).  Lithium therapy is also 
associated with the exaggerated TSH response to TRH in 50% to 100% of bipolar depressive patients  
(Singer et al., 1979, Lazarus, 1998).  Lithium has been reported to affect some aspects of cellular and 
humoral immunity, both, in vitro and in vivo (Lazarus, 1998). The effects of lithium on the brain may 
include deiodinase enzymes and alterations in the concentration of thyroid hormone receptor.  However 
further work is required in this area (Lazarus, 1998). 
 
1.5.8  The influence of thyroid hormones on the neurotransmitter systems that regulate mood 
disorders 
1.5.8.1  Thyroid-serotonin system 
Studies have provided evidence linking the serotonergic system in the pathogenesis of depression.  A 
central serotonergic deficiency in association with local hypo-thyroidism, may provide a pathological 
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factor in the development of depression (Cleare et al., 1995, Heinrich and Grahm, 2003).  Brain 
serotonin levels were found to correlate positively with T3 levels in the rat, suggesting that serotonin 
synthesis is reduced in the hypo-thyroid state (Cleare et al., 1995, Heinrich and Grahm, 2003).  
Serotonin has a constant inhibitory effect on TRH, which further suppresses secretion of TSH from the 
pituitary gland and subsequent production of thyroid hormones.   This inhibitory effect on the CNS, 
“calms, soothes and generates feelings of general contentment and satiation” (Ho, 1999).  It is not 
surprising then, that a deficiency in cerebral serotonin can alter mood and may provide a contributing 
factor for obsessive compulsive disorders and schizophrenia (Ho, 1999).   
 
1.5.8.2  Thyroid-catecholamine system 
In 1981, Whybrow and Prange (1981) suggested that thyroid hormones enhanced the beta-adrenergic 
receptor response to catecholamine stimulation thus promoting neurotransmission in central 
noradrenergic pathways and accelerating the recovery process from depression  
(Whybrow and Prange, 1981).  They further suggested that thyroid dysfunction may be associated with 
abnormalities in central noradrenergic neurotransmission. Puymirat (1985) further reported that 
alterations in thyroidal status, affects catecholaminergic neurons in the developing and adult brain 
(Puymirat, 1985).  Mano and co-workers (1998) reported that the alterations in catecholamine and 
catecholamine metabolites are responsible, in part, for the central nervous system symptoms that are 
observed in hyper-thyroidism and hypo-thyroidism (Mano et al., 1998).  The noradrenergic receptor 
system appears to respond to alterations in the HPT axis function as was demonstrated in the rat brain.  
The Tejani-Butt group (1994) showed that, following a thyroidectomy, region- and receptor-specific 
pre- and postsynaptic noradrenergic system alterations were noted (Tejani-Butt et al., 1994).  A 
thyroidectomy showed decreased ligand binding to β- and α2- adrenergic receptors in the cortex as well 
as the limbic regions of the rat brain.  However, these changes were reversed upon l-thyroxine 
administration and this suggests a neuro-modulatory link between thyroid hormones and the central 
noradrenergic systems (Tejani-Butt et al., 2000). 
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Thyroid hormones also regulate levels of dopamine receptors (Crocker and Overstreet, 1984, Crocker 
et al., 1986).  Dopamine is thought to inhibit TSH secretion (Rao et al., 1990), since treatment with 
dopamine blockers have resulted in elevated serum TSH levels (subclinical hypothyroidism)  
(Magliozzi et al., 1989).  Moreover, increased serum levels of dopamine were reported in schizophrenic 
patients, whilst the levels of other pituitary parameters, including TSH, T4 and prolactin were reduced 
(Rao et al., 1984).  “The increased dopaminergic activity was hypothesised to affect the pituitary 
secretory function, and decreased beta-adrenergic activity was thought to be a consequence of decreased 
serum TSH concentration” (Santos et al., 2012).  This is interesting since α1- and β- adrenergic 
catecholamines are critical in deiodinase activity maintenance, and thus brain thyroid status (Kundu et 
al., 2009).   
 
1.5.9  AITD antibodies in bipolar disorder 
There have been earlier studies, but not all, that have reported high prevalences of anti-thyroid 
antibodies during psychiatric disorders, mainly depression (Gold et al., 1982, Nemeroff et al., 1985, 
Reus et al., 1986, Joffe, 1987, Haggerty et al., 1990).  However, the generalisability of available data is 
limited because these studies failed to include control sample groups, used different antibody assay 
methods and varying means of addressing the demographic factors responsible for creating variability 
in the rate of occurrence of thyroid auto-immunity.  However, one particular study conducted by 
Haggerty and colleagues (1997), the authors investigated the prevalence of anti-thyroid antibodies  
(anti-microsomal and anti-TG antibodies) in unipolar and subtypes of bipolar affective disorder in 
comparison with two control groups: psychiatric inpatients with adjustment disorder and family 
medicine outpatients without current psychiatric illness (Haggerty et al., 1997).  Those authors reported 
the highest occurrence of anti-thyroid antibodies in the bipolar depressed and bipolar mixed groups, but 
not in the bipolar manic and unipolar depressed groups, when compared to the control groups.  In that 
study, they also found that older women with these diagnoses had high rates of antibodies: 40% in 
bipolar depressed group and 45.5% in bipolar mixed group.  Further, the authors report that positive 
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antibody occurrence was unrelated to lithium exposure.  In contrast to the Haggerty study, Joffe et al 
(1987) reported their findings of the presence of anti-thyroid antibodies  
(anti-microsomal and anti-TG antibodies) in 5 of 58 patients with unipolar major depressive disorder 
and prior to lithium treatment (Joffe et al., 1987).  However, the prevalence rate of detectable titers of 
antibodies was similar to that observed in healthy subjects.  
 
1.6  RATIONALE 
 
A pilot study that had been previously conducted by our group was the first to demonstrate the presence 
of TSH-R and TG in cortical neurons and cerebral vasculature, respectively, within specific regions of 
normal human adult cerebral cortex (Moodley et al., 2011).  In order to fully explore this novel 
possibility, in the present study, we extend this investigation of the distribution of thyroid-specific 
proteins associated with Hashimoto’s disease, in major limbic regions of normal and bipolar human 
adult cerebral cortex. The limbic system is comprised of several functionally- and anatomically-
interconnected cortical and subcortical structures.  These limbic structures are responsible for our 
emotions and emotional learning, behaviour, memory, motivation and reward (Krebs et al., 2012).  We 
postulate that thyroid-like antigens may be expressed in human limbic structures and where anti-thyroid 
antibodies may recognise and agonise limbic-associated thyroid-specific receptors.  This abnormal 
association, should it exist, may either have a stimulatory or inhibitory effect on the regulation of limbic 
thyroid-specific receptors.  Consequently, this could determine an up- or down-regulation in the 
expression levels of limbic-associated, thyroid-specific receptors. We further postulate that any 
differences identified in the thyroid protein expression levels between the two experimental groups 
(normal and bipolar limbic regions), may contribute to mood dysregulation symptoms often observed 
in bipolar disorder (a brain disease that is associated with unusual shifts in mood), thereby suggesting 
a significant role of the thyroid system in the implication of bipolar disorder.  Our findings will therefore 
contribute to the extensive school of thought that suggests an association between AITDs and neuro-
psychiatric disorders, with particular focus on bipolar disorder, an area where research is currently 
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lacking.  Further, this prevailing school of thought implicating hypo-thyroidism in bipolar disorder is 
neither well-understood nor universally-accepted.  Thus this lack of plausible data linking these two 
disorders provided the rationale for the present study. 
 
Curiously, our postulation of anti-thyroid antibodies binding limbic components together with the 
findings of our previous pilot study that demonstrated TG-like proteins in non-limbic areas of human 
brain, suggests a migratory potential of thyroid-specific proteins across the seemingly-impervious 
blood-brain barrier (BBB).  Interestingly, there does appear to be multiple modes of egress beyond the 
protective BBB.  Studies have reported that during neurological diseases such as HIV-associated 
dementia, multiple sclerosis, Alzheimer’s disease and bipolar disorder, the integrity of the BBB can be 
altered causing it to increase permeability to leukocytes and various other circulating compounds into 
the brain (Lou et al., 1997, Minagar et al., 2002, Patel and Frey, 2015).  This influx of leukocytes was 
reported to trigger signal transduction cascades that would cause the loss of tight junction proteins 
within the highly specialised cerebral endothelial cells of the BBB.  Consequently, this would result in 
the disruption of the protective BBB during various neuro-pathological conditions including bipolar 
disorder (Bolton et al., 1998).  Thus, those reports indicating an altered BBB during neuro-pathological 
conditions, lends support to our present postulate that circulating TG-like proteins as well as anti-
thyroid antibodies, may gain ingress into the CNS to reach limbic targets.   
 
There exists no previous evidence, until now, of any quantitative comparison of these thyroid-specific 
proteins in limbic regions. Whereas our previous pilot study had used semi-quantitative analysis to 
demonstrate TSH-R and TG-like protein localisation in various human brain regions, the present study 
focuses our attention specifically on limbic structures and utilises image analysis digitilisation and 
quantification.  In addition to quantitative comparisons, we will also obtain qualitative comparisons of 
thyroid proteins in limbic regions of normal and bipolar brain by molecular biological methods.   
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1.7  AIMS 
 To compare the normal protein and gene expression of thyroid-specific proteins,  
thyroid-stimulating hormone receptor (TSH-R) and thyroglobulin (TG), with that of bipolar 
brain limbic tissue. 
 To infer whether any change in limbic thyroid protein and gene expression could be related to 
the pathophysiology of bipolar disorder. 
 
 
1.8  OBJECTIVES 
 To determine the binding sites of antibodies directed against human TSH-R and TG in six 
primary limbic regions of adult human brain, viz. amygdala, cingulate gyrus, frontal cortex, 
hippocampus, hypothalamus and thalamus, in both normal and bipolar brain tissue using 
standard immuno-histochemical methods.  This will provide a limbic map of TSH-R and TG 
protein synthesis. 
 To obtain semi-quantitative determinations of the cellular localisation of TSH-R mRNA in 
normal and bipolar brain limbic tissue by in-situ reverse-transcriptase polymerase chain 
reaction (in-situ RT-PCR) 
 To determine the gene expression of TSH-R in normal and bipolar brain limbic tissue by 
reverse-transcriptase quantitative polymerase chain reaction (RTqPCR) in order to determine 
the fold-change in TSH-R mRNA transcription.  
 
 
1.9  HYPOTHESIS 
Cross-reactivity between anti-thyroid antibodies and human neurons (in human adult brain limbic 
regions) accounts for mood dysregulation (depression or mania) observed in patients with thyroid 
disorders (Hashimoto’s disease). 
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CHAPTER 2 
 
Materials and Methods 
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2.1  SAMPLE COLLECTION 
2.1.1  Ethical approval and Patient/Guardian Consent 
Ethical approval was granted by the University of KwaZulu-Natal (UKZN), Biomedical Research 
Ethics Committee (Reference EXPO42/06).  Consent for collection of post-mortem normal brain tissue 
samples was obtained from the families of the deceased.  Normal brain tissue was collected at autopsy 
by an attending forensic surgeon. 
 
Diseased (bipolar) brain tissue samples were obtained from the Netherlands Brain Bank (NBB) 
(Netherlands Institute for Neuroscience, Amsterdam, The Netherlands) which donates post-mortem 
specimens from clinically well-documented and neuro-pathologically confirmed cases.  Autopsies were 
performed on donors from whom written informed consent had been previously obtained, or obtained 
from next of kin.  The work of the NBB abides by the Ethical code of conduct approved by the ethics 
committee.   
 
2.1.2  Post-mortem normal brain and thyroid tissue 
Normal brain tissue (n=5) was collected at autopsy, within 24 hours from individuals whom had died 
in or soon after arrival at hospital, or were declared dead on arrival at hospitals in the Durban area.  
These individuals had succumbed to unnatural causes other than head injury.  There was no evidence 
of trauma to the head or brain disease and there was no apparent indication of psychological or physical 
abnormality.  In addition to collection of brain tissue, normal human thyroid gland tissue was also 
collected from these patients.  This served as control tissue.  Table 2.1 provides a summary of the 
demographic details of these patients.   
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Table 2.1  Demographics of individuals from whom tissue samples of normal human brains were 
obtained at autopsy 
Subject No. Gender Ethnic Origin Age 
9 female Indian/Coloured 25 
10 female Indian 40 
11 male Caucasian 24 
12 male Indian 46 
14 female Asian 31 
 
2.1.3  Bipolar brain tissue 
Tissue from the amygdala, cingulate gyrus and frontal cortex were obtained from five subjects with 
bipolar disorder.  Table 2.2 provides a summary of the demographic details of the bipolar patients.  
 
Table 2.2  Demographics of individuals from whom tissue samples of bipolar human brains were 
obtained at autopsy (Netherlands Institute for Neuroscience, Amsterdam, The Netherlands) 
Subject No. Gender Ethnic Origin Age 
2004-040 female unknown 76 
2006-075 female unknown 80 
2012-048 male unknown 81 
2012-127 male unknown 68 
2014-070 male unknown 66 
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2.2  SAMPLE PROCESSING 
2.2.1  Tissue fixation 
Post-mortem tissue samples were immediately immersed in 5% formal saline fixative [41% 
formaldehyde (Saarchem, Midrand, SA), 0.9% NaCl, 1:8 v/v (Sabax, Durban)], for 24 hours at room 
temperature (RT). 
 
2.2.2  Dissection and orientation of brain sections for microscopy 
The topographical distribution of the various brain regions (Figure 2.1) was established from  
neuro-anatomical texts with structural orientation maintained by the staining of histological landmarks 
with India ink (Reeves, London) and 1% Alcian blue (ph 2.5; Sigma Chemicals, St. Louis, USA), as 
described by Raidoo (Raidoo, 1999).  For the purposes of this study, cortical tissue obtained from the 
major limbic regions (from each of the 5 brains collected) were prepared for immuno-histochemistry 
(IHC), in-situ reverse-transcriptase polymerase chain reaction (in-situ RT-PCR) and  
reverse-transcriptase quantitative polymerase chain reaction (RTqPCR).  The limbic regions that were 
investigated included: amygdala; cingulate gyrus; frontal cortex; hippocampus; hypothalamus and 
thalamus. 
 
2.2.3  Tissue processing and wax embedding for light microscopy 
The formalin-fixed tissue sections were trimmed to 5 µm in thickness, orientated and set in plastic tissue 
cassettes.  These tissue samples were then processed by routine fixation and embedding techniques.  
This included fixation in 5% formalin for 24 hours, dehydration with absolute ethanol  
(Merck Chemicals, SA) and xylene (Merck Chemicals, SA), before embedding in paraffin-wax.  All 
steps were carried out at the Department of Histopathology, UKZN, under sterile conditions in an 
automatic tissue processor (Shandon, UK).  
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Figure 2.1:  Orientation of the dissected brain areas.  Adapted from Naidoo (2002) 
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Figure 2.1 legend:  Orientation of the dissected brain areas  
The numbered regions correspond to the following human brain areas: (1) spinal cord, (2) frontal cortex, 
(3) occipital cortex, (4) cingulate gyrus, (5) parieto-occipito-temporal association cortex, (6) primary 
sensory cortex (post-central gyrus), (7) primary motor cortex (pre-central gyrus), (8) pons, (9) medulla, 
(10) midbrain, (11) lateral lobe of the cerebellum, (12) vermis, (13) flocculo-nodular lobule, (14) 
dentate nucleus, (15) hypothalamus, (16) thalamus, (17) caudate nucleus, (18) choroid plexus, (19) 
lentiform nucleus, (20) insula and claustrum, (21) hippocampus, (22) amygdaloid, (23) pineal gland, 
and (24) pituitary gland.   
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2.3  LOCALISATION OF TSH-R AND TG BY IMMUNO-HISTOCHEMISTRY  
Background 
Immuno-histochemistry (IHC) is a combination of anatomical, immunological and biochemical 
methods performed for the localisation of discrete tissue components.  To achieve this, it requires the 
use of specific labelled monoclonal or polyclonal antibodies to detect specific antigens within tissue 
sections (Duraiyan et al., 2012).  The use of a labelled secondary antibody serves to link the antigen of 
interest to a stain that renders the antigen-antibody interaction visible under light or fluorescence 
microscopy (Figure 2.2).  Immuno-histochemistry allows determination of tissue distribution and 
localisation of specific cellular antigens and can therefore be employed for diagnostic and research 
purposes to determine the up-regulation or down-regulation of specific antigens in disease states 
compared to healthy controls.  
 
Immuno-localisation of thyroid-specific proteins, TSH-R and TG 
Formalin-fixed paraffin-embedded (FFPE) brain and thyroid tissue sections (section 2.2.3), adhered 
onto silane-coated glass slides, were used for the immuno-detection of the thyroid-stimulating hormone 
receptor (TSH-R) and thyroglobulin (TG) at the protein level. Standard immuno-histochemistry 
techniques were employed using polyclonal rabbit anti-human TSH-R and polyclonal rabbit anti-human 
TG serum as the primary antibodies, respectively.  This was followed by the application of conjugated 
antibodies containing streptavidin-horse radish peroxidase immuno-enzyme complex and 
diaminobenzidine (DAB) as the chromogen visualised by light microscopy (Figure 2.2).   
 
2.3.1  Antibodies and Reagents 
Polyclonal rabbit anti-human TSH-R (200 µg/mL, Santa Cruz Biotechnology, USA) and polyclonal 
rabbit anti-human TG (8.1 µg/mL, Dako, UK) IgGs were purchased for use with an avidin-biotin  
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Figure 2.2:  Localisation of TSH-R and TG by Immuno-histochemistry 
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Figure 2.2 legend:  Localisation of TSH-R and TG by Immuno-histochemistry 
An avidin-biotin immuno-complexation technique was used for the immuno-histochemical localisation 
of TSH-R and TG.  FFPE tissue sections were deparaffinised in xylene and rehydrated through a graded 
series of ethanols.  For antigen retrieval, the tissue sections were boiled in 0.1 M sodium citrate buffer, 
cooled and incubated with 20% hydrogen peroxide/80% methanol to quench endogenous peroxidases.  
The sections were then incubated with primary antibody followed by incubations with the streptavidin-
biotin peroxidase system.  Bound peroxidase was rendered visible with DAB chromogen substrate 
application which was used to immuno-precipitate and allow visualisation with light microscopy. 
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immuno-staining kit, (LSAB®, Dako) and chromogen, 3, 3’-diaminobenzidine (DAB), (Dako, UK).  All 
other bio-reagents were purchased from Roche Molecular (USA), unless otherwise indicated.  All 
chemicals were purchased from Merck Chemicals (SA).   
 
2.3.2 Silanation of glass slides  
Glass slides were silanated, in order to enhance the adherence of tissues, by immersion in a 2%  
3-aminopropyltriethoxysilane (Sigma) solution with acetone (Merck Chemicals, SA) as the solvent, for 
10 minutes.  The silane solution was made up fresh for immediate use.  Excess silane was washed off 
in acetone for 30 seconds.  The slides were then immersed in distilled water (dH2O) for  
30 seconds, to wash off excess acetone.  All the above steps were carried out at room temperature (RT).  
Slides were dried overnight in an oven at 50oC.  The following morning, the slides were removed from 
the oven and stored in dust-free boxes at RT.  
 
 2.3.3  Sectioning of control tissue 
Five µm tissue sections of formalin-fixed paraffin-embedded (FFPE) human brain and thyroid (control) 
were prepared using a rotary microtome system from Thermo Scientific (Shandon Finesse 325).  Tissue 
sections were immersed into a pre-warmed water-bath to facilitate adherence onto silanised glass slides 
and then left to dry overnight in an oven at 50oC.  The following day, all slides were stored in dust-free 
boxes at RT.  
 
2.3.4  Immuno-histochemistry  (IHC) 
Formalin-fixed paraffin-embedded tissue sections (5 µm) were deparaffinised in xylene twice for  
10 minutes each at RT and then rehydrated through a graded series of ethanol for 5 minutes each at RT 
[100% (twice), 90%, 70% and 50% ethanol] and finally into dH2O.  For antigen retrieval, the tissues 
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were boiled in 0.1 M sodium citrate buffer (pH 6.0) for 5 minutes and allowed to cool to RT for 
approximately 20 minutes. The sections were then allowed to reach equilibrium in dH2O for 5 minutes 
at RT.   Endogenous tissue peroxidases were quenched with methanol (20 minutes during rehydration) 
and 20% hydrogen peroxide/80% methanol (4x for 20 minutes each at RT).  The sections were then 
washed twice in tris-buffered saline (TBS) for 5 minutes each.  A hydrophobic pen (Dako) was used to 
create a temporary ‘incubation well’ around each tissue section.  Tissue sections were blocked for  
non-specific protein binding with a 150 µl volume of 3% bovine serum albumin (BSA)/tris-buffered 
saline (TBS) blocking buffer each and incubated for 30 minutes at RT, with one change of buffer for a 
further 30 minutes.  The buffer was then carefully aspirated and replaced with a 150 µl volume of 
primary antibody.  Commercial anti-TSH-R (diluted 1:200 in 3% BSA/TBS) and anti-TG (diluted 
1:1500 in 3% BSA/TBS) IgGs were used as primary antibodies for these experiments.  Incubation with 
primary antibody was performed at 4oC for 18 hours within a humidified chamber.  Following 
incubation, the sections were allowed to reach RT for approximately 20 minutes and then washed with 
TBS for 5 minutes.  Tissues were then incubated with the streptavidin-biotin system (biotinylated link, 
LSAB Plus, Dako, UK) to enhance specificity of localisation, and used according to the manufacturer’s 
instructions.  Bound peroxidase was then rendered visible with diaminobenzidine (DAB) chromogen 
substrate application which was used to immuno-precipitate and allow visualisation under light 
microscopy.  Following the first indication of a colour change, the sections were immediately immersed 
in TBS to stop the reaction. Sections were then counter-stained with Mayer’s haematoxylin (Sigma) for 
1 minute at RT, rinsed under streaming water for 5 minutes, followed by dH2O for 5 minutes, then 
dehydrated through a series of ethanol for 5 minutes, each at RT [50%; 70%; 90%; 100% (twice) 
ethanol].  The slides were allowed to dry in an incubator for 15 minutes before immersing twice in 
xylene for 5 minutes each at RT.  Finally the sections were mounted with DPX permanent mountant 
(Merck Chemicals, SA) and air-dried [See addendum A.1 for list of reagents (A.1.1) and for detailed 
procedure (A.1.2)]. 
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Normal human thyroid gland tissue served as method controls for these experiments and were incubated 
with and without primary antibody.  Negative controls were prepared by substituting the primary 
antibody with blocking/dilution buffer.  These controls served to validate the immuno-localisation 
methodology and demonstrate specificity of the antibody used. 
 
2.3.5  Image Analysis 
Immuno-stained tissue samples were captured as digital TIFF images using a Leica digital camera 
(DCF300X, Leica, Heidelberg, Germany) coupled to a Leica microscope (DMLB) and interfaced with 
Leica IM50 software.  Regions of interest (ROI) were obtained by using the following considerations:  
tissue integrity; presence of neurons; the least amount of white matter and minimal background staining.  
Immuno-localisation on the control and brain regions was determined by image analysis  
(AnalySIS v5, Soft Imaging Systems, Germany).  Briefly, the DAB intensity range was converted to an 
8-bit grey-scale with 255 phases.  This grey-scale intensity of specific label in the digitised images was 
quantified and pre-determined, threshold range-limited, pixel.µm-2 values were calculated for the mean 
intensity of immuno-labelling.  On the grey scale, we considered the upper range (160-255) as an 
indication of positive labelling, in order to exclude background and artifactual labelling of the tissue.  
For each limbic region (n=6) from each of 5 normal human brains (n=5), images were analysed from 5 
fields of view (n=5) at 40x magnification (Wright et al., 2008).  The average of mean integral intensities  
(x102 pixels.µm-2) was calculated for each limbic structure.  For our determinations, the mean integral 
intensity was considered to represent the mean value of the integral intensity of a specific ROI.  The 
integral intensity is the sum of all the labelling intensities within a ROI multiplied by the pixel area, 
and was obtained as an output of the analysis software.  
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2.3.6  Statistical Methods 
All statistical analyses were performed using STATA Software, v 13.1 (StatCorp, USA).  It appeared 
that some of the data analysis for the categories, TSH-R in cerebral neurons and TG in cerebral 
vasculature, did not meet the statistical assumption of normality; therefore, these categories were 
transformed from linear-linear data to natural log (Ln) ± SEM.  Parametric assessments were determined 
for both categories.  Firstly, an assessment of thyroid protein intensity levels for TSH-R and TG, across 
the three different limbic regions (amygdala, cingulate gyrus and frontal cortex) were determined in the 
normal control group.  A similar assessment was performed for limbic regions within the bipolar group.  
Statistical methods employed for both assessments included an F-test and Tukey’s multiple comparisons 
for significance test whereby significance was tested at p < 0.05.  Intra-group comparisons of thyroid 
protein intensity levels between matched normal and bipolar limbic groups were determined using a  
T-test followed by Tukey’s multiple comparisons for significance test.  Significance was tested at  
p < 0.05.  
 
For TG neuronal labelling, the data did not appear to follow a normal distribution.  As a result,  
non-parametric assessments were employed for statistical comparisons in this category.  The median 
values were obtained and transformed using the natural log (Ln) with accompanying inter-quartile 
range-error calculations.  A two-sample Wilcoxon rank-sum (Mann-Whitney) test along with 
Bonferonni’s multiple comparisons for significance test was used to correct for distribution in the 
normal group.  Thus, inter-group statistical comparisons for the normal groups was tested at  
p < 0.003.  Inter-group statistical comparisons for the bipolar groups were determined using the 
Kruskal- Wallis rank test followed by Dunn’s Pairwise comparisons with Sidák adjustment and 
significance was tested at p < 0.05.  Finally, a T-test followed by Tukey’s multiple comparisons for 
significance test was used to obtain intra-group comparisons of neuronal-labelled TG intensity levels 
between matched normal and bipolar limbic groups.  Significance was tested at p < 0.05.   
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When analysing the data obtained, the statistical comparisons were categorised as follows: (a) inter-
group (comparison within the same category, i.e. comparing various limbic regions within either the 
control group or the bipolar group), and  (b) intra-group (comparing various limbic regions between the  
control and bipolar groups). 
 
2.4 DETECTION OF TSH-R mRNA BY in-situ REVERSE-TRANSCRIPTASE 
POLYMERASE CHAIN REACTION (in-situ RT-PCR) 
Background 
In-situ reverse-transcriptase polymerase chain reaction (in-situ RT-PCR) is a histological technique that 
combines the methods of PCR and in-situ hybridization for the detection of minute copies of specific 
mRNA directly from freshly frozen or FFPE tissue sections and intact cells  
(Lossi et al., 2011).  Following reverse-transcription, digoxigenin (DIG)-labelled nucleotides that are 
included in the PCR mix, become incorporated within the resulting amplification products which is then 
detected using an anti-digoxigenin antibody that is conjugated to alkaline phosphatase  
(Lossi et al., 2011), (Figure 2.3). 
 
2.4.1  Silanation of glass slides 
Glass slides used to capture tissue sections were thoroughly cleaned of RNAses and other contaminants 
by immersion in chloroform for 30 minutes at RT followed by absolute ethanol for  
30 minutes at RT.  Slides were next immersed in a 2% 3-aminopropyltriethoxysilane (Sigma) solution 
with acetone (Merck) as the solvent, for 5 minutes.  The silane solution was made up fresh for immediate 
use.  Excess silane was washed off by dipping twice in acetone and then diethylpyrocarbonate  
(DEPC)-treated H2O.   All the above steps were carried out at RT under RNAse-free conditions.  Slides 
were dried overnight in an oven at 50oC.  The following morning, the slides were removed from the 
oven and placed into dust-free storage boxes at RT.    
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Figure 2.3:  Detection of TSH-R mRNA by in-situ RT-PCR 
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Figure 2.3 legend:  Detection of TSH-R mRNA by in-situ RT-PCR 
In-situ RT-PCR was used for the immuno-detection of TSH-R mRNA from FFPE tissue sections.  
Tissue sections were deparaffinised, rehydrated and permeabilised to make tissue cells accessible to 
bio-reagents.  Using specific primers, TSH-R mRNA sequences were reverse-transcribed to form 
resulting cDNA templates for use in the amplification reactions whereby digoxigenin (DIG)-labelled 
nucleotides were incorporated within amplification products.  All unbound reagents were removed 
following temperature-controlled SSC washes.  The DIG marker was immuno-probed with an anti-DIG 
antibody that was conjugated to alkaline phosphatase and detected by NBT/BCIP chromogen 
precipitation.   
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2.4.2  Sectioning of wax-embedded tissue 
Formalin-fixed, paraffin-embedded tissue blocks were frozen at -20oC overnight.  All surfaces of the 
microtome including bench top, water-bath, blades holder, handles etc, were cleaned with RNAse Zap 
(Sigma) before tissue was sectioned.  A water-bath was filled with DEPC-treated H2O and maintained 
at 55oC.  Briefly, 5 µm tissue sections of wax-embedded control thyroid and brain tissue were prepared 
using a rotary microtome system from Thermo Scientific (Shandon Finesse® 325).  Sliced tissue 
sections were immersed into the pre-warmed water-bath to allow easy adherence onto silanated glass 
slides and then left to dry overnight in an oven at 50oC.  The following day, all slides were stored in 
dust-free boxes that were cleaned with RNase Zap.   
 
2.4.3  Pre-treatment of tissue sections 
Tissue sections were dewaxed in xylene twice for 10 minutes each, and then rehydrated through a 
graded series of ethanol [100% (twice), 90%, 70%, and 50%] and finally into DEPC-treated H2O.   All 
these steps were carried out at RT in a laminar flow cabinet.  The tissues were then fixed in freshly-
prepared 4% paraformaldehyde (Merck) in 1 x phosphate buffered saline, pH 7.4 (PBS) for  
1 hour and rinsed in 1 x TBS, pH 7.5.  The tissues were then partially digested in 200 mM HCl (Merck) 
for 10 minutes and rinsed in 1 x TBS.  A 65 µl Gene Frame incubation chamber  
(Advanced Biotechnologies Ltd, UK) was carefully inserted around each tissue section to create an 
incubation compartment, and this was followed by proteinase K digestion (Sigma, USA) at optimal 
concentration (See addendum A.2.1.2 for table showing optimal proteinase K concentration) for  
30 minutes at 37oC in a thermocycler (Peltier Thermal Cycler-200, MJ Research).  The tissues were 
then rinsed extensively in cold TBS three times for 10 minutes each at 4oC, in order to inactivate the 
enzyme.  The tissues were then immersed in DEPC-treated H2O, followed by dehydration through a 
graded series of ethanol [50%, 70%, 90%, 100% (2x)], all at 5 minutes each at RT, in a laminar flow 
cabinet.  A drop of chloroform (Merck) was added to each section for 1 minute to remove all traces of 
ethanol, dried in a laminar flow cabinet for 10 minutes and finally stored in a dust-free slide box that 
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had been cleaned with RNase Zap [see addendum A.2.1 for list of reagents (A.2.1.1) and detailed 
procedure (A.2.1.3)]. 
 
2.4.4 Reverse-transcriptase (RTase) and polymerase chain reaction for first-strand cDNA 
synthesis of TSH-R mRNA 
2.4.4.1  RTase reaction 
For the optimisation of in-situ RT-PCR experiments, we used the mRNA expression of the ubiquitous 
housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in various normal human 
tissues including kidney, thyroid gland and brain (cingulate gyrus). 
 
The RTase reaction mixture was prepared using the First-Strand cDNA Synthesis Kit  
(Amersham, UK).  All reagents for this procedure with the exception of the reverse primer (Table 2.3) 
were included in this kit.  A 60 µl RT reaction mix containing 2 µl of external (GAPDH or TSH-R) 
reverse primer, 2 µl of 200 mM DTT and 8 µl of bulk first strand cDNA reaction mix [cloned, FPLCpure 
murine reverse transcriptase, RNAguard (porcine), RNase/DNase-free BSA, dATP, dCTP, dGTP, and 
dTTP in aqueous buffer] and 48 µl of RNase-free H2O was placed into each incubation chamber on a 
tissue section and covered with a plastic coverslip.  The slides were placed into the thermocycler and 
incubated at 37oC for 2 hours (See addendum A.2.2 for detailed description).  Negative control reactions 
were also carried out in which the primers were omitted from the RT reactions. 
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Table 2.3:  List of primers used for RT-PCR 
Gene Primer sequences 
(5’-3’) 
PCR 
product 
(bp) 
GAPDH Forward:  TGC ACC ACC AAC TGC TTA GC 
Reverse:  GGC ATG GAC TGT GGT CAT GAG 
87 
TSH-R Forward:  GGG TGC AAC ACG GCT GGT TT 
Reverse: CTG GGT TGT ACT GCG GAT TTC GG 
367 
GAPDH:  glyceraldehyde-3-phosphate dehydrogenase 
TSH-R:  thyroid-stimulating hormone receptor 
bp:  base pairs 
 
2.4.4.2  in-situ PCR  
After incubation, the RTase mixture was carefully aspirated from each incubation chamber and replaced 
with 50 µl of PCR mix that was prepared using the Kapa Hifi reaction kit (Kapa Biosystems, Inqaba 
Biotech). The reaction mix contained 10 µl of 5 x Kapa Hifi Fidelity buffer, 2 µl of appropriate 10 µM 
forward and reverse primers (Table 2.3), 5 µl of 10 x PCR digoxigenin (DIG) labelling mix (Roche), 1 
µl Kapa Hifi (Hotstart) DNA polymerase (1 U/µl) and 30 µl of PCR-grade H2O.   A plastic coverslip 
was used to seal the incubation chamber to prevent evaporation of the PCR mixture during thermal 
cycling. The following cycles were used:  initial denaturation at 95oC for 3 minutes, followed by 30 
cycles of denaturation of 98oC for 30 seconds, annealing at 60oC (GAPDH and TSH-R) for 30 seconds 
and extension at 72oC for 30 seconds, and a final extension at 72oC for 5 minutes.  Negative control 
reactions were also carried out in which the primers were omitted from the PCR mix [see addendum 
A.2.3 for list of reagents (A.2.3.1) and detailed procedure (A.2.3.2)].  After thermal cycling, the 
coverslip was carefully removed and the tissue washed (Wash Module, Hybaid, UK) in 2 x saline-
sodium citrate (SSC) at 37oC for 30 minutes, 1 x SSC at 55oC for 20 minutes, 0.5 x SSC at 55oC for 20 
minutes and 0.1 x SSC at 55oC for 20 minutes (see addendum A.2.4.1 for detailed description). 
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2.4.4.3  Immuno-detection of DIG-labelled amplificants 
Following the SSC washes, the slides were washed in TBS (pH 7.5) at RT and then treated with  
1 x Blocking Solution (DIG Wash and Block Buffer Set, Roche) for 15 minutes at RT.  Thereafter, the 
blocking solution was gently aspirated and the tissue was incubated for 1 hour at RT with polyclonal 
sheep anti-DIG (Fab fragments, Roche) conjugated to alkaline phosphatase (1:500 in 10% blocking 
solution). The slides were then washed with TBS at RT and the tissue was covered with a freshly 
prepared colour substrate solution consisting of a 1:50 dilution of nitro-blue tetrazolium/5-bromo-4-
chloro-3'-indolyphosphate (NBT/BCIP), (Roche) in 1 x detection buffer (1 mM Tris, 1 mM NaCl,  
0.5 mM MgCl2, pH 9.5).  The slides were incubated in the dark at RT until a reddish-purple precipitate 
became clearly visible.  Thereafter, the slides were washed with tap water, counter-stained with Mayer’s 
haematoxylin (Sigma) for 1 minute at RT and then rinsed under streaming tap water.  The slides were 
then immersed in dH2O, dehydrated through a graded series of ethanol and then xylene, all at 5 minutes 
each at RT, and then mounted with DPX permanent mountant (Merck) [see addendum A.2.4 for list of 
reagents (A.2.4.1) and detailed procedure (A.2.4.2)].   
 
2.4.4.4  Documentation of in-situ RT-PCR results 
DIG-labelled tissue sections were viewed with a phase contrast, bright field microscope  
(DMLB, Leica).  A DCF300x digital camera (Leica) was attached to the microscope and interfaced with 
AnalySIS ProTM image analysis software (Soft Imaging Systems, Germany).  Images were digitised and 
recorded as 24-bit tagged image format files (TIFF).  These images were properly scaled (according to 
the magnification of the microscope objective and digital camera) and archived.  Positive labelling for 
in-situ PCR experiments were identified as blue-black colour indicating the precipitation of the 
chromogen, NBT/BCIP. 
 
 
65 
 
2.4.4.5  Semi-quantitative grading system for the distribution of in-situ PCR mRNA 
A grading system for the in-situ PCR mRNA labelling studies was performed that comprised a  
two-step approach.  For each field of view observed under light microscopy, the cellular labelling of 
TSH-R was quantified according to (i) the visual intensity and (ii) extent of labelling.  A “0” was 
assigned when no cells were observed as stained, “1” indicated low labelling, “2” for moderate labelling 
and “3” for intense labelling.  Further, these scores were correlated with the extent of cellular labelling.  
A “0” was assigned when no cells stained, “1” indicated that < 25% of cells per field of view were 
observed for labelling, a “2” indicated labelling between 25 and 75% of cells and “3” for labelling in   
> 75% of cells.  Semi-quantitative analysis was performed on multiple fields of view for each of normal 
and bipolar brain limbic regions.  Further, semi-quantitative analysis was performed by two independent 
observers and the mean of the semi-quantitative scores collated.   
 
2.5 DETECTION OF TSH-R mRNA FROM FFPE TISSUE BY REVERSE- 
TRANSCRIPTION, QUANTITATIVE POLYMERASE CHAIN REACTION 
(RTqPCR) 
Background 
Reverse-transcription quantitative polymerase chain reaction (RTqPCR) is reported to be the most 
accurate, sensitive and simple method for quantifying mRNA transcripts in biological specimens  
(Pfaffl et al., 2004, Bustin, et al., 2009).  In addition, previous studies have shown that FFPE tissue 
specimens could also be subjected to this method (Kuramochi et al., 2006a, Kuramochi et al., 2006b, 
Shimizu et al., 2006, Vallbohmer et al., 2006a, Vallbohmer et al., 2006b, Soes et al., 2013).   
Reverse-transcription quantitative polymerase chain reaction is based on the detection and 
quantification of fluorescence that is emitted from a reporter molecule that gets incorporated into the 
PCR products during real-time reactions (Figure 2.4).  For the present study, the fluorescent chemistry 
that was employed to monitor the amplification of the target sequence, was SYBR Green 1, a  
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Figure 2.4:  Quantitative detection of TSH-R mRNA by RTqPCR 
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Figure 2.4 legend:  Quantitative detection of TSH-R mRNA by RTqPCR 
TSH-R mRNA was detected and quantified using RTqPCR.  Total RNA was isolated from FFPE tissue 
sections and reverse-transcribed to form cDNA templates for use in quantitative amplification reactions 
along with specific primers and SYBR Green 1 fluorescent DNA-binding dye.  When SYBR Green 1 
binds double-stranded DNA, it emits a fluorescence that increases up to a 1000-fold.  Therefore, as PCR 
products amplify during the reaction, the SYBR Green fluorescent signal also increases.   
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fluorescent DNA-binding dye. When free in solution, SYBR Green 1 emits little fluorescence.  
However, when SYBR Green 1 binds to double-stranded DNA, its fluorescence dramatically increases 
up to a 1000-fold.  The overall fluorescent signal obtained from RTqPCR is therefore proportional to 
the amount of double-stranded DNA that is present in the reaction.  Hence, as PCR product is amplified 
in the reaction, the SYBR Green 1 fluorescent signal will also increase (Bio Rad, 2006). 
 
The Comparative CT method was used to quantify the results obtained by RTqPCR.  This quantitative 
approach requires comparing the CT (threshold cycle) values of the test samples with a calibrator 
(control).  “The threshold cycle (CT) indicates the fractional cycle number at which the amount of 
amplified target reaches a fixed threshold” (Livak and Schmittgen, 2001).  A calibrator sample is known 
as a reference or control sample that represents the normal physiological state of the study and therefore 
can be an untreated or baseline sample.  When comparing multiple samples, a single sample is selected 
as the calibrator, and the expression of the target gene in all test samples is expressed as either, an 
increase or decrease relative to the calibrator sample (Bio Rad, 2006).  In the present study, RNA 
isolated from normal brain limbic tissue from each of amygdala, cingulate gyrus and frontal cortex, 
represented the calibrator samples for these experiments.   
 
Further to the requirements for an ideal RTqPCR assay, is the normalisation of samples with suitable 
reference genes for “correct data interpretation, since its accuracy is significantly affected by sample 
quality, reagents and operator technique” (Bustin et al., 2009).  Therefore the CT values of both the 
calibrator and samples of interest were normalised to an endogenous housekeeping gene.  In the present 
study, GAPDH was used as a reference gene for the normalisation of gene expression in human brain 
limbic tissue, since studies have reported GAPDH to be a suitable and stable endogenous reference gene 
in RTqPCR analysis of human brain samples (Grunblatt et al., 2004, Coulson et al., 2008,  
Kreth et al., 2010).   
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The data output for the Comparative CT method is determined by the normalised expression ratio,  
2-∆∆CT, and reported as a fold-change or fold-difference of the target gene expression levels between the 
experimental study groups (Livak and Schmittgen, 2001).  Therefore, in the present study, we 
determined the expression fold-change of our target gene (TSH-R) in bipolar brain limbic tissue, 
normalised to the endogenous reference gene, GAPDH, and relative to normal brain limbic tissue 
(calibrator). 
 
2.5.1 Extraction and quantification of RNA from FFPE tissue specimens for gene expression 
analyses  
2.5.1.1  Silanation of glass slides 
Glass slides used to capture tissue sections were cleaned and cleared of RNases and other contaminants 
by immersion in chloroform for 30 minutes at RT, followed by absolute ethanol for  
30 minutes at RT.  They were then silanated with 2% 3-aminopropyltriethoxysilane (Sigma) solution 
for 5 minutes, quickly dipped twice in acetone and DEPC-treated H2O, and then dried overnight at 50oC.  
The following morning, the silanated slides were stored in dust-free boxes at RT. 
 
2.5.1.2  Sectioning of wax embedded tissue 
Formalin-fixed, paraffin-embedded tissue blocks were frozen at -20oC overnight.  All surfaces of the 
microtome including: bench top, water-bath, blades holder, handles etc, were cleaned with RNAse Zap 
(Sigma) before tissue was sectioned.  A water-bath was filled with DEPC-treated H2O and maintained 
at 55oC.   
 
Briefly, 10 µm tissue sections of wax-embedded control thyroid and brain tissue were prepared using a 
rotary microtome system from Thermo Scientific (Shandon Finesse® 325).  Sliced tissue sections were 
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immersed into the pre-warmed water-bath to allow easy adherence onto silanised glass slides and then 
left to dry overnight in an oven at 50oC.  The following morning, all slides were stored in  
dust-free boxes at RT.   
 
2.5.1.3  RNA Isolation from FFPE tissue sections 
Total RNA was isolated from each tissue section using the ReliaPrep FFPE Total RNA MiniPrep 
System (Promega, USA) according to the manufacturer’s instructions.  This system requires 
deparaffinisation of FFPE tissue sections using mineral oil as opposed to xylene deparaffinisation or 
deparaffinisation with alternate organic solvents.  By eliminating the washing steps performed during 
xylene deparaffinisation, this method ensures that even small RNA fragments are retained.  Prior to 
deparaffinisation with mineral oil, with the aid of a sterile blade, the tissue section was carefully scraped 
off the slide and suspended into a sterile RNase/DNase-free microcentrifuge tube.  A total of 5 tissue 
sections of 10 µm each were processed per reaction.   
 
2.5.1.4  Determining total RNA concentration using spectrophotometry 
The concentration of purified total RNA was determined using the Nanodrop spectrophotometer 
(ThermoScientific).  Nuclease-free H2O was used as a blank, since it served as the elution buffer for 
purified total RNA.   
 
2.5.2 Reverse-transcriptase quantitative polymerase chain reaction (RTqPCR) 
2.5.2.1  Reverse-transcriptase (RT) reaction - synthesis of complementary DNA (cDNA) 
Following RNA isolation, the total RNA samples (undiluted) were subjected to reverse-transcription 
using the SuperScript IV First-Strand cDNA Synthesis System (ThermoFisher, SA) according to the 
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manufacturer’s instructions.  A 7 µl volume of undiluted total RNA along with random hexamer primers 
(provided with kit) were used for the cDNA synthesis reaction.   
 
Negative controls were prepared by substituting RNA template with DEPC-treated H2O.  Resulting 
cDNA concentration was measured spectrophotometrically as performed in section 2.5.1.4.  The cDNA 
concentrations occurred in the range 2458.7 - 3319.2 ng/µl and accompanying A260/A280 ratios occurred 
in the range 1.7 - 2.0.  Recovered cDNA were stored at -20oC until further use. 
 
2.5.2.2  Quantitative PCR (qPCR) - cDNA amplification 
Quantitative PCR (qPCR) assay 
Quantitative PCR (qPCR) was performed on the Applied Biosystems 7500 Real-time PCR Instrument 
(Applied Biosystems, Life Technologies) in 96-well microtitre reaction plates (Applied Biosystems, 
Life Technologies). The fluorescent DNA-binding dye, SYBR Green 1, was used to monitor the 
amplification of the target sequence. The endogenous housekeeping gene, GAPDH was used as a 
reference gene for the normalisation of gene expression in human brain limbic tissue.  Primer sequences 
and PCR product sizes for the target gene (TSH-R) and the reference gene (GAPDH) are presented in 
Table 2.3.   
 
Each reaction was performed in a final volume of 20 µl containing 6 µl nuclease-free H2O, 10 µl of  
2x PowerUp SYBR Green Master mix (ThermoFisher, SA), 1 µl (0.5 µM final) forward primer, 1 µl  
(0.5 µM final) reverse primer and 2 µl (undiluted) cDNA.  Non-template controls were also run in 
parallel under the same conditions for both target and reference genes to verify the purity of obtained 
measurements.  Amplification was performed at 95oC for 10 minutes for enzyme activation, followed 
by 40 cycles of 95oC for 15 seconds (denaturation), 60oC (GAPDH and TSH-R) for 30 seconds 
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(annealing) and 72oC for 30 seconds (extension).  All reactions were performed in duplicate and the 
mean was used for further calculations.  To assess the specificity of the amplification of the target gene 
(TSH-R), a melt curve analysis was included at the completion of each amplification reaction.  This 
comprised a single cycle that was performed at 95oC for 15 seconds, 60oC for 1 minute, 95oC for  
30 seconds and 60oC for 15 seconds [see addendum A.3 for list of reagents (A.3.1) and detailed 
procedure (A.3.2)]. 
 
2.5.2.3  Comparative CT method (2-∆∆CT) 
The Comparative CT method is also known as the double delta CT method and can be represented as the 
normalised ratio, 2-∆∆CT,  
where:  
∆∆CT = ∆CT sample - ∆CT calibrator  
where:  
∆CT sample = CT target - CT reference   
(i.e. ∆CT sample represents the CT value for the sample normalised to the housekeeping gene). 
Similarly,   
∆CT calibrator = CT target - CT reference  
(i.e. ∆CT calibrator represents the CT value for the calibrator normalised to the housekeeping gene). 
Therefore, the amount of target (TSH-R), normalised to an endogenous reference (GAPDH) and relative 
to a calibrator (normal brain), is given by the expression ratio:  
2-∆∆CT 
The threshold cycle (CT) was generated by the 7500 ABI real time PCR system software automatically.  
The raw fluorescent data, including CT means, ∆CT mean, ∆∆CT and 2-∆∆CT, was exported to an MS 
Excel spreadsheet that had been generated by the authors.  Normal brain limbic tissue for amygdala, 
cingulate gyrus and frontal cortex were chosen as the calibrator samples for these experiments.  The 
Comparative CT method (2-∆∆CT) was used to calculate fold-changes in gene expression differences 
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between the two experimental groups (normal and bipolar brain limbic tissue).  The data is presented 
as the fold-change in TSH-R gene expression normalised to the endogenous reference gene (GAPDH) 
and relative to the normal brain limbic areas, i.e. amygdala, cingulate gyrus and frontal cortex. 
 
2.5.2.4  Statistical Methods 
All statistical analyses were performed using STATA Software, v 13.1 (StatCorp, USA).  Statistical 
analyses were performed for the fold-change of expression of our target gene, TSH-R in the bipolar 
limbic group, relative to the normal control group.  However, the data did not appear to follow a normal 
distribution curve; therefore, non-parametric assessments were considered for this category.  This 
included obtaining median values which were transformed using the natural log (Ln) with  
inter-quartile range-error calculations.  The Wilcoxon rank test was the choice of test to determine 
intra-group statistical comparisons between the normal and bipolar limbic groups.  Significance was 
tested at p < 0.05.  
  
Further, bipolar inter-group statistical comparisons for the fold-change of TSH-R expression across the 
three bipolar limbic areas examined (amygdala, cingulate gyrus and frontal cortex) were established 
using the Kruskal-Wallis rank test followed by Dunn’s Pairwise comparison with Sidák adjustment and 
significance was tested at p < 0.05.  
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ADDENDUM (A) 
Buffers, Reagents and Methods 
A.1 IMMUNO-HISTOCHEMICAL LOCALISATION OF TSH-R AND TG BY 
IMMUNO-PRECIPITATION 
A.1.1  Reagents: 
(a) Xylene (Merck, SA)) 
(b) Absolute ethanol (Merck, SA) 
(c) Methanol (Merck, SA) 
(d) 0.1 M Sodium-Citrate, pH 6.0 (w/v) – dissolve 29.4 g Tri-sodium citrate (Sigma, SA) in 800 
ml dH2O, adjust to pH 6 with HCl and make up to final volume of 1 L.  
(e) 20% hydrogen peroxide (H2O2)/80% methanol (MeOH), (v/v) - mix 80 ml MeOH (Merck, SA) 
and 20 ml H2O2 (Merck, SA) just before use. 
(f) TBS (1 L) - mix 500 ml 1M Tris-HCl and 300 ml 5M NaCl, 
- 1 M Tris-HCl, pH 8.2 - dissolve 121.14 g Trizma base (Sigma, SA) in 800 ml dH2O, adjust 
to pH 8.2 with HCl, make up to final volume of 1 L and store at RT 
- 5 M NaCl - dissolve 292 g NaCl in 1 L dH2O and store at RT. 
(g)  Milk blocker - dissolve 1 ml milk blocker (Roche, SA) in 9 ml 3% BSA/TBS  
-      3% BSA/TBS - dissolve 3 g BSA in 100 ml TBS and store at 4oC. 
(h)  Primary (1o) Ab - polyclonal goat anti-human TSH-R IgG (Santa Cruz Biotechnology) and 
polyclonal rabbit anti-human TG IgG (DakoCytomation)  
(i) Anti-goat IgG Biotin link (LSAB K0690. Dako, UK) 
(j) Secondary (2o) Ab - Strepavidin-peroxidase (LSAB ) 
(k) Chromogen liquid DAB (K3465, Dako, UK) - dissolve 1 drop DAB chromogen in  1 ml DAB 
buffer just before use.   
(l) Counter-stain - Mayers haematoxylin (Sigma, SA) 
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A.1.2  Procedure: 
Step Solution 
 
Temp Time 
1. Deparaffinisation in xylene RT 2x 10 minutes 
2. Rehydrate in 100% ethanol RT 2x 5 minutes 
3. Quench endogenous peroxidase with 100% methanol RT 1x 20 minutes 
4. Rehydrate in 90% ethanol RT 1x 5 minutes 
5.  Rehydrate in 70% ethanol RT 1x 5 minutes 
6. Rehydrate in 50% ethanol RT 1x 5 minutes 
7. Rehydrate in dH2O RT 1x 5 minutes 
8.  Antigen retrieval – boil in 0.1 M sodium-citrate, pH 
6.0 in microwave.   
80oC 3 minutes high  
9.  Allow to cool under laminar flow RT 20 minutes 
10.  Allow to equilibrate in dH2O RT 1x 5 minutes 
11. Block endogenous peroxidase in 20% H2O2 / 80% 
MeOH 
RT 4x 15 minutes 
12.  Wash in TBS  RT 2x 5 minutes 
13.  Block non-specific binding sites 3% BSA/TBS 
blocking buffer  
RT 2x 30 minutes 
14.  Incubate with 1o Ab  
- goat anti-human TSH-R IgG diluted 1: 200 with 
blocking buffer 
- rabbit anti-human TG IgG diluted 1: 1500 with 
blocking buffer  
4oC 
 
18 hours 
15. Allow slides to reach RT RT 20 minutes 
16. Wash in TBS  RT 2x 5 minutes 
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17.  Incubate with anti-goat/rabbit biotin link RT 1x 20 minutes 
18. Wash in TBS RT 1x 5 minutes 
19. Incubate with strepavidin-peroxidase RT 1x 20 minutes 
20. Wash in TBS RT 1x 5 minutes 
21. Add DAB chromogen RT 2-5 minutes 
22.  Stop reaction by immersing slides in TBS RT 5 minutes 
23. Counter-stain with Mayers’ haematoxylin  RT 1 minute 
24. Rinse slides under streaming tap H2O RT 5 minutes 
25.  Dehydrate in dH2O RT 1x 5minutes 
26. Dehydrate in 50% ethanol RT 1x 5 minutes 
27. Dehydrate in 70% ethanol RT 1x 5 minutes 
28.  Dehydrate in 90% ethanol RT 1x 5 minutes 
29. Dehydrate in 100% ethanol RT 2x 5 minutes 
30. Dry slides in the incubator  50oC 10 minutes 
31.  Immerse slides in xylene RT 2x 5 minutes 
32. Mount with DPX permanent mountant and allow 
slides to dry in fumehood 
RT 45 minutes 
33. View slides under light microscope and capture 
images 
  
34. Store slides away at 4oC 4oC  
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A.2  DETECTION OF TSH-R mRNA BY in-situ RT-PCR 
A.2.1  Pre-treatment of tissue sections for in-situ RT-PCR 
A.2.1.1  Reagents and consumables: 
1. Xylene (Merck, SA) 
2. Absolute Ethanol (Merck, SA) - dilute to 90%, 70%, 50% with DEPC-treated H2O 
3. 0.1% (v/v) DEPC-treated H2O - add 1 ml DEPC (Sigma) to 1 L dH2O, leave to stand O/N at 
RT and autoclave the following day. 
4. 10 x PBS - dissolve 5 PBS tablets (Sigma, pH 7.4) in 1 L DEPC-treated H2O. 
5. 1 x PBS - dilute 100 ml of 10 x PBS, pH 7.4 in 900 ml of DEPC-treated H2O. 
6. 4% (w/v) paraformaldehyde - dissolve 20 g of paraformaldehyde (Merck) in 400 ml of 1 x PBS 
by slowly heating the solution to 70oC on a heating plate.  Once the solution is clear, top up the 
volume to 500 ml with 1 x PBS and allow to cool.  Prepared fresh on day of use. 
7. 200 mM HCl - dilute 5 ml of 10.4 M (37%) HCl with 255 ml DEPC-treated H2O. 
8. 1 m Tris, pH 7.5 - dissolve 121 g Trizma base (Sigma) in 800 ml of DEPC-treated H2O, adjust 
pH to 7.5 with HCl and make up to final volume of 1 L 
9. 5 M NaCl (w/v) dissolve 292.2 g of NaCl (Merck) in 800 ml of DEPC-treated H2O. Once 
dissolved, make up to final volume of 1 L.   
10. TBS - dilute 50 ml of 1 M Tris-HCl, 7.5 and 30 ml of 5 M NaCl in 1 L DEPC-treated H2O 
11.  65 µl Gene Frame incubation chamber and coverslips (Inqaba Biotec) 
12.  Proteinase K - dissolve 1 mg of proteinase K Tritirachiu album (Sigma) in 1 ml DEPC-treated 
H2O to prepare a stock solution of 1 mg/ml concentration which was aliquoted and stored at -
20oC.  This stock solution was used to prepare a dilution series (refer to A.2.1.2 below).   
13. Chloroform (Merck) 
14. RNase Zap (Sigma) 
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A.2.1.2  Optimal proteinase K concentrations at 37oC for 30 minutes 
Proteinase K 
concentration 
(µg/ml) 
Starting concentration of 
proteinase K 
concentration 
Volume 
(µl) 
Volume of 0.1% (v/v) 
DEPC-H2O (µl) 
Dilution 
50 (A) 
45 
40 
35 
30 
25 
20 
15 
10 
5 
0 
1 mg/ml 
50 µg/ml (A) 
50 µg/ml (A) 
50 µg/ml (A) 
50 µg/ml (A) 
50 µg/ml (A) 
50 µg/ml (A) 
50 µg/ml (A) 
50 µg/ml (A) 
50 µg/ml (A) 
0 
50 
900 
800 
700 
600 
500 
400 
300 
200 
100 
0 
950 
100 
200 
300 
400 
500 
600 
700 
800 
900 
1000 
1: 20 
9: 10 
8: 10 
7: 10 
6: 10 
1: 2 
2: 5 
3: 10 
1: 5 
1: 10 
0 
 
Control tissue Proteinase K concentration (µg/ml) 
Control salivary gland 50 
Control kidney 20 
Control brain 
Control thyroid  
10 
10 
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A.2.1.3  Procedure: 
 
Step Solution 
 
Temp Time 
1. Deparaffinisation in xylene RT 2 x 10 minutes each 
2. Rehydrate in 100% Ethanol RT 2 x 5 minutes each 
3. Rehydrate in 90% Ethanol RT 1 x 5 minutes 
4. Rehydrate in 70% Ethanol RT 1 x 5 minutes 
5.  Rehydrate in 50% Ethanol RT 1 x 5 minutes 
6. Rehydrate in DEPC-treated H2O RT 1 x 5 minutes 
7. Fixation in freshly prepared 4% paraformaldehyde RT 1 hour 
8.  Rinse in TBS RT 2 x 2 minutes each 
9. Digest in 200 mM HCl RT 10 minutes 
10. Rinse in 2 changes of fresh TBS RT 2 x 2 minutes each 
11. Protease digestion with proteinase K, in order to 
permeabilise cell membrane 
37oC 30 minutes 
12. 
 
Rinse in 3 changes of fresh, cold TBS to inactivate 
enzyme 
4oC 3 x 10 minutes 
13. Dehydrate in DEPC-H2O RT 1 x 5 minutes 
14. Dehydrate in 50% Ethanol RT 1 x 5 minutes 
15. Dehydrate in 70% Ethanol RT 1 x 5 minutes 
16. Dehydrate in 90% Ethanol RT 1 x 5 minutes 
17. Dehydrate in 100% Ethanol RT 1 x 5 minutes 
18. Dry in Chloroform RT 1 minute 
19. Dry in fumehood RT 10 minutes 
20. Store in RNase-free/dust-free slide box RT  
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A.2.2  Reverse-Transcriptase and Polymerase Chain Reaction - RTase reaction 
A.2.2.1  Reagents: 
1.  First-strand cDNA kit (Separation Scientific, SA, Pty Ltd) 
- Bulk first-strand cDNA mix [cloned, FPLCpure murine reverse transcriptase, RNAguard 
(porcine), RNase/DNase-free BSA, dATP, dCTP, dGTP, and dTTP in aqueous buffer] 
- DTT solution (200 mM) 
- DEPC-treated H2O 
2. Reverse primer - GAPDH/TSH-R (IDT)  
3. Parafilm sheets 
 
A.2.2.2  in-situ RT reaction mix: 
Reagents Positive reaction (µl) Negative control (µl) 
DEPC-H2O 48 50 
Bulk mix  8 8 
DTT (200mM) 2  2 
Reverse primer (10 µM) 2  - 
TOTAL 60 60 
Incubation: 
 37oC for 2 hours 
 
A.2.3  in-situ PCR Reaction 
A.2.3.1  Reagents: 
1. PCR-grade H2O 
2. Kapa Hifi reaction kit (Kapa Biosystems, Inqaba Biotech) 
- 5x Kapa Hifi Fidelity Buffer 
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- Kapa Hifi (Hotstart) DNA polymerase (1U/µl) 
3. Forward and Reverse Primers - GAPDH/TSH-R (IDT) 
4. 10x PCR DIG labelling mix (Roche) 
5. 65 µl Gene Frame incubation chamber and coverslips (Inqaba Biotec) 
 
A.2.3.2  PCR mix: 
Reagents Positive reaction (µl) Negative control (µl) 
PCR-grade H2O 30 34 
5x Kapa Hifi Fidelity Buffer 10 10 
10x DIG labelling mix 5 5 
Forward primer (10 µM) 2 - 
Reverse primer (10 µM) 2 - 
Kapa Hifi (Hotstart) DNA 
polymerase (1U/µl) 
1 1 
TOTAL 50 50 
 
Cycling conditions: GAPDH and TSH-R 
 Initial denaturation:    98oC for 3 minutes                  1 cycle 
 Denaturation:             95oC for 30 seconds  
 Annealing:                 60oC for 30 seconds                 30 cycles 
 Extension:                  72oC for 30 seconds 
 Final extension:         72oC for 5 minutes                   1 cycle  
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A.2.4 Post-hybridisation washes and immuno-detection of bound DIG-labelled amplificants 
A.2.4.1  Reagents: 
1.  20x Sodium citrate (SSC, w/v) - dissolve 175.3 g NaCl and 88.2 g sodium citrate in 800 ml 
DEPC-treated H2O, adjust the pH to 7.0 and make up to a final volume of 1 L.  Filter and 
autoclave. 
Prepare SSC solutions (2 x, 1 x, 0.5x, 0.1x) as follows: 
 2x SSC:  dilute100 ml 20 x SSC with 900 ml DEPC-treated H2O 
 1x SSC:  dilute 50 ml 20 x SSC with 950 ml DEPC-treated H2O 
 0.5x SSC:  dilute 25 ml 20 x SSC with 975 ml DEPC-treated H2O 
 0.1x SSC:  dilute 10 ml 20 x SSC with 990 ml DEPC-treated H2O 
2. 1x TBS (refer to A.2.1.1)   
3. DIG Wash and Block Buffer Set (Roche).  Contains washing, blocking and detection buffers 
(each at 10x concentration) for the immunological detection of DIG-labelled amplificants 
 1x Blocking Solution:  dilute 1 ml of 10x Maleic acid buffer with 9 ml of dH2O to 
prepare a 1x Maleic acid buffer solution.  Then dilute 1 ml of 10x Blocking solution 
with 9 ml of the freshly prepared 1x Maleic acid buffer solution.  Always prepared 
fresh. 
 1x Detection Buffer:  dilute 1 ml of the 10 x Detection buffer with 9 ml of dH2O.  Store 
at 4oC and allow it to reach RT before each use. 
4. Polyclonal Sheep Anti-DIG-Alkaline Phosphatase-Conjugate (Fab) [150 U (200 µl), Roche] 
 Alkaline Phosphatase Solution:  the anti-DIG-AP (Fab) was diluted 1:500 with 1x 
Blocking solution just before use 
5. Chromogen, NBT/BCIP Stock Solution (Roche) 
 Detection Solution:  The NBT/BCIP stock solution was diluted 1:50 with 1x Detection 
buffer just before use.  The solution contains NBT (18.75 mg/ml) and BCIP (9.4 mg/ml) 
in 67% DMSO. 
6. Mayer’s Haematoxylin (Sigma) 
7. DPX permanent mountant (Merck) 
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A.2.4.2  Procedure: 
Step Solution 
 
Temp Time 
1. Wash tissue slides in 2 x SSC 37oC 30 minutes 
2. Wash tissue slides in 1 x SSC 55oC 20 minutes 
3. Wash tissue slides in 0.5 x SSC 55oC 20 minutes 
4. Wash tissue slides in 0.1 x SSC 55oC 20 minutes 
5.  Rinse slides in TBS  RT 2 x 2 minutes 
6. Block non-specific binding sites with 1x blocking 
buffer application per tissue section 
RT 15 minutes 
7. Polyclonal sheep anti-DIG-IgG alkaline phosphatase 
conjugate was diluted 1:500 in blocking solution and 
added to each tissue section 
4oC 18 hours 
8.  
 
 
Rinse slides in TBS RT 2 x 2 minutes 
9. Chromogen - NBT/BCIP diluted 1:50 in 1x detection 
buffer was added to each tissue section and left to 
develop in the dark 
RT ≤ 15 minutes 
 
10. Upon colour change, the slides were immersed in 
dH2O to stop the reaction 
RT 5 minutes 
11. Counter-stain with Mayer’s haematoxylin RT 2 minutes 
12. 
 
 
Slides were rinsed under running tap water RT 5 minutes 
13. 
 
 
Dehydrate tissue sections in dH2O RT 5 minutes 
14. Dehydrate in 50% Ethanol RT 5 minutes 
15. Dehydrate in 70% Ethanol RT 5 minutes 
16. Dehydrate in 90% Ethanol RT 5 minutes 
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17. Dehydrate in 100% Ethanol  RT 2 x 5 minutes each 
18. Dry slides in incubator 50oC 10 min 
19. Immerse slides in Xylene  RT 2 x 5 minutes each 
20. 
 
Mount with DPX permanent mountant and allow to 
dry in fumehood 
RT 45 minutes 
21. 
 
 
View slides under light microscope and capture 
images 
  
22. 
 
 
Store slides away at 4oC 4oC  
 
  
85 
 
A.3  DETECTION OF TSH-R mRNA BY QUANTITATIVE PCR (qPCR) 
 
A.3.1  Reagents and consumables: 
1.  96-well microtitre plates (Applied Biosystems)   
2.  PowerUp 2x SYBR Green master mix (Applied Biosystems) 
3.  PCR-grade H2O 
4.  Forward primers (GAPDH/TSH-R) 
5.  Reverse primers (GAPDH/TSH-R) 
6.  Undiluted cDNA (limbic brain) 
7.  Undiluted calibrator sample (representative normal limbic group) 
 
A.3.2 qPCR mix 
Reagents Volume (µl) 
PCR-grade H2O 6 
SYBR Green master mix (2x) 10 
Forward primer (GAPDH/TSH-R, 10µM) 1 
Reverse primer (GAPDH/TSH-R, 10µM) 1 
cDNA (undiluted) or calibrator (undiluted) 2 
TOTAL 20 
 
Cycling conditions: GAPDH and TSH-R 
 Initial denaturation:    95oC for 10 minutes                1 cycle 
 Denaturation:             95oC for 15 seconds 
 Annealing:                 60oC for 30 seconds                 40 cycles 
 Extension:                  72oC for 30 seconds 
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Melt Curve Analysis:  Cycling conditions:  
 Step 1:   95oC for 15 seconds                1 cycle 
 Step 2:   60oC for 1 minute                   1 cycle 
 Step 3:   95oC for 30 seconds               1 cycle            
 Step 4:   60oC for 15 seconds               1 cycle 
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CHAPTER 3 
 
Results 
  
88 
 
3.1  LOCALISATION OF TSH-R AND TG BY IMMUNO-HISTOCHEMISTRY 
3.1.1  Control tissues 
Immuno-labelling of normal human thyroid tissue demonstrated TSH-R in the thyroid follicular cells 
that constitute the simple cuboidal, follicular epithelia (Figure 3.1A).  The colloid, colloidal spaces and 
colloidal vesicles were devoid of TSH-R labelling. Further, TSH-R could not be detected within thyroid 
vasculature.  
 
Thyroid protein (TG) expression in brain tissue is described in detail under section (3.1.3).  However, 
controls for TG immuno-staining on normal thyroid tissue is described here.  Immuno-reactive TG was 
evident within the cytoplasm of thyroid follicular cells (Figure 3.1C).  In addition, intense TG labelling 
was visualised within the colloidal space and colloidal vesicles, and within the smooth muscle cells of 
the tunica media and tunica adventitia of thyroidal vasculature.   
 
Method controls for thyroid tissue demonstrated the absence of staining when TSH-R (Figure 3.1B) 
and TG (Figure 3.1D) antibodies were substituted with dilution buffer. 
 
3.1.2  Thyroid-stimulating hormone receptor (TSH-R) 
(a)  Observations 
Immuno-reactive TSH-R was observed in all six limbic regions in all five brains examined for normal 
brain, as well as all three matched limbic regions (amygdala, cingulate gyrus and frontal cortex) 
investigated in all five brains of bipolar subjects.  Positive immuno-labelling was demonstrated in the 
large motor neurons of the frontal cortex (Figure 3.2A and B), hippocampus (Figure 3.2C), cingulate 
gyrus (Figure 3.2D), amygdala (Figure 3.2E and F), hypothalamus and thalamus of normal brain.   
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Figure 3.1:  Immuno-localisation of TSH-R and TG in normal human control thyroid tissue  
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Figure 3.1 legend:  Immuno-localisation of TSH-R and TG in normal human control thyroid 
tissue  
Immuno-labelling of normal control thyroid tissue demonstrated TSH-R in the thyroid follicular cells 
(black arrows), (A, x400).  Antibody method control for TSH-R in thyroid tissue was devoid of stain 
(B, x400).  Immuno-reactive TG was demonstrated within the cytoplasm of thyroid follicular cells 
(yellow arrow), colloid (red arrow) and colloidal vesicles (blue arrow) of normal thyroid tissue  
(C, x 400).  Antibody method control for TG in thyroid tissue demonstrated the absence of stain within 
thyroidal structures (D, x400).  Positive labelling for TSH-R and TG in thyroid tissues were identified 
as brown colour.  Scale bars = 200µm. 
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Figure 3.2:  Immuno-localisation of TSH-R in normal human adult brain limbic areas  
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Figure 3.2 legend:  Immuno-localisation of TSH-R in normal human adult brain limbic areas 
 In brain limbic areas, immuno-reactive TSH-R was evident in neuronal cell bodies (red arrows) in the 
frontal cortex (A and B, x400), hippocampus (C, x400), cingulate gyrus (D, x400) and amygdala  
(E and F, x400).  Antibody method controls for brain tissue showed absence of stain in neurons  
(A, inset, x400).  Positive labelling for TSH-R in brain tissues were identified as brown colour.  Scale 
bars = 200µm. 
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Similarly, in bipolar brain limbic areas, immuno-reactive TSH-R was demonstrated within large motor 
neuronal cell bodies in the amygdala (Figure 3.3B), cingulate gyrus (Figure 3.3C and D) and frontal 
cortex (Figure 3.3E and F).  Further, TSH-R was not detected in either cerebral vasculature or neuronal 
support cells that include the oligodendrocytes, astrocytes, neuroglia and satellite cells, in both normal 
and bipolar limbic areas. 
 
(b)  Image Analysis 
The labelling intensities of TSH-R across all normal brain limbic regions were analysed and quantified 
by image analysis, and appeared to be confined to within the range 4.62 - 540.42 x102 pixels.µm-2 
(arithmetic mean intensity values).  Specifically, regions such as the frontal cortex  
(540.42 x102 pixels.µm-2) and cingulate gyrus (395.47 x102 pixels.µm-2) displayed more intense 
staining, whilst the hypothalamus (11.24 x102 pixels.µm-2) and thalamus (4.62 x102 pixels.µm-2) stained 
to a lesser degree by a few hundred-fold (Table 3.1).  Figure 3.4 displays the Log mean (Ln) intensity 
for TSH-R immuno-labelling in all normal brain limbic regions examined in the range 1.5 - 5.8. These 
results demonstrate an approximate 3-fold difference each for cingulate gyrus (5.80), frontal cortex 
(5.80), hippocampus (5.50) and amygdala (5.10) when compared to both, hypothalamus (1.90) or 
thalamus (1.50) (Table 3.1, Figure 3.4).  Statistical comparisons demonstrated that TSH-R in both the 
hypothalamus and thalamus differed significantly when compared to each of the other four normal 
limbic areas (p < 0.0001) but not when compared to each other (Table 3.1, Figure 3.4).  Further, no 
appreciable significance was noted among the remaining four normal limbic regions when compared 
amongst each other.  
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Figure 3.3:  Immuno-localisation of TSH-R in bipolar human adult brain limbic areas and normal 
human control thyroid tissue 
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Figure 3.3 legend:  Immuno-localisation of TSH-R in bipolar human brain limbic areas and 
normal human control thyroid tissue 
Immuno-labelling of normal control thyroid tissue demonstrated TSH-R within the thyroid follicular 
cells especially on the luminal edge of the thyroid follicular cells bordering the colloidal spaces  
(black arrows) (A, x400).  In bipolar brain limbic areas, immuno-reactive TSH-R was evident within 
neuronal cell bodies (red arrows) in the amygdala (B, x 400), cingulate gyrus (C and D, x400) and the 
frontal cortex (E and F, x400).  Positive labelling for TSH-R in thyroid and brain sections were 
identified as brown colour.  Scale bars = 200µm. 
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Table 3.1:  Quantification of TSH-R neuronal labelling intensity in normal brain limbic regions  
 
TSH-R in normal brain limbic neurons 
 
 
 
Limbic 
Regions 
Arithmetic Mean Labelling Intensity Log (Ln) Intensity 
Mean 
(pixels.µm2) 
±SEM Log Mean (Ln) ±Log SEM 
Amygdala 243.99 
395.47 
540.42 
353.97 
11.24 
4.62 
50.23 
62.71 
85.38 
41.06 
3.05 
0.30 
5.10*Ϯ 
5.80*Ϯ 
5.80*Ϯ 
5.50*Ϯ 
1.90 
1.50 
0.29 
0.17 
0.25 
0.23 
0.28 
0.06 
Cingulate gyrus 
Frontal cortex 
Hippocampus 
Hypothalamus  
Thalamus 
*  vs hypothalamus, p < 0.0001 
Ϯ  vs thalamus, p < 0.0001 
n = 6 limbic regions 
n = 5 normal human brains 
n = 5 fields of view for each specimen 
Image analysis:  AnalySIS 5 (Soft Imaging Systems, Germany) 
Statistical comparisons:  STATA Software, v13.1 (StataCorp, USA) 
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Figure 3.4:  Log mean (Ln) intensity of immuno-labelling for TSH-R in cortical neurons of normal 
human brain limbic regions 
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Figure 3.4 legend:  Log mean (Ln) intensity of immuno-labelling for TSH-R in cortical neurons of 
normal human brain limbic regions 
Log mean (Ln) intensity values obtained for TSH-R in neuronal staining occurred in the range  
1.5 - 5.8.  These results indicate an approximate 3-fold difference when the cingulate gyrus (5.80), 
frontal cortex (5.80), hippocampus (5.50) and amygdala are each compared to the hypothalamus (1.90) 
or thalamus (1.50).  Inter-group statistical comparisons showed that TSH-R in the hypothalamus and 
thalamus differed significantly when compared to each of the other limbic areas but not against each 
other.  Further, there was no difference noted among the other four limbic regions when compared to 
each other.   
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Quantification of TSH-R immuno-labelling across all matched bipolar brain limbic regions provided a 
narrow arithmetic mean intensity range of 14.15 - 19.15 x102 pixels.µm-2 (Table 3.2).  Specifically, the 
cingulate gyrus (19.15 x102 pixels.µm-2) displayed the greatest intensity within this category, whilst the 
amygdala (14.15 x102 pixels.µm-2) was reported to have the least intensity for TSH-R.  Table 3.2 also 
displays the Log mean (Ln) intensity for TSH-R immuno-labelling in all bipolar brain limbic regions in 
the range 1.97 - 2.30.  Due to the narrow range reported in both arithmetic mean values and Log mean 
(Ln) intensity values, there is no notable fold difference amongst these regions.  In addition, statistical 
comparisons among all bipolar regions indicates no appreciable difference within this category  
(Table 3.2, Figure 3.5).  Hence, there appeared to be a fairly consistent level of TSH-R in these diseased 
limbic regions. 
 
(c)  Statistical comparisons between normal and bipolar limbic regions 
Statistical comparisons obtained for TSH-R labelled neurons in normal versus bipolar brain limbic 
regions indicates a significant difference in all matched regions examined, i.e. amygdala (p < 0.0001), 
cingulate gyrus (p < 0.0001) and frontal cortex (p < 0.0001), (Figure 3.5).  All demonstrate an 
appreciable decrease in TSH-R levels in the bipolar brain regions, respectively.   
 
3.1.3  Thyroglobulin (TG) 
3.1.3.1 TG in cerebral vasculature 
(a)  Observations 
Positive immuno-labelling for TG was detected within the cerebral vasculature of all normal limbic 
regions.  Specifically, immuno-reactive TG was localised to the smooth muscle cells of the tunica media 
and tunica adventitia of cerebral blood vessels in the amygdala (Figure 3.6A), frontal cortex  
(Figure 3.6B), thalamus (Figure 3.6C), hypothalamus (Figure 3.6D), cingulate gyrus (Figure 3.6E) and 
hippocampus (Figure 3.6F).   
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Table 3.2:  Quantification of TSH-R neuronal labelling intensity for bipolar brain limbic regions  
TSH-R in bipolar brain limbic neurons 
 
 
Limbic 
Regions 
(Bipolar) 
Arithmetic Mean Labelling Intensity Log (Ln) Intensity 
Mean 
(pixels.µm2) 
±SEM Log Mean (Ln) ±Log SEM 
Amygdala 14.15 2.53 
3.65 
2.42 
1.97 0.16 
0.17 
0.16 
Cingulate gyrus 19.15 2.30 
Frontal cortex 15.01 2.09 
n = 5 human bipolar brains 
n = 3 limbic regions 
n = 10 fields of view for each specimen 
Image analysis:  AnalySIS 5 (Soft Imaging Systems, Germany) 
Statistical comparisons:  STATA Software, v13.1 (StataCorp, USA) 
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Figure 3.5:  Log mean (Ln) intensity of immuno-labelling for TSH-R in cortical neurons of 
matched normal versus bipolar brain limbic regions 
 
             Normal  
                
             Bipolar 
  
 * p < 0.0001 
   
  
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
Amygdala Cingulate gyrus Frontal cortex
Lo
g 
m
e
an
 (
Ln
) 
in
te
n
si
ty
 ±
L
o
g
 S
E
M
Brain limbic regions
*
* 
* 
102 
 
Figure 3.5 legend:  Log mean (Ln) intensity of immuno-labelling for TSH-R in cortical neurons of 
matched normal versus bipolar brain limbic regions 
Log mean (Ln) intensity values were obtained for TSH-R neuronal staining in normal and bipolar brain 
limbic areas.  Intra-group statistical comparisons demonstrates significant differences between matched 
normal and bipolar limbic areas examined, amygdala (p < 0.0001), cingulate gyrus (p < 0.0001) and 
frontal cortex (p < 0.0001).  Further, there was no inter-group difference noted among the bipolar groups 
when compared to each other. 
  
103 
 
Figure 3.6:  Immuno-localisation of TG in normal human adult brain limbic areas  
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Figure 3.6 legend:  Immuno-localisation of TG in normal human adult brain limbic areas 
Immuno-reactive TG was highly concentrated within smooth muscle of the tunica media and tunica 
adventitia of cerebral vasculature in the amygdala (A, x400), frontal cortex (B, x400), thalamus  
(C, x400), hypothalamus (D, x400), cingulate gyrus (E, x400) and hippocampus  
(F, x400).  Positive labelling for TG in brain tissues were identified as brown colour and are indicated 
by arrows.  Scale bars = 200µm. 
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In matched bipolar limbic regions, immuno-reactive TG was identified within cerebral vasculature in 
all areas examined.  However, the degree of staining distribution compared to that in normal limbic 
vasculature, was observed to be less.  Similar to normal brain, TG immuno-labelling was localised 
specifically to smooth muscle cells of the tunica media and tunica adventitia of cerebral vasculature in 
the frontal cortex (Figure 3.7B), amygdala (Figure 3.7C and D), and cingulate gyrus  
(Figure 3.7E and F).   
 
(b) Image Analysis 
Quantification of TG immuno-labelling within limbic vasculature of the normal group, demonstrated a 
wide arithmetic mean intensity range of 423.84 - 2994.00 x102 pixels.µm-2 (Table 3.3).  Specifically, 
the cingulate gyrus (2994.00 x102 pixels.µm-2), thalamus (1474.34 x102 pixels.µm-2) and hippocampus 
(1407.14 x102 pixels.µm-2) displayed the greatest intensities within this category, whilst the 
hypothalamus (571.04 x102 pixels.µm-2) and amygdala (423.84 x102 pixels.µm-2) stained with lesser 
intensities, by a few thousand-fold.  Table 3.3 also displays the Log mean (Ln) intensity values for TG 
in limbic vasculature which occurs in the range of 5.14 - 6.40 (Table 3.3).  Inter-group statistical 
comparisons demonstrated that when compared to the amygdala, there was a significant difference in 
the cingulate gyrus (p = 0.02), frontal cortex (p = 0.03) and thalamus (p = 0.02).  None of the other 
inter-regional comparisons showed statistical differences (Figure 3.8).   
 
Quantification of TG immuno-labelling within limbic vasculature of the bipolar regions, presented an 
arithmetic mean intensity range of 75.48 - 98.96 x102 pixels.µm-2 (Table 3.4).  The cingulate gyrus 
(98.96 x102 pixels.µm-2) indicated the greatest intensity within this category, whilst the frontal cortex 
(75.48 x102 pixels.µm-2) stained the least.  Log mean (Ln) intensity values were also obtained in the 
range of 2.99 - 3.96 (Table 3.4).  Inter-group statistical comparisons among all bipolar limbic regions 
demonstrated that when compared to the frontal cortex, there were significant differences in the 
cingulate gyrus (p < 0.005) and amygdala (p < 0.002), (Table 3.4, Figure 3.9) 
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Figure 3.7:  Immuno-localisation of TG in bipolar human brain limbic areas and normal human 
control thyroid tissue  
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Figure 3.7 legend:  Immuno-localisation of TG in bipolar human brain limbic areas and normal 
human control thyroid tissue  
Immuno-labelling of normal control thyroid tissue demonstrated TG within the cytoplasm of thyroid 
follicular cells (yellow arrow), colloid (red arrow) and colloidal vesicles (blue arrow) (A, x400).  
Immuno-reactive TG was highly concentrated within the smooth muscle of the tunica media/adventitia 
of cerebral vasculature in the frontal cortex (B, x200), amygdala (C and D, x200) and cingulate gyrus 
(E and F, x200) of bipolar brain.  Positive labelling for TG in thyroid and brain tissues were identified 
as brown colour.  Scale bars = 200µm. 
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Table 3.3:   Quantification of TG cerebral vasculature labelling intensity in normal brain limbic 
regions  
TG in normal brain limbic cerebral vasculature 
 
Limbic Regions Arithmetic Mean Labelling Intensity Log (Ln) Intensity 
 Mean 
(pixels.µm2) 
±SEM          Log Mean (Ln) ±Log SEM 
Amygdala 423.84 132.30 5.14 0.37 
Cingulate gyrus 2994.00 2315.11   6.40* 0.30 
Frontal cortex 884.70 229.70   6.28* 0.19 
Hippocampus 1407.14 922.26 5.97 0.26 
Hypothalamus  571.04 94.44 6.09 0.15 
Thalamus 1474.34 500.46   6.35* 0.28 
* vs amygdala, p < 0.05 
n = 6 limbic regions 
n = 5 normal human brains 
n = 5 fields of view for each specimen 
Image analysis:  AnalySIS 5 (Soft Imaging Systems, Germany) 
Statistical comparisons:  STATA Software, v13.1 (StataCorp, USA) 
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Figure 3.8:  Log mean (Ln) intensity of immuno-labelling for TG in cerebral vasculature of normal 
human brain limbic regions 
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Figure 3.8 legend:  Log mean (Ln) intensity of immuno-labelling for TG in cerebral vasculature 
of normal human brain limbic regions 
Log mean (Ln) intensity values obtained for TG in normal limbic cerebral vasculature occurred in the 
range 5.14 - 6.40.  Statistical comparisons indicates that the cingulate gyrus, frontal cortex and thalamus 
differed significantly from the amygdala.  No statistical differences occurred among other inter-regional 
comparisons. 
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Table 3.4:  Quantification of TG cerebral vasculature labelling intensity in bipolar brain limbic 
regions  
TG in bipolar brain limbic cerebral vasculature 
 
Limbic Regions 
(Bipolar) 
Arithmetic Mean Labelling Intensity Log (Ln) Intensity 
 Mean 
(pixels.µm2) 
±SEM          Log Mean (Ln) ±Log SEM 
Amygdala 89.82 14.36   3.96* 0.15 
Cingulate gyrus 98.96 17.14   3.88* 0.18 
Frontal cortex 75.48 18.34 2.99 0.25 
* vs frontal cortex, p < 0.05 
n = 5 human bipolar brains 
n = 3 limbic regions 
n = 10 fields of view for each specimen 
Image analysis:  AnalySIS 5 (Soft Imaging Systems, Germany) 
Statistical comparisons:  STATA Software, v13.1 (StataCorp, USA) 
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(c)  Statistical comparisons between normal and bipolar limbic regions 
Intra-group statistical comparisons determined for TG in cerebral vasculature in matched normal versus 
bipolar limbic regions demonstrated significant differences in all areas, amygdala (p = 0.0007), 
cingulate gyrus (p < 0.0001) and frontal cortex (p < 0.0001), (Figure 3.9).  Thus, there appeared to be 
appreciable decreases in the TG levels found in bipolar brain regions 
 
3.1.3.2  TG in cerebral neuronal cells 
(a)  Observations 
In normal limbic brain, immuno-reactive TG was demonstrated in most neuronal cell bodies and axons 
of the cingulate gyrus (Figure 3.10A-D), whilst similar cellular structures in the frontal cortex exhibited 
less staining distribution (Figure 3.10E and F).  There was no evidence of positive TG labelling within 
neuronal cell bodies and supporting cerebral cellular structures in the other four limbic regions.   
 
In matched bipolar brain limbic regions, immuno-reactive TG was evident within neuronal cell bodies 
of the amygdala (Figure 3.11A and B), cingulate gyrus (Figure 3.11C and D) and the frontal cortex 
(Figure 3.11E and F).  In contrast to normal brain, bipolar brain neuronal axons, specifically within the 
cingulate gyrus, were devoid of stain.  Further, there was no evidence of TG labelling within other 
supporting cerebral cellular structures in all matched bipolar limbic regions.   
  
113 
 
Figure 3.9:  Log mean (Ln) intensity of immuno-labelling for TG in cerebral vasculature of 
matched normal versus bipolar brain limbic regions 
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Figure 3.9 legend:   Log mean (Ln) intensity of immuno-labelling for TG in cerebral vasculature 
of matched normal versus bipolar brain limbic regions 
Log mean (Ln) intensity values were obtained for TG in normal and bipolar brain limbic cerebral 
vasculature.  Intra-group statistical comparisons demonstrates significant differences between 
respective normal and bipolar limbic areas examined, amygdala (p = 0.0007), cingulate gyrus  
(p < 0.0001) and frontal cortex (p < 0.0001).  Within the bipolar groups only, inter-group significant 
increases were demonstrated in the cingulate gyrus (p < 0.005) and amygdala (p < 0.002), when 
compared to the frontal cortex. 
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Figure 3.10:  Immuno-localisation of TG in normal human brain limbic neurons  
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Figure 3.10 legend:  Immuno-localisation of TG in normal human brain limbic neurons 
Immuno-reactive TG was highly concentrated in neuronal cell bodies (red arrows) and axons  
(yellow arrows) of normal cingulate gyrus (A, x400), (B, x400), (C, x400) and (D, x400).  TG was also 
evident within neuronal cell bodies of normal frontal cortex (E, x400) and (F, x400).  Positive labelling 
for TG in brain tissues were identified as brown colour.  Scale bars = 200µm. 
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Figure 3.11:  Immuno-localisation of TG in bipolar human brain limbic neurons 
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Figure 3.11 legend:  Immuno-localisation of TG in bipolar human brain limbic neurons 
Immuno-reactive TG was evident within neuronal cell bodies (red arrows) of the amygdala  
(A and B, x400), cingulate gyrus (C and D, x400) and frontal cortex (E and F, x400) of bipolar brain.  
Neuronal axons and other cerebral structures were devoid of stain.  Positive labelling for TG in brain 
sections were identified as brown colour.  Scale bars = 200µm. 
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(b)  Image Analysis 
Quantification of TG-neuronal staining in the normal group, presented arithmetic mean intensity values 
for the cingulate gyrus (118.20 x102 pixels.µm-2), whilst the frontal cortex (91.90 x102  pixels.µm-2) 
stained to a lesser degree, by approximately 30% (Table 3.5).  Log median (Ln) intensity values obtained 
for this category had a range of -3.23 - 3.05 (Table 3.5).  Specifically, the cingulate gyrus obtained a 
Log mean (Ln) value of 1.25, whilst the frontal cortex was reported to be -3.00.  Inter-group statistical 
comparisons, tested at p < 0.003, demonstrated that the normal hypothalamus was significantly higher 
than all other normal limbic regions except the cingulate gyrus (p = 0.07). 
 
Quantification of the staining intensities in the matched bipolar group, presented arithmetic mean values 
for amygdala (2.33 x102 pixels.µm-2), cingulate gyrus (5.53 x102 pixels.µm-2) and frontal cortex  
(4.73 x102 pixels.µm-2), (Table 3.6).  Further, Log median (Ln) intensity values obtained for this 
category had a range of 0.43 - 0.89 (Table 3.6).  Specifically, the following Log median (Ln) values 
were obtained: Amygdala (0.43), cingulate gyrus (0.79) and frontal cortex (0.89).  Bipolar inter-group 
statistical comparisons tested at p < 0.05 demonstrated that the amygdala was significantly less than the 
frontal cortex (p = 0.0183) but not the cingulate gyrus (p = 0.0876). 
 
(c)  Statistical comparison between normal and bipolar limbic regions 
Intra-group statistical comparisons of neuronal-labelled TG in matched normal versus bipolar brain 
limbic regions, indicates a significant difference in the amygdala groups (p < 0.0001) and in the frontal 
cortex groups (p < 0.001).  In contrast, there was no appreciable difference in TG immuno-localisation 
observed between normal and bipolar cingulate gyrus.   
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Table 3.5:   Quantification of TG neuronal labelling intensity in normal brain limbic regions  
 
TG in normal brain limbic neurons 
 
 
Limbic 
Regions 
Arithmetic Mean Labelling Intensity Log (Ln) Intensity 
Mean 
(pixels.µm2) 
±SEM Log Median (Ln)  p25 p75 
Amygdala 0.10 
118.20 
91.90 
0.20 
145.10 
9.10 
0.02 
56.41 
46.90 
0.10 
52.62 
3.77 
-2.52¥ 
1.25 
-3.00¥ 
-3.23¥ 
3.05 
-1.72¥ 
-3.72 -1.85 
Cingulate gyrus -1.81 5.02 
Frontal cortex -3.18 0.43 
Hippocampus -3.50 -2.67 
Hypothalamus  1.84 4.71 
Thalamus -2.83 0.43 
¥  vs hypothalamus, p < 0.003 
n = 6 limbic regions 
n = 5 normal human brains 
n = 5 fields of view for each specimen 
Inter-quartile range errors:  p25 and p75 
Image analysis:  AnalySIS 5 (Soft Imaging Systems, Germany) 
Statistical comparisons:  STATA Software, v13.1 (StataCorp, USA) 
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Table 3.6:  Quantification of TG neuronal labelling intensity for bipolar brain limbic regions  
 
TG in bipolar brain limbic neurons 
 
 
Limbic 
Regions 
(Bipolar) 
Arithmetic Mean Labelling Intensity Log (Ln) Intensity 
Mean 
(pixels.µm2) 
±SEM Log Median (Ln)  p25 p75 
Amygdala 2.33 
5.53 
4.73 
0.24   0.43* 
0.79 
0.89 
0.21 1.04 
Cingulate gyrus 1.17 0.23 1.54 
Frontal cortex 0.68 0.25 2.04 
* vs frontal cortex, p < 0.05 
n = 5 human bipolar brains 
n = 3 limbic regions 
n = 10 fields of view for each specimen 
Inter-quartile range errors: p25 and p75 
Image analysis:  AnalySIS 5 (Soft Imaging Systems, Germany) 
Statistical comparisons:  STATA Software, v13.1 (StataCorp, USA) 
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3.2  CELLULAR DISTRIBUTION OF TSH-R mRNA BY in-situ RT-PCR 
3.2.1  GAPDH and TSH-R mRNA expression in various human control tissues 
(a)  Observations 
For the optimisation of the in-situ RT-PCR experiments, we used the mRNA expression of the 
ubiquitous control (housekeeping) gene, GAPDH, in various normal human tissues.  Tissue controls for 
these experiments included kidney, thyroid and brain (cingulate gyrus).  The GAPDH mRNA was 
positively localised in all normal human tissue examined (Figure 3.12).  In normal human kidney tissue, 
labelled GAPDH mRNA was observed within the renal tubular epithelial cells of the proximal and distal 
convoluted tubules (Figure 3.12A).  In thyroid tissue, GAPDH mRNA was evident within the thyroid 
follicular cells (Figure 3.12C).  Normal human brain (cingulate gyrus) tissue demonstrated GAPDH 
mRNA within the cytoplasm of neuronal cell bodies (Figure 3.12E).  Methods controls that were 
included for each type of human tissue, by the omission of primers from the PCR reactions, showed no 
localisation of GAPDH mRNA (Figure 3.12B, D and F).   
 
For our target gene, TSH-R, we used normal human control thyroid tissue to demonstrate TSH-R 
mRNA labelling in thyroid follicular cells (Figure 3.13A).   There was no evidence of TSH-R mRNA 
in other thyroidal structures such as the colloid and colloidal vesicles.  Method control for thyroid tissue 
showed absence of TSH-R mRNA in all thyroidal structures when PCR primers were omitted from the 
reactions (Figure 3.13A, inset).   
 
3.2.2  TSH-R gene expression in normal and bipolar brain limbic regions 
(a)  Observations 
In normal cingulate gyrus, positive labelling for TSH-R mRNA expression was observed in neuronal 
cell bodies as well as some axons and dendrites (Figure 3.13E and F). Similarly, normal frontal cortex  
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Figure 3.12:  The distribution of GAPDH mRNA in various normal human tissue by in-situ  
RT-PCR  
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Figure 3.12 legend:  The distribution of GAPDH mRNA in various normal human tissue by  
in-situ RT-PCR  
Examination of normal human kidney tissue, demonstrated GAPDH mRNA within renal tubular 
epithelial cells of the proximal and distal convoluted tubules (A, x400).  Human thyroid tissue showed 
GAPDH mRNA within thyroid follicular cells (C, x400).  Human brain (cingulate gyrus) tissue 
demonstrated GAPDH mRNA within the cytoplasm of neuronal cell bodies (E, x400).  Method controls 
for normal kidney (B), thyroid (D) and cingulate gyrus (F) were devoid of GAPDH mRNA labelling.  
Arrows in A, C, E indicate immuno-localised GAPDH mRNA, due to the blue-black NBT/BCIP 
precipitate.  Scale bars = 200µm.    
Note: due to the colloid in the normal thyroid tissue sample in C, there were multiple focal planes.  The focal 
plane selected in C was optimal for the colloidal epithelial cells, in which the control (housekeeping) gene 
expression for GAPDH was localised. 
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Figure 3.13:  The distribution of TSH-R mRNA in normal human brain limbic areas and normal 
human control thyroid tissue by in-situ RT-PCR 
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Figure 3.13 legend:  The distribution of TSH-R mRNA in normal human brain limbic areas and 
normal human control thyroid tissue by in-situ RT-PCR  
Examination of normal human control thyroid tissue demonstrated TSH-R mRNA labelling in thyroid 
follicular cells (A, x400).   Method control for thyroid tissue showed absence of TSH-R mRNA when 
primers were omitted from the PCR reactions (A, inset, x 400).  In normal limbic areas, intense labelling 
for TSH-R mRNA was detected in neuronal cell bodies (red arrows) in the frontal cortex (B, x400), 
amygdala (C and D, x400) and the cingulate gyrus (E and F, x400).  The frontal cortex (B, x400) and 
cingulate gyrus (E and F, x400) also demonstrated TSH-R in neuronal axons (yellow arrows).  Further, 
TSH-R mRNA was also evident in neuronal dendrites (light blue arrows) of the cingulate gyrus (E and 
F, x400).  Method controls for brain tissue showed absence of TSH-R mRNA label in limbic structures 
(D and F, insets, x400).  Positive labelling for TSH-R mRNA in thyroid and brain tissues were identified 
as blue-black colour indicating the precipitation of the chromogen NBT/BCIP.  Scale bars = 200µm. 
Note: due to the colloid in the normal thyroid tissue sample in A, there were multiple focal planes.  The focal 
plane selected in A was optimal for the colloidal epithelial cells, in which the target gene expression for TSH-R 
was localised. 
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demonstrated TSH-R mRNA in neuronal cell bodies and axons; however, there was no labelling evident 
within dendrites (Figure 3.13B).  In normal amygdala, TSH-R mRNA labelling was confined to 
neuronal cell bodies only (Figure 3.13C and D).  Further, TSH-R mRNA was not identified in cerebral 
vasculature nor in neuronal support cells including oligodendrocytes, astrocytes, neuroglia and satellite 
cells, in any of the normal limbic areas.  Method controls for normal brain tissue showed the absence 
of label for TSH-R mRNA expression in limbic structures, when primers were omitted from the PCR 
reactions (Figure 3.13D and F, insets).   
 
In bipolar brain limbic areas, TSH-R mRNA expression was confined exclusively to neuronal cell 
bodies in the amygdala (Figure 3.14A and B), frontal cortex (Figure 3.14C and D) and cingulate gyrus 
(Figure 3.14E and F).  There was no evidence of TSH-R mRNA in cerebral vasculature nor in neuronal 
support cells including oligodendrocytes, astrocytes, neuroglia and satellite cells, in both normal and 
bipolar limbic areas.  Method controls for brain tissue demonstrated an absence of immuno-localised 
TSH-R mRNA label in limbic structures (Figure 3.14B, D and F, insets, x400).   
 
(b)  Semi-quantitative analysis  
The distribution of the TSH-R mRNA in normal and bipolar experimental groups, by in-situ RT-PCR, 
was semi-quantitatively graded on a scale of 0 to 3 according to (i) visual intensity of labelling, as well 
as (ii) the extent of cellular distribution.  Determinations were performed by two independent observers 
and the mean scores were collated (Table 3.7).  
 
Semi-quantitative analysis of the normal limbic groups indicated intense visual labelling intensity as a 
maximum score of (3) in limbic structures of the frontal cortex, amygdala and cingulate gyrus  
(Table 3.7).  The extent of TSH-R mRNA distribution within these regions ranged from 25-75% in the  
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Figure 3.14:  The distribution of TSH-R mRNA in bipolar human brain limbic areas by in-situ 
RT-PCR 
 
129 
 
Figure 3.14 legend:  The distribution of TSH-R mRNA in bipolar human brain limbic areas by 
in-situ RT-PCR 
Examination of bipolar limbic areas demonstrated a sparse distribution of labelling for TSH-R mRNA 
in neuronal cell bodies (red arrows) of the amygdala (A and B, x400).  Moderate distribution of  
TSH-R mRNA labelling was detected in neuronal cell bodies (red arrows) of the frontal cortex  
(C and D, x400) and cingulate gyrus (E and F, x400).  Method controls for brain tissue showed absence 
of TSH-R mRNA label in limbic structures (B, D and F, insets, x400).  Positive labelling for TSH-R 
mRNA in thyroid and brain tissues were identified as blue-black colour.  Scale bars = 200µm.   
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Table 3.7:  Semi-quantitative comparison of in-situ RT-PCR cellular labelling intensity and extent 
of regional distribution of TSH-R mRNA in normal and bipolar brain limbic regions 
Experimental 
group 
 
Limbic region Cellular 
distribution 
Visual intensity of 
labelling 
Extent of cellular 
labelling 
 
Normal 
Amygdala Neurons 3 3 
Cingulate gyrus Neurons, axons & 
dendrites 
3 2 
Frontal cortex Neurons & axons 3 2 
 
Bipolar 
Amygdala Neurons 1 2 
Cingulate gyrus Neurons 2 3 
Frontal cortex Neurons 2 2 
Determination by 2 independent observers 
 
Semi-quantitative grading scale of TSH-R mRNA distribution in normal and bipolar limbic areas: 
 
(i) Visual intensity of labelling (0) zero labelling 
                        (1) low labelling 
                        (2) moderate labelling 
                        (3) intense labelling 
 
(ii) Extent of cellular labelling (0) no cells stained 
                                                  (1)  < 25% 
                                                  (2)  25-75% 
                                                  (3)  > 75% 
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cingulate gyrus and frontal cortex and > 75% in the amygdala (Table 3.7).  In contrast, the visual 
labelling intensity of TSH-R mRNA distribution in the bipolar experimental groups indicated low 
labelling with a score of (1) in the amygdala, whilst moderate labelling (2) was observed in the frontal 
cortex and cingulate gyrus (Table 3.7).  The extent of cellular distribution in the amygdala and frontal 
cortex were observed to be within 25-75%, whilst the cingulate gyrus demonstrated labelling in > 75% 
of cells (Table 3.7).  In-situ RT-PCR semi-quantitative comparisons between normal and bipolar groups 
therefore indicated an under-expression of the TSH-R mRNA in all bipolar limbic areas examined when 
compared to their matched normal limbic groups.  
 
In other normal limbic areas (non-matched for bipolar disorder) that were examined for the distribution 
of TSH-R mRNA by in-situ RT-PCR.  TSH-R mRNA was detected only in hypothalamic neurons, 
albeit at low labelling intensity (1), (see addendum B1 for this non-matched normal limbic data).  The 
extent of TSH-R distribution in the hypothalamus occurred in < 25% of cells.  There was no evidence 
of TSH-R mRNA labelling in the other areas examined (hippocampus and thalamus).   
 
3.3  REAL-TIME QUANTITATIVE PCR OF TSH-R GENE EXPRESSION 
3.3.1  TSH-R gene expression in normal versus bipolar group 
Statistical analyses for the fold-change in gene expression of our target gene, TSH-R, in the bipolar 
group, relative to the normal control limbic group was determined.  Table 3.8 presents data where the 
target (TSH-R) and reference (GAPDH) genes were amplified in separate wells of a 96-well microtitre 
plate.  Figure 3.15 displays the fold-change of TSH-R gene expression in the normal and bipolar groups.  
The method formulated by Livak and Schmittgen (2001) was used in qPCR calculations to determine 
relative change in expression of the target gene (Livak and Schmittgen, 2001).  The normal (control) 
group was considered to be the reference against which the bipolar regions were measured.  The double 
delta CT (∆∆CT) values obtained from qPCR for each normal control was considered to be zero (0).  
Therefore, calculating 2-∆∆CT for the controls (i.e. 20) gave a value of one (1) for each control (normal)  
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Table 3.8:  RTqPCR data calculations to determine TSH-R gene regulation in bipolar human 
limbic regions 
Limbic 
Regions 
 
Sample 
 Number 
TSH-R CT 
Mean 
GAPDH CT 
Mean 
∆ CT Mean ∆∆CT Fold 
difference 
2-∆∆CT 
Amygdala 
(Normal) 
Calibrator 36.57124 32.92617 3.645073 0 1 
Cingulate 
(Normal) 
Calibrator 9.059217 33.12026 -24.061 0 1 
Frontal 
(Normal) 
Calibrator 28.20495 32.17434 -3.96939 0 1 
 1 36.86412 29.19463 7.669487 4.024414 0.061451 
Amygdala 
(Bipolar) 
2 21.92845 28.8778 -6.94935 -10.5944 1546.11 
3 
4 
35.57757 27.33126 8.246309 4.601236 0.041199 
 36.84208 30.66835 6.173722 2.528649 0.173301 
 5 38.01571 27.30877 10.70695 7.061874 0.007485 
 1 26.54842 30.00072 -3.4523 20.60874 6.25E-07 
Cingulate 2 37.13113 28.3683 8.762827 32.82387 1.32E-10 
(Bipolar) 3 17.77519 26.7646 -8.98942 15.07163 2.9E-05 
 4 36.02329 29.49221 6.531087 30.59213 6.18E-10 
 5 - - - - - 
 1 21.73064 29.60411 -7.87347 -3.90408 14.97081 
Frontal 2 36.86812 28.60583 8.262291 12.23168 0.000208 
(Bipolar) 3 28.72767 25.72587 3.001803 6.97119 0.00797 
 4 35.43441 30.46318 4.971224 8.940611 0.002035 
 5 35.41467 27.38278 8.031889 12.00128 0.000244 
TSH-R:  target gene 
GAPDH:  reference gene 
Calibrator:  normal brain limbic samples were selected as reference samples for these experiments  
- : below the detection threshold limits of the real-time PCR system 
CT : threshold cycle for target amplification 
∆ CT = CT(Target) - CT(Reference) i.e. CT(TSH-R) - CT(GAPDH) 
∆ CT Mean= Mean of (CT(TSH-R) - CT(GAPDH)) 
∆∆CT = ∆ CTsample - ∆ CTcalibrator 
2-∆∆CT: Expression fold-change of the target (TSH-R), normalised to the endogenous reference (GAPDH), and 
relative to the calibrator 
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Figure 3.15:   Log median (Ln) fold-change of TSH-R gene expression in normal versus bipolar 
limbic groups 
 
*  normal vs bipolar, p = 0.05 
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Figure 3.15 legend:  Log median (Ln) fold-change of TSH-R gene expression in normal versus 
bipolar limbic groups 
The Log median (Ln) expression fold-change difference of TSH-R mRNA in normal and bipolar limbic 
groups were determined.  Statistical comparisons demonstrates the down-regulation of TSH-R gene 
expression in the bipolar group when compared to the normal control group.   
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limbic region.  Thus, the resulting ∆∆CT values obtained from qPCR for each of the bipolar limbic 
regions were calculated as a fold-change relative to the control (equal to one).   
 
Therefore, when compared to the normal control group, the expression levels of TSH-R in the bipolar 
limbic region appeared to be down-regulated (Figure 3.15).  Further, statistical comparisons by 
Wilcoxon rank test between normal and bipolar categories, confirmed a significant down-regulation  
(p = 0.05). 
 
3.3.2  Inter-regional and intra-regional differences of TSH-R gene expression in bipolar limbic 
areas 
For gene expression in specific bipolar regions, the fold-change in gene expressions had to be compared 
to the expression in normal tissue (calibrated to 1 as the external control).  Thus, in contrast to  
immuno-histochemistry (section 3.1.2) where inter-group variations could be determined within normal 
and bipolar tissue separately, here the inter-group comparison had to be calibrated for each bipolar 
limbic region against a single combined normal control.  Table 3.9 provides Log median (Ln) 
quantification values for TSH-R expression fold-change differences among all matched bipolar limbic 
areas examined viz. amygdala, cingulate gyrus and frontal cortex.  Log median (Ln) values obtained for 
this category had a range of -2.78951 to -17.7449.   Bipolar inter-group statistical comparisons 
demonstrated a significant difference in the cingulate gyrus group (p = 0.0037) when compared to the 
amygdala (Figure 3.16).  In contrast, none of the other comparisons showed appreciable statistical 
differences.  Thus, these results demonstrate that TSH-R expression is significantly reduced in the 
cingulate gyrus when compared to the other two limbic groups.    In addition, we obtained intra-group 
comparisons in all individual normal and bipolar limbic groups (Figure 3.16).  Statistical analyses 
demonstrated a down-regulated TSH-R in all bipolar limbic groups when compared to their normal 
control groups.   
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Table 3.9:  Log median (Ln) quantification of TSH-R gene expression fold-change differences in 
bipolar brain limbic areas           
TSH-R mRNA Expression 
 
Limbic Areas 
(Bipolar) 
                                          Log  Fold-change (Ln) 
Log median (Ln) p25 p75 
Amygdala -2.78951* -3.18933 -1.75273 
Cingulate gyrus             -17.7449 -21.9783 -12.3659 
Frontal cortex             -6.19716 -8.31865 -4.83206 
* vs cingulate gyrus, p = 0.0037 
Inter-quartile range errors: p25 and p75 
Fold-change vs normal calibrator sample (=1) 
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Figure 3.16:  Log median (Ln) TSH-R gene expression fold-change differences in bipolar brain 
limbic areas 
.  
*  vs amygdala, cingulate gyrus and frontal cortex, p < 0.05 
¥   vs amygdala, p = 0.0037 
Normal: calibrator samples for amygdala, cingulate gyrus and frontal cortex comparison 
No error bars for individual data since each region is a comparison to the calibrator 
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Figure 3.16 legend:  Log median (Ln) TSH-R gene expression fold-change differences in bipolar 
brain limbic areas 
The Log median (Ln) expression fold-change differences of TSH-R mRNA among all bipolar limbic 
regions were determined.  Bipolar inter-group statistical comparisons demonstrated a significant 
difference in the cingulate gyrus group when compared to the amygdala.  These results illustrate that 
the largest down-regulation of TSH-R gene expression in bipolar limbic regions was observed in the 
cingulate gyrus.  
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Table 3.10:  Overview of the results obtained for TG and TSH-R gene expression and protein localisation in matched normal and bipolar brain limbic 
regions 
 Immuno-histochemistry 
 
in-situ RT-PCR RT-qPCR 
 
Limbic 
region 
TG protein TSH-R protein TSH-R mRNA TSH-R expression 
fold-change 
Cellular location Up-/down-
regulation 
Cellular location Up-/down-
regulation 
Cellular location  Semi-quantitative 
grading 
 
Up-/down-
regulation 
Up-/down-regulation 
Amygdala 
(normal) 
 
Vasculature * 
 - 
Neurons (cell 
bodies)* - 
Neurons (cell 
bodies) 
intense labelling 
> 75% -  - 
Amygdala 
(bipolar) 
Vasculature 
Neurons 
 
 Neurons (cell 
bodies) 
 Neurons (cell 
bodies) 
low labelling 
25-75% 
     * 
 
 Immuno-histochemistry 
 
in-situ RT-PCR RT-qPCR 
 
Limbic 
region 
TG protein TSH-R protein TSH-R mRNA TSH-R expression 
fold-change 
Cellular location Up-/down-
regulation 
Cellular location Up-/down-
regulation 
Cellular location Semi-quantitative 
grading 
 
Up-/down-
regulation 
Up-/down-regulation 
Cingulate 
(normal) 
Vasculature * 
Neurons (cell 
bodies, axons)* 
 
- 
Neurons *(cell 
bodies) - 
Neurons (cell 
bodies, axons, 
dendrites) 
intense labelling 
25-75% -  - 
Cingulate 
(bipolar) 
Vasculature 
Neurons (cell 
bodies) 
 Neurons (cell 
bodies) 
 Neurons (cell 
bodies) 
moderate labelling 
> 75% 
     * 
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 Immuno-histochemistry 
 
in-situ RT-PCR RT-qPCR 
 
Limbic 
region 
TG protein TSH-R protein TSH-R mRNA TSH-R expression 
fold-change 
Cellular location Up-/down-
regulation 
Cellular location Up-/down-
regulation 
Cellular location Semi-quantitative 
grading 
 
Up-/down-
regulation 
Up-/down-regulation 
Frontal 
(normal) 
Vasculature * 
Neurons * (cell 
bodies,  axons) 
 
- 
Neurons * (cell 
bodies) - 
Neurons (cell 
bodies, axons) 
intense labelling 
25-75% -  - 
Frontal 
(bipolar) 
Vasculature 
Neurons (cell 
bodies) 
 
 Neurons (cell 
bodies) 
 Neurons (cell 
bodies) 
moderate labelling 
25-75% 
                      * 
 
     up-regulation of target gene/protein 
     down-regulation of target gene/protein 
*   p < 0.05 
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ADDENDUM (B) 
 
B.1  Semi-quantitative comparison of in-situ RT-PCR labelling intensity and extent of regional 
distribution of TSH-R mRNA in normal limbic regions that were non-matched for bipolar 
disorder  
Experimental 
group 
 
Limbic region Cellular 
distribution 
Visual intensity of 
labelling 
Extent of cellular 
labelling 
 
Normal 
Hippocampus Neurons 0 0 
Hypothalamus Neurons 1 1 
Thalamus Neurons 0 0 
Determination by 2 independent observers 
Semi-quantitative grading scale of TSH-R mRNA distribution in normal limbic areas (non-matched for bipolar 
disorder): 
 
(i) Visual intensity of labelling (0) zero labelling 
                        (1) low labelling 
                        (2) moderate labelling 
                        (3) intense labelling 
 
(ii) Extent of cellular labelling (0) no cells stained 
                                                  (1) < 25% 
                                                  (2) 25-75% 
                                                  (3) > 75% 
 
The results shown in Table B1 of Addendum (B) are for the normal limbic regions that could not be matched with 
commercial bipolar tissue.  However, we have included these results should there be any future project that is 
able to do a comparative assessment with bipolar tissue 
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CHAPTER 4 
Discussion  
 
 
 
 
 
 
 
 
 
 
143 
 
Following extensive review of the literature, we report for the first time the expression and cellular 
distribution of thyroid-specific proteins specifically in the limbic regions of normal and bipolar human 
adult brains.  The aim of our study was to determine whether our previous pilot findings of TG and 
TSH-R on other areas of normal brain could be reflected in normal human adult limbic brain at the 
protein level as well as a molecular level.  Further, we aim to determine whether increased or decreased 
thyroid-specific protein expression in limbic brain is specific for bipolar disorder.   
 
Interestingly, our comparisons obtained from protein chemistry methods indicates a significant 
reduction of both TSH-R and TG in limbic regions of bipolar subjects when compared to our 
observations in normal brain.  In addition, molecular methods including in-situ RT-PCR and RTqPCR 
were also employed to confirm the down-regulation of TSH-R gene expression in the bipolar state.  
Immuno-reactive TSH-R mRNA and protein was detectable in the large neurons in all matched normal 
and bipolar brain limbic regions examined.  Our findings of TSH-R in human brain tissue is consistent 
with the work of Prummel and colleagues (2000), who immuno-detected TSH-R proteins in  
folliculo-stellate cells of human anterior pituitary tissue (Prummel et al., 2000).  Those authors 
postulated that the expression of TSH-R in the anterior pituitary gland may provide a short-loop 
regulatory function within the HPT axis, by modulating TSH secretion at the pituitary level.  In the 
present study, we also demonstrate TSH-R in normal human hypothalamus, albeit at a lower 
concentration.  Although, the scope of our investigation did not extrapolate to TSH-R localisation within 
the HPT axis, our observations of TSH-R in hypothalamus is consistent with the findings of Bockmann 
(1997), Crisanti (2001) and Bolborea (2015), (Bockmann et al., 1997, Crisanti et al., 2001,  
Bolborea et al., 2015).  The Crisanti group identified TSH-R in hypothalamic neurons of rat brain, 
whilst the Bolborea group reported TSH-R gene expression in tanycytes of rat hypothalamus.  The 
Bockmann group confirmed the expression of TSH-R in sheep hypothalamus.  More specifically, we 
identified TSH-R in human neurons and these observations correlate with Crisanti’s reports of TSH-R 
mRNA in a rodent neuronal cell model (Crisanti et al., 2001).  Interestingly, neurons are a primary 
target of thyroid hormones, specifically T3, and the effects of thyroid hormones are exerted mainly by 
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regulation of gene expression following T3 binding to thyroid hormone nuclear receptors expressed in 
rodent brain neuronal cells as well as human cultured neurons (Freitas et al., 2010).  In addition, the 
Crisanti group (2001) also identified TSH-R in human primary cultured astrocytes  
(Crisanti et al., 2001).  In contrast, our observations do not include TSH-R in astrocytes or any other 
neuronal support cells of human limbic tissue.  However, our observations did demonstrate an absence 
of TSH-R in astrocytes which are consistent with the findings of Carlson (1994) and Munoz (1991) 
(Munoz et al., 1991, Carlson et al., 1994).  The Carlson group (1994) demonstrated the  
immuno-fluorescent localisation of thyroid hormone receptors in neurons (and oligodendrocytes) in rat 
brain, but not in astrocytes.  In addition, the Munoz group (1991) suggested that astrocytes may not be 
a target of thyroid hormones since the alteration of astrocyte-specific genes, due to changes in thyroidal 
status, were not observed.  Moreover, Carlson and colleagues (1994) suggested that any effect the 
thyroid hormones may have on astrocyte structure and function may be indirectly mediated by  
thyroid-hormone interaction with receptors expressed on non-astrocytic cells, or the result of  
non-nuclear mechanisms (Carlson et al., 1994). 
 
We detected TG-like proteins in neuronal cell bodies and axons of the cingulate gyrus and some neurons 
of the frontal cortex in normal brain.  Similarly, the bipolar cingulate gyrus and frontal cortex groups 
also demonstrated TG-like proteins in neurons.  However, in contrast to our observations for normal 
amygdala, the bipolar amygdala group showed evident neuronal labelling for TG-like proteins.  
Interestingly, structural and functional neuro-imaging studies associates bipolar disorder with increased 
amygdala volume (Phillips et al., 2003, Strakowski et al., 2005) and elevated activity in the amygdala, 
respectively (Kruger et al., 2003, Chang et al., 2004, Lawrence et al., 2004).  Our findings of TG-like 
proteins exclusive to bipolar amygdala neurons, is suggestive of an increase in amygdala content when 
compared to normal amygdala.  Further, it is reasonable to speculate that the presence of TG-like 
proteins specifically in amygdala neurons of bipolar brain may alter neuronal transmission and 
functioning, thereby contributing to a hyperactive amygdala in bipolar subjects. Interestingly, 
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Miklowitz and Johnson (2006) suggest that elevated amygdala activity may contribute to emotional 
sensitivity, and these are clinical features of bipolar disorder (Miklowitz and Johnson, 2006). 
 
Other novel findings in the present study includes TG-like proteins within the cerebral vasculature of 
all limbic areas in both, normal and bipolar groups.  Specifically, immuno-reactive TG was localised to 
the smooth muscle cells of the tunica media and tunica adventitia of cerebral vasculature; however, 
quantification of TG-staining intensity in cerebral vasculature indicated a significant reduction in the 
bipolar groups compared with the normal groups.  Our observations of TG-like proteins in smooth 
muscle of cerebral vasculature is supported by the work of Ojamaa and colleagues (1996) where those 
authors described the effects of thyroid hormones on vascular smooth muscle cells of rat aorta  
(Ojamaa et al., 1996).  Specifically, they reported on the vasodilatory effects of T3 when it acts directly 
on vascular smooth muscle cells in vitro to cause rapid relaxation of coronary arteries.  Similarly, 
Mizuma and colleagues (2001) demonstrated the local T3 production by DII activation in human 
vascular smooth muscle cells (Mizuma et al., 2001).  Further, the significant role of mammalian thyroid 
hormones in the development, homeostasis and regeneration of skeletal muscle has been  
well-documented (Ramsay 1966, Nwoye et al., 1982, Yu et al., 2000, Clement et al., 2002,  
Udayakumar et al., 2005, Brent, 2012).  In addition, muscular alterations that occur secondary to thyroid 
dysfunction (including hypo-thyroidism and hyper-thyroidism) has been described previously, further 
illustrating the important role of thyroid hormones in mammalian muscle physiology (Ramsay, 1966,  
Nwoye et al., 1982, Yu et al., 2000, Clement et al., 2002, Udayakumar et al., 2005, Brent, 2012). 
 
Our findings of TG-like proteins in cerebral vasculature of human brain together with our postulate that 
circulating anti-thyroid antibodies may bind limbic targets during AITD, suggests the migratory 
potential of these proteins across the seemingly-impervious BBB.  In the recent past, there has been 
much controversy generated around the findings of non-CNS proteins and enzymes in brain areas, thus, 
appearing to breach the seemingly-impervious BBB.  Our study has also faced some criticism with 
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regards to the presence of thyroid-associated proteins in the human limbic system.  Thus, we provide in 
the following paragraphs a detailed description of numerous studies that demonstrate translocation of 
non-CNS agents via the BBB.  Multiple modes of egress beyond the BBB have been described, whereby 
the integrity of the BBB may be altered during neuro-pathological diseases including Alzheimer’s 
disease, HIV-associated dementia, multiple sclerosis, and bipolar disorder  
(Lou et al., 1997, Minagar et al., 2002, Patel and Frey, 2015).  Alteration of the protective BBB increases 
its permeability to leukocytes and other circulating compounds.  The consequential influx of leukocytes 
triggers signal transduction mechanisms that facilitate the loss of tight junction proteins that constitute 
the highly specialised cerebral endothelium of the BBB (Bolton et al., 1998).  Normally, the BBB 
restricts the entry of endogenous IgG from plasma, as well as exogenously-administered monoclonal 
antibodies (Rojko and Price-Schiavi, 2008).  However, one study by Terasaki and Ohtsuki (2005), 
reported that the BBB can be breached by endogenous IgG and some larger hydrophilic molecules by 
the brain-to-blood transport mechanism (Terasaki and Ohtsuki, 2005).  Their proposed mechanism 
involves several transporters that are located within the brain capillary endothelial cells of the BBB 
whose function is to reduce accumulating levels of hydrophilic endogenous molecules generated within 
the brain.  More recently, the translocation of large macromolecules such as amyloid-β protein into 
mice CNS has also been described (Bu et al., 2017), whereby it induces Alzheimer’s disease-related 
pathologies.   
 
Further evidence of BBB breach occurs via transferrin receptor molecules that are expressed in high 
concentration by brain capillary endothelial cells of the BBB, and which can be targeted by specific 
monoclonal antibodies, as described in a rat model (Pardridge et al., 1991).  It is thought that these  
anti-transferrin antibodies could function as potential drug transport vectors across the BBB and into 
the CNS.  The process of cellular uptake of antibodies into the brain is known as receptor-mediated 
transcytosis.  Moreover, St-Amour and co-workers (2013) reported the migration of up to 0.1% of 
peripherally-administered IgG into mice brain parenchyma (St-Amour et al., 2013).  Further reports 
indicate that antibodies traverse the BBB by penetrating the CSF and then progressing through the 
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ventricular circulation to reside in brain parenchymal regions (Berer et al., 2011,  
Saunders et al., 2012).  Lastly, whilst the BBB is known to protect brain parenchymal regions, it is 
unable to protect the meningeal tissue, since the meninges lack a barrier (Bard et al., 2000).  Thus, there 
appears to be an accumulation of evidence that illustrate the probability of antibodies such as those in 
AITD crossing the BBB and affecting various cerebral regions. 
 
There are reports that suggest an association between BBB disruption and bipolar disorder  
(Patel and Frey, 2015), and these interactions bear relevance to the present study.  Similar to the major 
neuro-psychiatric disorders, bipolar disorder also involves inflammatory processes.  Several reports also 
suggest an association between bipolar disorder and increased inflammation as well as oxidative stress 
(Patel and Frey, 2015).  Increased neuro-inflammation is believed to facilitate cognitive decline as well 
as gray and white-matter abnormalities in bipolar patients (Patel and Frey, 2015).  Studies have 
demonstrated increased levels of pro-inflammatory cytokines (such as IL-1, IL-6 and TNFα) in plasma 
(Stertz et al., 2013, Haarman et al., 2014) and an abnormal expression of pro-inflammatory genes in 
circulating monocytes (Padmos et al., 2008).  In addition, psychotropic agents have been shown to have 
modulatory effects on the immune system (Drzyzga et al., 2006, Haarman et al., 2014).  Further, 
“activation of the immune system is linked with neuro-inflammation through activation of microglia 
which is a central player in neuro-inflammatory pathways” (Patel and Frey, 2015).  It has also been 
demonstrated that neuro-inflammation is linked with increased microglial activity within the 
hippocampal brain regions of bipolar patients (Stertz et al., 2013).  In addition, decreased expression of 
growth-associated proteins as well as oxidative damage to RNA have roles in neuro-inflammation and 
interestingly, these have been observed in the hippocampal regions of bipolar patients (Kato et al., 2003, 
Tian et al., 2007, Che et al., 2010).  The oxidative stress reported in bipolar disorder is thought to be 
due to mitochondrial alterations (Scola et al., 2013) as well as the increased levels of circulating markers 
of oxidative damage to lipids, RNA and DNA in bipolar patients (Andreazza et al., 2008,  
Brown et al., 2014).   
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Interestingly in bipolar disorder research, there is growing evidence that available treatment such as 
mood-stabilising and anti-depressant agents may reverse or prevent the effects of inflammation and 
oxidative stress (Patel and Frey, 2015).  Lithium has been shown to protect against the effects of 
oxidative stress and reactive oxygen species (ROS)-induced damage, thus preserving the BBB integrity 
(Gonzalez-Mariscal et al., 2008, Maurer et al., 2009, Cummins, 2012, Lochhead et al., 2012).  Further, 
chronic lithium treatment down-regulates the arachidonic acid-prostaglandins pathway  
(Murphy et al., 1973, Karmazyn et al., 1978) which has implications in neuro-inflammation  
(Chang et al., 1996, Rao et al., 2008).  In addition, several other studies have demonstrated how lithium 
treatment significantly increased the levels of anti-inflammatory cytokines (Sztein et al., 1987, Kucharz 
et al., 1993, Rapaport et al., 1999, Ballanger et al., 2008, Tay et al., 2012, Agrawal et al., 2013), whilst 
attenuating levels of pro-inflammatory cytokines (Boufidou et al., 2004, Beurel and Jope, 2009, Wang 
et al., 2009, Zhang et al., 2009, Tan et al., 2010, Green and Nolan, 2012, Rowse et al., 2012, Tay et al., 
2012, Agrawal et al., 2013, Chen et al., 2013, Himmerich et al., 2013, Wang et al, 2013).   
 
There does appear to be a strong link between oligodendrocyte dysfunction with accompanying myelin 
damage in bipolar disorder. Studies have also demonstrated alterations in oligodendrocyte structure and 
function in bipolar disorder (Patel and Frey, 2015).  “Oligodendrocytes facilitates the formation and 
stability of neural circuits by insulating axons with myelin sheath” (Patel and Frey, 2015).  The  
down-regulation of oligodendrocyte-specific markers were reported in the brain of bipolar subjects  
(Konradi et al., 2012).  In addition, Uranova and colleagues (2001) demonstrated possible apoptosis 
and necrosis of oligodendrocyte cells in prefrontal cortical areas of bipolar patients  
(Uranova et al., 2001).  Previously these authors had reported decreased levels in oligodendrocyte 
density within layer VI of bipolar patients thus further implicating the disruption of oligodendrocytes 
in the pathophysiology of bipolar disorder (Orlovskaya et al., 2000).  In addition, several other studies 
have demonstrated myelin abnormalities in bipolar subjects (Aston et al., 2005, Sokolov, 2007,  
Heng et al., 2010, Herring and Konradi, 2011, Konradi et al., 2012).   
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In summary, increased peripheral inflammation, oxidative stress as well as white matter and 
oligodendrocyte alterations have been implicated in the pathogenesis of bipolar disorder  
(Patel and Frey, 2015).  Further, treatment for bipolar disorder such as lithium has been shown to 
modulate the effects of inflammatory and oxidative stress pathways (Patel and Frey, 2015).  Recent 
neuro-imaging and post-mortem studies have reported increased neuro-inflammation during bipolar 
disorder through elevated microglial activation (Patel and Frey, 2015).  The microglia along with other 
neuronal support cells, i.e. oligodendrocytes and astrocytes lie in close proximity to the BBB.  Taking 
this into consideration along with expanding reports suggesting BBB disruption in various other  
neuro-psychiatric conditions, Patel and Frey (2015) have proposed a novel model that depicts BBB 
disruption with consequent permeability increase in bipolar disorder (Figure 4.1),  
(Patel and Frey, 2015). 
 
It appears that BBB disturbance can occur during various neuro-pathological conditions including 
bipolar disorder, and this supports our present postulate that circulating auto-antibodies (as well as  
TG-like proteins) gain ingress into the CNS to bind brain limbic targets.  The Patel and Frey (2015) 
model suggests that loss of BBB integrity (transient or persistent) may lead to an influx of  
pro-inflammatory molecules such as cytokines and ROS from the peripheral blood into the brain. This 
influx will trigger the activation of localised microglial cells which together with ROS would promote 
neuro-inflammatory processes, by inducing damage to nearby oligodendrocytes and the resulting 
myelin sheath, thereby compromising myelination and the integrity of the neural circuit.   
 
A study by Rybakowski and colleagues (2013), provides support for the proposed model in bipolar 
disorder, where those authors report increased levels of matrix metalloproteinase-9 (MMP9), which 
promotes increased BBB permeability during bipolar depression, by aiding proteolysis of the basal 
lamina, tight junctions and extracellular matrix that constitute the protective BBB  
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Figure 4.1:  Novel model depicting BBB disruption in bipolar disorder.  Adapted from Patel and 
Frey (2015) 
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Figure 4.1 legend:  Novel model depicting BBB disruption in bipolar disorder 
The loss of BBB integrity in bipolar disorder, may increase the permeability of BBB to circulating 
inflammatory molecules such as cytokines and ROS, into the brain.  This influx will activate nearby 
microglial cells thus facilitating neuro-inflammatory processes by inducing localised oligodendrocyte 
damage and thereby compromising the process of myelination. 
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(Rybakowski et al., 2013).  Further, Goldstein and colleagues (2009) report increased levels of  
pro-inflammatory cytokines during the manic and depressive episodes, thereby suggesting increased 
BBB permeability during these major episodes in bipolar patients (Goldstein et al., 2009).  
 
It is well-documented that thyroid hormones (T3 and T4) mediate their effects in the CNS by binding to 
thyroid hormone receptors that are widely distributed within predominant cell types of the mammalian 
CNS including neurons, astrocytes and oligodendrocytes (Mellstrom et al., 1991, Strait et al., 1991, 
Bradley et al., 1992, Carlson et al., 1994, Carlson et al., 1996, Strait et al., 1997, Carre et al., 1998,  
Ahmed et al., 2008).  There are two major CNS isoforms of thyroid hormone receptors, viz. TRα1 and 
TRβ1 (Chan and Privalsky, 2009, Shroeder and Privalsky, 2014).  Whilst TRα1 is expressed during 
early embryonic development and thereafter widely distributed in the adult brain, in contrast, TRβ1 
occurs in the latter stages of embryonic development and demonstrates restricted-tissue expression in 
the adult brain (Calvo et al., 1990, Murata, 1998, Forrest and Vennstrom, 2000, Zhang and Lazar, 2000, 
Wondisford, 2003, Cheng, 2005, Chatonnet et al., 2013).  Functionally, thyroid hormones have critical 
roles in mammalian foetal and post-natal brain development and maturation whereby they affect 
neuronal processing and integration, myelination, proliferation of glial cells, and the synthesis of 
important enzymes essential for neurotransmission (Porterfield and Hendrich, 1993, Bernal and Nunez, 
1995, Morreale de Escobar et al., 2004, Wallis et al., 2010).  In the developing brain, thyroid hormones 
are also involved in the regulation of energy metabolism (Bernal and Nunez et al., 1995).  Severe thyroid 
hormone deficiency during the early developmental stages is associated with structural and functional 
abnormalities that results in various neurological and behavioural impairments including cretinism 
(Bernal and Nunez et al., 1995).  In the adult mammalian brain, thyroid hormones have been reported 
to regulate energy metabolism (Lindvall-Axelssonm et al., 1985, Atterwill and Collins, 1987,  
St Germain and Galton, 1997) and influence gene expression (Ceccatelli et al., 1992, Giordano et al., 
1992, Iniguez et al., 1992).  Further, in adults, altered thyroidal status appears to correlate with various 
neurological and behavioural conditions which can then be corrected with proper circulating thyroid 
hormone adjustment (Krishnan, 2005, Whybrow and Bauer, 2005a, Whybrow and Bauer, 2005b, 
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Bernal, 2007).  It has also been reported that circulating thyroid hormone levels decrease as a function 
of age in humans (Chakraborti et al., 1999, Hertoghe, 2005) and rodents (Cao et al., 2012).  
Interestingly, neurogenesis is also known to decrease with age (Enwere et al., 2004, Gould et al., 1999, 
Kuhn et al., 1996) and this has been attributed to the vital role of thyroid hormones in adult neurogenesis 
(Lemkine et al., 2005).  Therefore, decreasing age-related thyroid hormone levels with a consequent 
reduction in neurogenesis may be associated with adverse cognitive effects reported in adults  
(Flamant et al., 2015).  Thus, the importance of thyroid hormones, T3 and T4, in mammalian CNS during 
various life stages is well-established.  It is important to bear in mind that our commercial bipolar 
samples were obtained from older individuals than the normal controls.  This may influence the 
functional capacity of circulating thyroid levels in bipolar individuals.  In the current project, however, 
we chose to consider age-related physiological endocrine function separate from the influence on 
neuropathology such as in bipolar-related AITD since the focus of the project was the co-incidence of 
thyroid-related factors in this disease rather than the regulation associated with changes in endocrine 
levels.   In the present study, we demonstrate thyroid-related proteins, TSH-R and TG in limbic 
structures of normal human adult brain (Naicker and Naidoo, 2017). Limbic-derived TSH-R/TG may 
provide an alternate neuro-physiological purpose, specifically related to mood control.  In addition, we 
provide evidence demonstrating down-regulated TSH-R and TG protein expression in matched bipolar 
limbic regions.  Thus, we may indeed speculate that a reduced expression of TSH-R and TG in limbic 
structures (e.g. neurons) will result in reduced thyroid function in the adult brain, which may then 
predispose or exhibit some involvement in the pathophysiology of mood dysregulation.  In the 
following paragraphs we provide a detailed description of previous studies that suggest potential neuro-
functional roles of TSH-R and how these correlate with our present findings.  
 
In the thyroid gland, the TSH-R is located on the basolateral surface of thyroid follicular cells and is 
regulated by TSH that is secreted by the thyrotropes of the anterior pituitary gland, thereby functioning 
as the main pituitary regulator of thyroid hormone synthesis (Landek and Caturegli, 2009).  TSH binds 
to, and agonises TSH-R causing an increase in intracellular cAMP followed by the stimulation of 
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secondary messenger systems for the synthesis of thyroid hormones, T3 and T4.  Our findings of TSH-
R expression in limbic structures suggests that TSH does not only serve as a hormonal messenger for 
the thyroid gland, but may also have a neuro-functional role in human limbic brain.  We speculate that 
TSH may act directly on limbic components by first binding TSH-R (we were the first to report TSH-
R in limbic neurons, Naicker and Naidoo, 2017).  Similarly, as described in thyroid physiology, the 
interaction between TSH and TSH-R may stimulate intra-cellular signalling  
(Landek and Caturegli, 2009); however, the precise role of TSH in human limbic brain remains 
unknown.  We can further speculate that the presence of functional TSH-R in limbic brain could provide 
an additional short-loop feedback mechanism on the neuro-endocrine control of the thyroid gland; 
hence, the regulation of thyroid hormone synthesis.  Our postulate does not appear to be so far-fetched 
if one considers other seemingly-improbable theories.  One such is the potential role of brain-derived 
TSH-R which was proposed by Hosaka and co-workers (1992) where those authors related the increase 
in GLUT1 glucose transporter mRNA, along with an increase in GLUT1 protein and 2-deoxyglucose 
transport activity, to the interaction between TSH and TSH-R on cAMP dependent pathways  
(Hosaka et al., 1992).  Further, Morgello and co-workers (1995) performed electron-microscopy studies 
to localise GLUT1 to the CNS endothelium and in astrocytes that constitute the BBB of gray matter in 
humans and monkeys (Morgello et al., 1995).  The site of location of GLUT1 suggests its involvement 
in glucose and glucose metabolite transport to astrocytic and neuronal areas.  Thus, there appears to be 
evidence that supports the work of the Hosaka group (1992) that proposes a direct role of TSH in the 
regulation and facilitation of glucose uptake into brain cells, where glucose is an important source of 
energy (Hosaka et al., 1992).  Our present study results demonstrate a significant reduction of TSH-R 
in limbic neurons of bipolar brain.  We can, therefore, speculate that a reduced expression of TSH-R in 
limbic neurons will likely result in a decreased ligand-receptor interaction and this may have a direct 
effect on the uptake of glucose for utilisation by neuronal cells, thereby contributing to altered neuronal 
functioning within the mood-regulatory centres of the human brain.  Altered neuronal functioning in 
mood control regions may be associated with disturbed mood in these patients.  Interestingly, this 
correlates with previous reports describing neuro-inflammation due to microglial alterations in 
depressed and suicidal bipolar subjects, where microglial alterations may lead to reduced glucose uptake 
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and metabolism, thus directly effecting normal neuronal functioning in these patients  
(Ongur et al., 1998, Cotter et al., 2002, Steiner et al., 2008, Holmes et al., 2017). 
 
An alternative clinically-related school of thought is that the presence of TSH-R in limbic brain may 
provide an extra-thyroidal target for auto-immunity.  The evidence is particularly convincing when one 
considers the paradigms resulting from the following studies:  Patients with AITD display  
immuno-reactivity directed against thyroid factors such as TSH-R, TG and TPO, and can present as 
either hyper-thyroidism or hypo-thyroidism (Davies et al., 2002, Ai et al., 2003, Parvathaneni et al., 
2012). During hyper-thyroidism (Grave’s disease), stimulatory-type anti-thyroid antibodies bind to 
TSH-R causing an over-activity of the thyroid gland resulting in the classical goiter presentation  
(Davies et al., 2002, Szkudlinski et al., 2002, Ai et al., 2003).  In contrast, the inhibitory-type  
anti-thyroid antibodies bind to TSH-R in hypo-thyroidism (Hashimoto’s disease), causing cell-mediated 
destruction of thyroid follicular cells thus resulting in thyroid follicle atrophy.  As a result, this leads to 
reduced TSH-R, TG, TPO, with a compensatory rise in TSH, a classical hallmark for clinical  
hypo-thyroidism (Ai et al., 2003, Jameson and Weetman, 2005).  Similarly, we can speculate that during 
AITD, especially in Hashimoto’s disease (the most common form of hypo-thyroidism), inhibitory-type 
auto-antibodies may recognise and agonise TSH-R expressed in limbic neurons.  This interaction may 
well lead to cell-mediated destruction or inactivation of limbic neurons with a consequential reduction 
in the levels of expressed TSH-R.  Interestingly, in the present study, we report the reduced expression 
of TSH-R in limbic neurons of bipolar brains.  It is therefore possible that a loss of limbic neurons or 
diminished neuronal activity in limbic regions (due to thyroid auto-immunity such as in Hashimoto’s 
disease) may indeed contribute towards the development of symptoms of mood dysregulation as 
observed in bipolar disorder (Figure 4.2).  Alternatively, the consequential loss of TSH-R (i.e. loss of 
localised thyroid function), due to limbic neuronal damage, will result in decreased ligand-receptor 
interaction.  As discussed in the previous paragraph, this decreased ligand-receptor interaction may lead 
to reduced glucose uptake into limbic brain cells, thus depriving limbic regions of an energy source and 
creating an imbalance affecting mood regulation.  
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Figure 4.2:  Overview of how the study postulate relates to the results 
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Figure 4.2 legend:  Overview of how the study postulate relates to the results 
The expression of thyroid-specific proteins, associated with Hashimoto’s disease, in limbic neurons of 
human bipolar brain provides an extra-thyroidal target for auto-immunity.  The abnormal association 
between inhibitory-type auto-antibodies and thyroid-specific receptors may inactivate or destroy limbic 
neurons with consequential reduction of limbic-derived TSH-R.  Both, loss of normal neuronal 
functioning and decreased TSH-TSH-R interaction in limbic regions, may predispose to mood 
dysregulation and bipolar disorder.   
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Interestingly, intra-group comparisons obtained for normal and bipolar limbic brain in the present study, 
demonstrate a significant down-regulated expression of thyroid proteins (TSH-R and TG) in all bipolar 
limbic areas.  This reduction of thyroid factors in bipolar brain suggests that these thyroid-specific 
proteins may exhibit a much greater role in neuro-physiology in addition to its primary role in the 
regulation of the synthesis of thyroid hormones (T4 and T3) in the thyroid gland.  Since the limbic brain 
is responsible for mood and behaviour control, we postulate that a significant reduction of thyroid 
protein concentration in human limbic brain may be associated with developing symptoms of mood 
dysregulation (i.e. depression and/or mania), the classical manifestations of bipolar disorder.  Our 
present findings therefore implicate a significant, yet unknown role of the thyroid system and thyroid 
auto-immunity in the development of bipolar disorder.  
 
There are some other theories that also support an association between bipolar disorder and  
anti-thyroid antibodies:  Firstly, the anti-thyroid antibodies may present initially as a marker for  
sub-clinical hypo-thyroidism and may predispose patients to specific types of bipolar disorder  
(Haggerty et al., 1997).  Cowdry (1983) and Bauer (1990a) have reported increased prevalences of  
sub-clinical and overt hypo-thyroidism in patients with the rapid-cycling type of bipolar disorder 
(Cowdry et al., 1983, Bauer et al., 1990a).  However, the mechanism by which these patients develop 
bipolar disorder is unclear.  Secondly, an association may exist “between the predisposition to bipolar 
disorder and the predisposition to thyroid auto-immunity” (Haggerty et al., 1997).  This arises from 
evidence that bipolar disorder has been previously associated with other auto-immune diseases 
including multiple sclerosis (Schiffer et al., 1988, Haggerty et al., 1997).  Thirdly, a linked 
predisposition together with the effects of a thyroid hormone deficit could determine the clinical course 
of the bipolar disorder.  Thus, bipolar disorder may predispose to auto-immunity, and those patients 
that develop a thyroid auto-immune disorder will most likely display a gradual decline in thyroid 
function.  This low thyroid capacity could influence whether the bipolar patient develops predominantly 
depressed or mixed symptoms (Haggerty et al., 1997).   
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Bipolar disorder is not considered to be a disease caused by neuro-degeneration. Unlike conventional 
neuro-degenerative disorders which are characterised by both neuronal loss as well as glial cell 
pathology, the clinical manifestations of bipolar disorder are mainly attributed to glial cell abnormalities 
rather than neuronal pathology (Muneer et al., 2016).  However, several reports from neuro-imaging 
studies provide evidence of both structural (Rajkowska et al., 2001, Lopez-Larsen et al., 2002,  
Phillips et al., 2003, DelBello et al., 2004, Lochhead et al., 2004, Lyoo et al., 2004,  
Strakowski et al., 2005, Abe et al., 2015) and functional  (Kruger et al., 2003, Chang et al., 2004, 
Lawrence et al., 2004, Lennox et al., 2004, Mayberg et al., 2004, Townsend et al., 2013) abnormalities 
in key limbic regions of bipolar subjects (discussed in greater detail in subsequent paragraphs),  
(Figure 4.3).  In parallel with neuro-imaging reports, biochemical studies have reported neuronal 
alterations in limbic regions of bipolar subjects by investigating important neuronal metabolic marker 
measurements that indicate neuronal loss or dysfunction during bipolar disorder (Moore et al., 2000, 
Winsberg et al., 2000, Cecil et al., 2002).  Altogether, these various findings (discussed in greater detail 
below) suggest degeneration within key limbic regions and this may be associated with clinical 
symptoms of bipolar disorder.  Interestingly, our findings of a down-regulated expression of TSH-R 
and TG in major limbic regions of human bipolar brain correlates with neuro-imaging reports that 
associates bipolar disorder with both structural and functional alterations to these specific brain regions 
that are important in regulating emotion (Figure 4.3).  Moreover, we have also localised this reduction 
of thyroid proteins in neurons.  Further, we suggest the possibility of a yet unknown neuro-physiological 
role of thyroid-specific proteins in limbic regions of normal human brain (Naicker and Naidoo, 2017).  
Thus, it is reasonable to assume that reduction of thyroid-specific proteins in limbic neurons affects 
normal neuronal functioning in limbic brain which may predispose to mood disturbance (Figure 4.3).    
 
An important finding in several functional imaging studies in bipolar disorder demonstrates elevated 
activity in the amygdala (Kruger et al., 2003, Chang et al., 2004, Lawrence et al., 2004).  The amygdala 
is “a key brain structure involved in identifying the significance of emotionally relevant stimuli of both 
negative and positive valence” (Miklowitz and Johnson, 2006).  Hence, amygdala hyperactivity appears 
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Figure 4.3:  Evidence of degeneration of limbic structures in bipolar disorder 
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Figure 4.3 legend:  Evidence of degeneration of limbic structures in bipolar disorder 
Structural, functional and histological neuro-imaging studies provide evidence that suggest  
neuro-degeneration within major limbic regions of bipolar brain (black font).  Other biochemical studies 
indicate neuronal alterations in bipolar disorder by specific neuronal marker determinations  
(green font).  The present study also suggests neuronal alterations indicated by reduced levels of 
expressed thyroid-specific protein receptors in bipolar limbic neurons (blue font).  Further, present 
study findings correlate with structural and functional imaging studies (blue font). Altogether, these 
various study findings indicate that bipolar disorder may be associated with neuro-degeneration in key 
limbic regions (red font). 
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to be associated with enhanced emotional sensitivity.   Interestingly, whilst we did not observe TG-like 
protein in limbic neurons of normal amygdala in the current study, we did find evidence of TG-like 
proteins in neurons in the bipolar amygdala group.  The current study did not include  
neuro-physiological studies; however, we may speculate that the presence of TG-like proteins in bipolar 
limbic neurons may alter normal neuronal functioning. 
 
Other interesting functional observations in limbic regions of bipolar subjects include the decreased 
neuro-physiological activity of the hippocampus and prefrontal cortex (Kruger et al., 2003), whilst 
decreased activity in the anterior cingulate was reported in clinically-depressed patients  
(Mayberg et al., 2004).  It has been suggested that the decreased activity of these cortico-limbic regions 
hinders “effective planning and goal pursuit in relation to emotion, thus resulting in a reduced capacity 
to regulate emotion” (Miklowitz and Johnson, 2006).  This, then, allows us to speculate that our findings 
of reduced TSH-R/TG protein expression in cortico-limbic neurons of bipolar brain, may be a 
contributing factor for the decreased neuro-physiological activity within limbic regions in bipolar 
disorder.  Our speculation is based on reports indicating neurons as a primary target for thyroid 
hormones, specifically T3, (Freitas et al., 2010) and that the effects of thyroid hormones are exerted 
mainly by regulation of gene expression following binding to thyroid hormone receptors that are widely 
expressed in neurons, as well as astrocytes and oligodendrocytes of mammalian CNS  
(Mellstrom et al., 1991, Strait et al., 1991, Bradley et al., 1992, Carlson et al., 1994, Carlson et al., 1996, 
Strait et al., 1997, Carre et al., 1998, Ahmed et al., 2008).   
 
Curiously, the neural activity in limbic regions appears to alter according to “episode status” in bipolar 
disorder (Lennox et al., 2004).  In fact, during the manic phase of bipolar disorder, patients demonstrate 
a decreased reactivity to negative stimuli when compared with healthy or euthymic control subjects 
(Lennox et al., 2004).  In that study, the authors identified decreased activation of the amygdala and 
subgenul anterior cingulate in manic subjects.  Hence, it appears that during manic episodes, the level 
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of activity in limbic regions that is responsible for identifying negative stimuli and then regulating 
appropriate responses, becomes reduced (Lennox et al., 2004).  A more recent neuro-imaging study by 
Abe and co-workers (2015) correlated decreased cortico-frontal volume with the manic phase of bipolar 
disorder (Abe et al., 2015).  Moreover, neuro-imaging studies by Townsend and co-workers (2013) 
investigating the functioning of the neural network during down-regulated emotion in euthymic bipolar 
subjects demonstrated the hypo-activation of the ventral lateral prefrontal cortex in these subjects 
(Townsend et al., 2013).  Those authors related their findings of reduced frontal connectivity in bipolar 
disorder to decreased emotion-regulation and predisposition towards acute mood-state relapse.  Thus, 
they were able to report that “ventral lateral prefrontal cortex inhibitory inputs to the amygdalae may 
be abnormal in bipolar disorder due to local alterations (e.g. neuronal) and/or disrupted connections 
(e.g. white matter tracks) between regions” (Townsend  et al., 2013).  Interestingly, in the present study 
we have also identified neuronal alterations in these limbic regions of bipolar subjects, whereby the 
expression of TSH-R was significantly down-regulated in bipolar limbic neurons when compared with 
normal limbic brain.  In addition, we found TG-like proteins in neurons of bipolar amygdala but not in 
neurons of normal amygdala and this may possibly relate to an enhanced emotional sensitivity. 
 
Numerous previous studies have examined functional and structural imaging in bipolar disorder.  
Interestingly, many findings indicate structural brain abnormalities in bipolar disorder that positively 
correlate with observations in functional studies.  These include a smaller-than-average volume of the 
prefrontal cortex, hippocampus and anterior cingulate, whilst the amygdala demonstrates an  
above-average volume (Phillips et al., 2003, Strakowski et al., 2005).  In contrast, DelBello and  
co-workers (2004) reported decreased amygdala volumes in bipolar adolescents (DelBello et al., 2004).  
“These findings suggest that amygdala enlargement may therefore be a consequence of abnormal 
development of this structure during adolescence and early adulthood” (Strakowski et al., 2005).  
Further related studies of the bipolar prefrontal cortex has demonstrated reduced volumes of gray matter 
in prefrontal cortical regions (Lopez-Larsen et al., 2002, Lochhead et al., 2004, Lyoo et al., 2004, 
Strakowski et al., 2005).  These neuro-anatomical abnormalities in the prefrontal cortex are consistent 
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with prefrontal histological abnormalities that have been reported in bipolar patients and which included 
decreased glial and neuronal density with glial hypertrophy (Rajkowska et al., 2001,  
Strakowski et al., 2005).  Glia (astrocytes, oligodendrocytes and microglia) abnormalities have also 
been identified in other limbic regions, including the anterior cingulate gyrus, orbito-frontal cortex and 
amygdala of untreated bipolar patients (Rajkowska et al., 2001); however, upon treatment with lithium, 
the loss of glia appear to be reduced (Bowley et al., 2002).  The diminished volumes of the  
cortico-limbic regions in bipolar disorder positively correlate with our findings demonstrating a reduced 
expression of thyroid proteins in these regions.  Similarly, previous findings of an enlarged amygdala 
in bipolar disorder (Phillips et al., 2003, Strakowski et al., 2005), correlate well with our demonstration 
of TG protein in amygdala neurons of the bipolar brain and its absence in normal controls.  Further, 
whilst previous structural imaging studies have described glial cell abnormalities in bipolar disorder, 
we did not detect thyroid proteins in any neuronal support cells including oligodendrocytes, astrocytes, 
neuroglia and satellite cells, in both normal and bipolar limbic areas.   
 
In a major post-mortem study conducted by Steiner and co-workers (2008), the possible role of 
microglial cells in the pathophysiology of suicidal mood disorders, including bipolar disorder, was 
investigated (Steiner et al., 2008).  Those authors demonstrated elevated microglial density in the 
prefrontal cortex, anterior cingulate gyrus and thalamus of suicidal patients.  Further, the critical role of 
microglia in inflammation of the CNS is well-documented (Stertz et al., 2013, Watkins et al., 2014).  
Thus, it has been proposed that the association between suicidality and neuro-inflammation is caused 
by microglial cell alterations.  More recently, Holmes and co-workers (2017) positively correlated 
neuro-inflammation (attributed to increased microglial activity) in depressed patients to suicidal 
tendencies (Holmes et al., 2017).  Further, that group identified the highest microglial activity in the 
anterior cingulate cortex.  “Glia affect several processes, including regulation of extracellular 
potassium, glucose storage and metabolism, and glutamate uptake, all of which are crucial for normal 
neuronal activity” (Ongur et al., 1998).  Considering the important influence that glial cells have on 
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neurons, it is presumed that a glial cell deficit would have negative consequences on normal neuronal 
functioning (Cotter et al., 2002). 
 
Previous studies have used proton magnetic resonance spectroscopy (MRS) to describe altered 
neurochemical and metabolic markers for neuronal volume and functioning in cortico-limbic regions 
of bipolar subjects, in the implication of neuro-degenerative processing in bipolar disorder  
(Moore et al., 2000, Winsberg et al., 2000, Cecil et al., 2002).  Those studies report a decrease in  
N-acetyl aspartate (NAA) concentrations in bipolar frontal-gray matter; NAA is an amino acid that is 
highly concentrated in neurons and believed to relay information on neuronal viability  
(Winsberg et al., 2000, Cecil et al., 2002).  Hence, low concentrations of an important neuronal marker 
such as NAA would likely indicate neuronal dysfunction or decreased neuronal number and density.  
Other important factors that were investigated for neurochemical and metabolic abnormalities in 
neurons included choline-containing compounds (CHO) and composite amino acid (AA), where 
changes in gray matter CHO concentration was associated with alterations in membrane phospholipid 
metabolism and, thus, associated with cellular loss (Cecil et al., 2002).  That same group demonstrated 
reduced CHO concentration in bipolar frontal gray matter, thus, suggesting decreased neuronal volume. 
In addition, elevated levels of AA in bipolar frontal white matter, was related to altered neuronal 
transmission.  The reduced concentrations of NAA and CHO in gray matter are consistent with findings 
from radio-isotope studies that indicate hypo-metabolism (Drevets et al., 1997) and suggests the 
occurrence of a neuro-degenerative process in gray matter of the frontal cortex (Cecil et al., 2002).  This 
finding is extremely important since bipolar disorder is not classified as a typical neuro-degenerative 
disorder as it is mainly characterised by glial cell pathology rather than neuronal abnormalities  
(Muneer et al., 2016).   
 
Currently, there exists limited literature implicating neuronal changes in the pathophysiology of mood 
disorders.  Moreover, available evidence does not lend enough support to bipolar disorder being 
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considered a neuro-degenerative type disorder.  However, those studies that describe altered 
neurochemical and metabolic neuronal marker abnormalities in cortico-limbic regions of bipolar 
subjects, implicate neuro-degenerative processing in the pathophysiology of bipolar disorder  
(Moore et al., 2000, Winsberg et al., 2000, Cecil et al., 2002).  In the present study, we report the  
extra-thyroidal expression and localisation of thyroid-specific proteins in limbic components of the 
bipolar human brain, possibly providing potential targets in thyroid auto-immunity whereby the 
abnormal interaction of auto-antibodies and thyroid-related proteins may facilitate the inactivation 
and/or destruction of limbic neurons.  The proposed loss of normal neuronal functioning in primary 
mood regulatory centres may predispose to mood dysregulation.  Thus, it would appear that our 
hypothesis inferring that the presence of Hashimoto’s disease-related AITD targets in the human limbic 
system having a neuro-pathological relevance to bipolar disease warrants merit. 
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CHAPTER 5 
 
Conclusions 
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The association between thyroid auto-immunity and neuro-psychiatric disorders is well-documented 
(Krishnan, 2005, Whybrow and Bauer, 2005a, Whybrow and Bauer, 2005b, Hage and Azar, 2012).  
However, there exists limited literature linking AITD, specifically with clinical features of bipolar 
disorder.  The present study identifies this lack of available research and explores a possible relationship 
between these two disease states, through the extra-thyroidal localisation of thyroid-specific proteins, 
TSH-R and TG, in major limbic regions of human brain.  Thus, let us now summarise and conclude our 
discussion on the relevance of this limbic-derived thyroid protein expression in providing potential 
therapeutic targets in future bipolar disorder research endeavours:  
 
 We found TG-like proteins to be present in amygdala neurons of bipolar brain, thus associating 
this with findings of amygdala hyperactivity and heightened emotional sensitivity in bipolar 
disorder (Kruger et al., 2003, Chang et al., 2004, Lawrence et al., 2004, Miklowitz and Johnson, 
2006). 
 Taking into account the significant roles of thyroid hormones, T3 and T4 in foetal and post-natal 
brain development as well as the maintenance of adult brain functioning including mental and 
psychological stability (Morreale de Escobar et al., 2004, Bernal, 2007, Wallis et al., 2010), it is 
reasonable to speculate that our findings of thyroid-related proteins, TSH-R and TG, in normal 
limbic brain components, may also exhibit an important alternate neuro-physiological role, 
specifically related to mood control.  Related to this are the additional findings in the present study 
of reduced TSH-R/TG protein expression levels in limbic regions that may very likely predispose 
or, at least, bear some relevance in the pathophysiology of mood dysregulation and clinical 
manifestations of bipolar disorder. 
 Further, we attribute symptoms of mood dysregulation in bipolar disorder to limbic-derived  
TSH-R which may provide potential targets for thyroid auto-immunity during Hashimoto’s 
disease. Consequently, this may lead to inactivated neurons and/or neurodegeneration. 
 An area that has yet to be explored, and perhaps will prove to be extremely controversial, is the 
fact that we have demonstrated both TSH-R and TG proteins within neurons of the same limbic 
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regions.  In the traditional HPT axis, TSH-R and TG represent significant-role players in thyroid 
hormone synthesis.  It is therefore tempting to speculate that stimulation of TSH-R expressed in 
limbic neurons may initiate a series of intra-cellular processes to synthesize and modify TG into 
T3 and T4, the classical thyroid hormones that are produced in the thyroid gland.  However, there 
is no evidence to suggest that the presence of TG-like proteins in those same limbic neurons that 
also express TSH-R, is the result of downstream activation of TSH-R-ligand binding.  Further, 
where this inference falls short is the lack of evidence indicating the cerebral location of other  
key-role players in thyroid hormone synthesis such as TPO and NIS.   
 Bipolar disorder has not been previously classified as a neuro-degenerative type disorder since it 
is mainly attributed to glial cell pathologies rather than neuronal (Muneer et al., 2016).  Our study 
suggests that neuronal alterations may be due to changes in thyroidal status in bipolar disorder.  
However, further research in this area needs to correlate our study findings of reduced thyroid 
protein levels with neuronal structural and functional determinations in bipolar limbic areas before 
one can ascertain whether neuronal pathology (due to altered thyroidal status) may be implicated 
in the pathophysiology of bipolar disorder. 
 Nevertheless, our findings of reduced bipolar limbic thyroid protein expression correlates well with 
neuro-imaging study reports that demonstrate reduced cortico-limbic volumes and activity during 
bipolar disorder (Lopez-Larsen et al., 2002, Kruger et al., 2003, Lyoo et al., 2004,  
Lochhead et al., 2004, Mayberg et al., 2004, Strakowski et al., 2005, Townsend et al., 2013,  
Abe et al., 2015) and is, therefore, suggestive of degenerative processing in limbic brain.  This may 
very well provide an alternate mechanism for a neuro-degenerative aetiology in bipolar disorder. 
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Abstract Expression of the human thyroid-specific proteins,
thyroid-stimulating hormone receptor (TSH-R) and thyro-
globulin (TG) in non-thyroid tissue is well-documented.
TSH-R has been identified in the heart, kidney, bone, pituitary,
adipose tissue, skin and astrocyte cultures. TG has been iden-
tified in the skin, thymus and kidney. However, none of those
previous studies had identified TSH-R or TG in specific hu-
man brain regions. Previously, a pilot study conducted by our
group on normal adult human brain demonstrated TSH-R and
TG in cortical neurons and cerebral vasculature, respectively,
within various brain areas. In the present study, we extend this
investigation of thyroid proteins specifically in limbic regions
of normal human brain. Forensic human samples of amygda-
lae, cingulate gyrii, frontal cortices, hippocampii,
hypothalamii, and thalamii were obtained from five individ-
uals who had died of causes unrelated to head injury and had
no evidence of brain disease or psychological abnormality.
Tissues were probed with commercial polyclonal antibodies
against human TSH-R and TG which resulted in the signifi-
cant demonstration of neuronal TSH-R in all limbic regions
examined. Other novel results demonstrated TG in vascular
smooth muscle of all limbic regions and in some neurons.
Finding thyroid proteins in limbic areas of the human brain
is unique, and this study demonstrates that cerebro-limbic
localisation of thyroid proteins may have potential roles in
neuro-psycho-pharmacology.
Keywords Thyroid-stimulating hormone receptor .
Thyroglobulin . Thyroid gland . Limbic regions .
Auto-immune thyroid disease . Immuno-histochemistry
Abbreviations
TSH-R thyroid-stimulating hormone receptor
TG thyroglobulin
AITD auto-immune thyroid disorders
HPT hypothalamic-pituitary-thyroid axis
BBB blood-brain barrier
CNS central nervous system
DAB diaminobenzidine
ROI region of interest
RT room temperature
Introduction
During auto-immune thyroid disorders (AITD), patients ex-
press immuno-sensitivity towards thyroid proteins such as
thyroid stimulating hormone receptor (TSH-R) and thyroglob-
ulin (TG). The resulting auto-immune anti-thyroid antibodies
bind to and stimulate TSH-R causing hyper-activity of the
thyroid gland, for example, following the clinical onset of
hyperthyroidism in Grave’s disease (Ai et al. 2003; Davies
et al. 2002; Szkudlinski et al. 2002). In contrast, during auto-
immune hypothyroidism that presents in Hashimoto’s disease,
auto-antibodies to TG can cause cell-mediated destruction of
thyroid follicular cells resulting in lymphocytic infiltration,
thyroid follicular atrophy, glandular fibrosis and hypofunction
(Ai et al. 2003). However, anti-thyroid antibodies are not lim-
ited to recognising thyroid-specific proteins located in thyroid
tissue only. Several studies have demonstrated the expression
and presence of TSH-R in mammalian extra-thyroid tissues
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including the heart, kidney, bone, lymphocytes, testis, thymus,
pituitary, adipose, skin, hair follicles, astrocyte cultures as well
as in fish testis (Szkudlinski et al. 2002; Bodo et al. 2009;
Chabaud and Lissitzky 1977; Cianfarani et al. 2010; Crisanti
et al. 2001; Drvota et al. 1995; Endo et al. 1995; Inoue et al.
1998; Kumar et al. 2000; Murakami et al. 1996; Perkonen and
Weintraub 1978; Prummel et al. 2000; Sellitti 2000; Valyasevi
et al. 1999). Further, TG has also been identified in mamma-
lian extra-thyroid tissue such as skin, hair follicles, thymus
and kidney (Bodo et al. 2009; Cianfarani et al. 2010; Sellitti
2000; Spitzweg et al. 1999). Immuno-reactive TSH-R was
previously demonstrated in the human pituitary (Prummel
et al. 2000), cultured human and rat astrocytes, and in rat brain
(Crisanti et al. 2001), but not in other human cerebral cortical
regions. This presented some interesting contradictions as
some of the findings of those older studies differed with more
recent work by our research group. In a pilot study, we were
the first to demonstrate the immuno-localisation of anti-TSH-
R IgG in normal adult human cortical neurons of the occipital
lobe, frontal lobe, parieto-occipito-temporal lobe, cingulate
gyrus, primary motor cortex and primary sensory cortex
(Moodley et al. 2011). In addition, we had localised anti-TG
IgG within the cerebral vasculature of the above regions. The
results of that study contributes to the extensive school of
thought that suggests a neuro-immunological association be-
tween auto-immune thyroid disorders and psychiatric disor-
ders. Thus, in the present study, we postulate that thyroid-like
antigens may be expressed in human limbic structures, and
where anti-thyroid antibodies may then recognise and bind
these regions during auto-immune thyroid disorders.
Therefore, the present study aimed to immuno-localise TSH-
R and TG-like proteins in limbic and limbic-associated re-
gions; these regions represent the cerebral control centres for
human emotional and behavioural responses as well as moti-
vational drive (Guyton and Hall 2000).
Materials and methods
Samples
Ethical approval was granted by the University of KwaZulu-
Natal Biomedical Research Ethics Committee (Reference
EXPO42/06). Normal human brain tissues were obtained at
post-mortem from 3 males (mean age: 36.7 years) and 2 fe-
males (mean age: 28.0 years) (Raidoo et al. 1996). All patients
had died of sudden causes unrelated to head injuries. There
were also no evidence of histopathological brain disease or
clinical psychological abnormality. A single slice of cortical
tissue was harvested from each of the following limbic re-
gions: amygdala, cingulate gyrus, frontal cortex, hippocam-
pus, hypothalamus and thalamus, from each of the 5 brains.
Normal human thyroid gland tissue that was previously
collected and verified as histologically normal (Raidoo et al.
1996), was used as thyroid protein tissue controls in these
experiments. The brain and thyroid tissues were formalin-
fixed and paraffin-embedded in preparation for immuno-his-
tochemistry, as per conventional protocols.
Antibodies and reagents
Commercial polyclonal rabbit anti-human TSH-R (200 μg/
mL, Santa Cruz Biotechnology, California, USA) and anti-
human TG (8.1 g/L, Dako, Ely, UK) IgGs were used as pri-
mary antibodies along with an avidin-biotin immuno-staining
kit (LSAB, Dako, UK) and chromogen substrate, 3, 3′-diami-
nobenzidine (DAB, Dako, UK). Themanufacturers confirmed
the specificity of the antibodies for TG and TSH-R where
traces of contaminating non-related antibodies had been re-
moved by solid-phase adsorption with human plasma proteins
(Santa Cruz Biotechnology, California, USA, Dako, Ely, UK).
For immuno-chemical staining, primary antibodies were
diluted in 3% bovine serum albumin/tris-buffered saline
(TBS/BSA). All other bio-reagents were purchased from
Roche Diagnostics (Johannesburg, South Africa) and all
chemicals were obtained fromMerck (Durban, South Africa).
Localisation of TSH-R and TG
by Immuno-histochemistry
A conventional avidin-biotin immuno-complexation tech-
nique (Wright et al. 2008), using polyclonal rabbit anti-
human TSH-R and TG antibodies was used for the
localisation of proteins in normal thyroid and brain tissue.
Briefly, the fixed thyroid and brain tissues were sectioned
(3 μm) onto silane-coated glass slides, dewaxed in xylene,
and rehydrated through a graded series of ethanol solutions
for 5 min each at room temperature [2 × 100%, 90%, 70% and
50% ethanol] and finally into distilled water, all at room tem-
perature (RT). For antigen retrieval, the tissues were boiled in
0.1 M sodium citrate buffer, pH 6.0 (80 °C) for 5 min and
allowed to cool to RT for approximately 20 min. The sections
were then allowed to reach equilibrium in distilled water for
5 min/RT. The tissues were partially-permeabilised with meth-
anol (20 min/RT) and any endogenous tissue peroxidases
were quenched with 20% hydrogen peroxide/80% methanol
(four times for 20 min each/RT). The sections were then
washed twice in TBS for 5 min each/RT. A hydrophobic pen
(Dako) was used to create a temporary Bincubation well^
around each tissue section. Tissue sections were blocked for
non-specific protein binding with TBS/BSA/10% casein buff-
er and incubated for 30 min/RT, with one change of buffer for
a further 30 min. The buffer was then carefully aspirated and
replaced with a 150 μl volume of primary antibody (anti-
TSH-R, 1:200; anti-TG, 1:1500). Incubation with primary an-
tibody was performed at 4 °C for 18 h within a humidified
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chamber. Following incubation, the sections were allowed to
come to RT and then washed with TBS for 5 min. Tissues
were then incubated with a streptavidin-biotin system
(LSAB, Dako, UK), according to the manufacturer’s instruc-
tions. Bound targets were then rendered visible with diamino-
benzidine (DAB) chromogen application in order to facilitate
visualisation under light microscopy. Following sufficient col-
our change, the sections were immediately immersed in TBS,
counter-stained with Mayer’s Haematoxylin for 5 min/RT,
rinsed under tap-water for 5 min, and then dehydrated through
a series of ethanols and finally into xylene. The sections were
then mounted with DPX (Merck, SA) and air-dried. Normal
human thyroid gland tissue served as thyroid protein method
controls for these experiments and negative controls were pre-
pared by substituting the primary antibody with dilution
buffer.
Image analysis
Stained tissue results were captured as digital TIFF images
using a Leica digital camera (DCF300X, Leica, Heidelberg,
Germany) coupled to a Leica microscope (DMLB) and
interfaced with Leica IM50 software. Regions of interest
(ROI) were obtained by using the following considerations:
Tissue integrity; presence of neurons; the least amount of
white matter and minimal background staining. Immuno-
localisation on the control and brain regions was then quanti-
fied by image analysis (AnalySIS v5, Soft Imaging Systems,
Germany). Briefly, the DAB intensity range was converted to
an 8-bit grey-scale with 255 phases. This grey-scale intensity
of specific label in the digitised images was quantified and
pre-determined, threshold range-limited, pixel.μm−2 values
were calculated for the mean intensity of immuno-labelling.
On the grey scale, we considered the upper range (160–255)
as an indication of positive labelling, in order to exclude back-
ground and artifact. For each limbic region (n = 6) from each
of 5 normal human brains (n = 5), images were analysed from
5 fields of view (n = 5) at 40× magnification (Wright et al.
2008). The average of mean integral intensities (×102
pixels.μm−2) was calculated for each limbic structure. For
our determinations, the mean integral intensity was considered
the mean value of the integral intensity of a specific ROI. The
integral intensity is the sum of all the staining intensities of an
ROI multiplied by the pixel area, and was obtained as an
output of the analysis software.
Statistical methods
All statistical analyses were performed using STATA
Software, v 13.1 (StataCorp, USA). It was found that some
data analysis for TSH-R in neurons and TG in blood vessels
did not statistically meet the assumption of normality and was
therefore transformed using the natural log (Ln) ± SEM for
mean (Ln) intensity. Parametric assessments were performed
for both categories. This comprised an F-test followed by
Tukey’s multiple comparisons for significance test.
Significance was therefore tested at p < 0.05.
Statistical analyses of TG in neurons did not appear to
follow a normal distribution curve; therefore, non-parametric
measures were considered for statistical comparisons. Median
values were obtained for this category and then transformed
using the natural log (Ln) with inter-quartile range error cal-
culations. A two-sample Wilcoxon rank-sum (Mann-Whitney)
test followed by Bonferonni’s multiple comparisons for
significance tests was used to correct for distribution. Thus,
statistical significance was established at p < 0.003 for this
category.
Results
Control tissues
Immuno-labelling of normal thyroid tissue demonstrated
TSH-R in the cytoplasm of the follicular cells that constitute
the simple cuboidal, follicular epithelia (Fig. 1A). Colloid,
colloidal spaces and colloidal vesicles were devoid of TSH-
R immuno-labelling. Further, no TSH-R could be detected
within thyroid vasculature. Positive immuno-labelling for
TG was evident within the cytoplasm of thyroid follicular
cells (Fig. 1B). In addition, intense TG labelling was
visualised within the colloidal space and colloidal vesicles,
and within the smooth muscle cells of the tunica media and
tunica adventitia of thyroid blood vessels. Method controls
demonstrated the absence of staining when each respective
antibody was substituted with dilution buffer (Fig. 1A and
B, insets).
Normal human limbic tissue
Thyroid-stimulating hormone receptor (TSH-R)
Immuno-reactive TSH-R was observed in all six limbic re-
gions in all five brains examined. Positive immuno-labelling
was demonstrated in large motor neurons of the cingulate
gyrus (Fig. 1C), amygdala (Fig. 1D), frontal cortex (Fig.
1E), hippocampus, hypothalamus and thalamus. TSH-R label-
ling was confined to the neuronal cell bodies whilst cell nuclei
were negative. In contrast, there was no evidence of TSH-R
immuno-labelling within the cerebral vasculature and neuro-
nal support cells such as the oligodendrocytes, astrocytes,
neuroglia and satellite cells, for any of the limbic regions
examined.
The labelling intensities of TSH-R across all limbic regions
were analysed and quantified by image analysis, and were
confined to the range 4.62–540.42 × 102 pixels.μm−2
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(arithmetic mean intensity values). Specifically, regions such
as the frontal cortex (540.42 × 102 pixels.μm−2) and cingulate
gyrus (395.47 × 102 pixels.μm−2) displayed more intense
staining, whilst the hypothalamus (11.24 × 102 pixels.μm−2)
and thalamus (4.62 × 102 pixels.μm−2) stained to a lesser
degree (Table 1).
Fig. 2 displays the mean (Ln) intensity for TSH-R immuno-
labelling in all normal brain limbic regions examined in the
range 1.5–5.8. These results demonstrate an approximate 3 fold
difference each of cingulate gyrus (5.80), frontal cortex (5.80),
hippocampus (5.50) and amygdala (5.10) when compared to
hypothalamus (1.90) or thalamus (1.50) (Table 1, Fig. 2).
Statistical comparisons demonstrated that TSH-R in both
the hypothalamus (p < 0.0001) and thalamus (p < 0.0001)
differed significantly when compared to each of other limbic
areas but not when compared to each other (Fig. 2). Further,
no appreciable significance was noted among the remaining
limbic regions when compared amongst each other.
Thyroglobulin (TG)
(a) TG in cerebral vasculature
Positive immuno-labelling for TG was detected within the
cerebral vasculature of all six limbic regions. Specifically,
immuno-reactive TG was localised to smooth muscle cells
of the tunica media and tunica adventitia of cerebral blood
vessels (Fig. 3B, C and D). Image analysis of TG within
limbic vasculature demonstrated an arithmetic mean intensity
range of 423.84–2994.00 × 102 pixels.μm−2 and mean (Ln)
Fig. 1 Immuno-localisation of
thyroid-stimulating hormone
receptor (TSH-R) in normal adult,
human brain limbic areas (n = 5)
and normal control human
thyroid tissue. Immuno-labelling
of normal control thyroid tissue
demonstrated TSH-R in the
cytoplasm of thyroid follicular
cells (arrows) and its absence in
colloid (A, ×400). Thyroglobulin
was demonstrated within the
cytoplasm of thyroid follicular
cells (green arrow), colloid (red
arrow) and colloidal vesicles
(blue arrow) (B, ×400). Method
controls demonstrated the
absence of staining when each
antibody was replaced with
dilution buffer (A and B, insets,
×400). In brain limbic areas,
immuno-reactive TSH-R was
evident in neuronal cell bodies
(arrows) in the cingulate gyrus (C,
×400), amygdala (D, ×400),
frontal cortex (E, ×400).
Antibody method controls for
brain tissue showed absence of
stain in neurons and blood vessels
(C, inset, ×400). Positive labelling
for TSH-R in thyroid and brain
tissues were identified as brown
colour. Scale bars = 200 μm
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intensity range of 5.14–6.40 (Table 2, Fig. 4). The cingulate
gyrus and amygdala displayed the highest (2994.00 × 102
pixels.μm−2) and lowest (423.84 × 102 pixels.μm−2) labelling
intensities, respectively. Statistical comparisons demonstrated
that when compared to the amygdala, there was a significant
difference in the cingulate gyrus (p = 0.02), frontal cortex
(p = 0.03) and thalamus (p = 0.02). None of the other inter-
regional comparisons showed statistical differences.
(b) TG in cerebral neuronal cells
Intense immuno-reactive TG was demonstrated in most
neuronal cell bodies and axons of the cingulate gyrus
(Fig. 3A), whilst similar cellular structures in the frontal cortex
exhibited less staining. Quantification of these staining inten-
sities presented arithmetic mean values for cingulate gyrus
(118.20 × 102 pixels.μm−2) and frontal cortex (91.90 × 102
pixels.μm−2), (Table 1). There was no evidence of positive TG
labelling within neuronal cell bodies and supporting cerebral
cellular structures in the other four limbic regions. Median
(Ln) values obtained for this category had a range of −3.23 -
3.05 (Table 1). Statistical comparisons, tested at p < 0.003,
demonstrated that the hypothalamus significantly differed
from all other limbic regions except the cingulate gyrus
(p = 0.07, Table 1).
When performing statistical analyses of comparison for
immuno-labelling in this project, measurement of protein in-
tensities were subject to the detection threshold limits of the
avidin-biotin complexation system. Thus, the amount of TG
within neurons was observed to be so minute in quantity that it
could not be practically measured and was therefore consid-
ered to be negligible.
Discussion
Following extensive review of the literature, we report that
this is the first study to demonstrate the localisation of
thyroid-specific proteins specifically in the limbic regions of
Table 1 Quantification of neuronal labelling intensity by image analysis
Limbic Neurons
Limbic Regions Arithmetic Mean Labelling Intensity (Ln) Intensity
TSH-R TG TSH-R TG
Mean (pixels.μm2) SEM Mean (pixels.μm2) SEM Mean (Ln) SEM Median (Ln) p25 p75
Amygdala 243.99 50.23 0.1 0.02 5.10* 0.29 −2.52¥ −3.72 −1.85
Cingulate gyrus 395.47 62.71 118.2 56.41 5.80* 0.17 1.25 −1.81 5.02
Frontal cortex 540.42 85.38 91.9 46.9 5.80* 0.25 −3.00¥ −3.18 0.43
Hippocampus 353.97 41.06 0.2 0.1 5.50* 0.23 −3.23¥ −3.5 −2.67
Hypothalamus 11.24 3.05 145.1 52.62 1.9 0.28 3.05 1.84 4.71
Thalamus 4.62 0.3 9.1 3.77 1.5 0.06 −1.72¥ −2.83 0.43
*vs hypothalamus, p < 0.0001
vs thalamus, p < 0.0001
¥ vs hypothalamus, p < 0.003
n = 6 limbic regions
n = 5 normal human brains
n = 5 fields of view
Inter-quartile range errors: p25 and p75
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Fig. 2 Mean (Ln) intensity ± SEM of immuno-labelling for TSH-R in
cortical neurons of human brain limbic regions. * vs amygdala, cingulate
gyrus, frontal cortex, hippocampus, p < 0.05. Mean (Ln) intensity values
obtained for TSH-R in neuronal staining occurred in the range 1.5 - 5.8.
These results indicate an approximate 3-fold difference when the
cingulate gyrus (5.80), frontal cortex (5.80), hippocampus (5.50) and
amygdala (5.10) are each compared to the hypothalamus (1.90) or
thalamus (1.50). Statistical comparisons showed that TSH-R in the
hypothalamus and thalamus differed significantly when compared to
each of the other limbic areas but not against each other. Further, there
was no difference noted among other limbic regions of higher immuno-
labelling intensity values when compared to each other
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Fig. 3 Immuno-localisation of
thyroglobulin (TG) in normal
adult, human brain limbic areas
(n = 5). Immuno-reactive TG was
evident in neuronal cell bodies
and axons of the cingulate gyrus
(A, ×400). TG was highly
concentrated within smooth
muscle of the tunica media/
adventitia of cerebral vasculature
in the frontal cortex (B, ×400),
thalamus (C, ×400) and
hypothalamus (D, ×400). Positive
labelling for TG in brain tissues
were identified as brown colour.
Scale bars = 200 μm
Table 2 Quantification of cerebral vasculature labelling intensity by
image analysis
Limbic Blood Vessels (TG)
Limbic Regions Arithmetic Mean
Labelling Intensity
(Ln) Intensity
Mean (pixels.μm2) SEM Mean (Ln) SEM
Amygdala 423.84 132.3 5.14 0.37
Cingulate gyrus 2994 2315.11 6.40* 0.3
Frontal cortex 884.7 229.7 6.28* 0.19
Hippocampus 1407.14 922.26 5.97 0.26
Hypothalamus 571.04 94.44 6.09 0.15
Thalamus 1474.34 500.46 6.35* 0.28
*vs amygdala, p < 0.05
n = 6 limbic regions
n = 5 normal human brains
n = 5 fields of view
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Fig. 4 Mean (Ln) intensity ± SEM of immuno-labelling for TG in
cerebral vasculature of human brain limbic regions. * versus cingulate
gyrus, frontal cortex, thalamus, p < 0.05. Mean (Ln) intensity values
obtained for TG in limbic cerebral vasculature occurred in the range
5.14 - 6.40. Statistical comparisons indicates that the cingulate gyrus,
frontal cortex and thalamus differed significantly from the amygdala.
No statistical differences occurred among other inter-regional
comparisons
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the adult human brain. The presence of TSH-R in human brain
tissue is supported by Prummel et al. (2000), who immuno-
detected TSH-R proteins within folliculo-stellate cells in hu-
man anterior pituitary tissue (Prummel et al. 2000). Further,
they postulated that the presence of the TSH-R in the anterior
pituitary gland has a short-loop regulatory function within the
hypothalamic-pituitary-thyroid (HPT) axis by modulating
TSH secretion at the pituitary level. In the present study, we
also demonstrate TSH-R in human hypothalamus, albeit at a
low concentration. However, the scope of our investigation
did not extrapolate to TSH-R localisation within the HPTaxis.
Our observations of TSH-R in hypothalamus is consistent
with the findings of Crisanti et al. (2001) who demonstrated
TSH-R within hypothalamic neurons of rat brain (Crisanti
et al. 2001) as well as Bockmann et al. (1997) who reported
expression of TSH-R in the hypothalamus of sheep
(Bockmann et al. 1997). In contrast to the Prummel study
(2000), we have also demonstrated for the first time, the
localisation of TSH-R in non-HPT axis cerebral tissue (viz,
amygdala, cingulate gyrus, frontal cortex, hippocampus and
thalamus).
A pilot study previously conducted by our group was the
first to demonstrate the presence of TSH-R and TG in cortical
neurons and cerebral vasculature, respectively, within specific
regions of normal adult human cerebral cortex (Moodley et al.
2011). In the present study, we further investigated the distri-
bution of these thyroid proteins in major limbic regions of
normal adult human cerebral cortex. Here, we demonstrate
the presence of TSH-R in large neuronal cell bodies within
all six limbic regions in all five normal human brains
reviewed. Interestingly, we also report the localisation of
TSH-R to the four primary mood centres, i.e. amygdala, cin-
gulate gyrus, hippocampus and hypothalamus.
Our observations of TSH-R expression in human neuronal
cell bodies is consistent with findings reported by the Crisanti
group (2001) where those investigators localised TSH-R
mRNA within a rodent neuronal cell model (Crisanti et al.
2001). It has also been reported that neurons are a primary
target of thyroid hormone, T3, and that thyroid hormone action
is exerted mostly by regulation of gene expression following
the binding of T3 to thyroid hormone nuclear receptors
expressed in neuronal cells of rodent brain and human cul-
tured cells (Freitas et al. 2010). In addition, the Crisanti group
(2001) also detected TSH-R in human primary cultured astro-
cytes (Crisanti et al. 2001). However, we do not report find-
ings of TSH-R in astrocytes or any other neuronal support
cells of human limbic tissue.
Other novel findings in the present study include TG-like
proteins in neuronal cell bodies and axons of the cingulate
gyrus and some neurons of the frontal cortex. In addition,
we demonstrated TG-like proteins in smooth muscle of the
tunica media and tunica adventitia of cerebral vasculature in
all six limbic areas examined. The presence of TG-like
proteins in the smooth muscle of cerebral vasculature also
correlates with the findings of Ojamaa et al. (1996) who re-
ported on the effects of thyroid hormones on vascular smooth
muscle cells obtained from adult rat aorta (Ojamaa et al.
1996). Specifically, those authors demonstrated the rapid re-
laxation of vascular smooth muscle cells in culture, by the
actions of T3 (Ojamaa et al. 1996). In addition, other authors
report that mammalian thyroid hormones are critical in the
development, homeostasis and regeneration of skeletal muscle
and that muscular alterations occur secondary to thyroid dys-
function, thus further illustrating the crucial role of thyroid
hormones in mammalian muscle physiology (Yu et al. 2000;
Brent 2012; Nwoye et al. 1982; Clement et al. 2002;
Udayakumar et al. 2005; Ramsay 1966).
The strong neuro-immunological association between thy-
roid disorders and psychiatric illness is well-documented.
Thus, the present study focuses only on the limbic areas which
are responsible for the control of mood and emotional behav-
iour (Guyton and Hall 2000). This relates to our observation
of TSH-R in limbic structures and it appears reasonable to
then propose that auto-immune anti-thyroid antibodies may
recognise and agonise limbic-associated thyroid-specific re-
ceptors. Thus, it can be speculated that such an abnormal
association, should it exist, could contribute to mood dysreg-
ulation symptoms such as those often observed in bipolar
disease, a brain disorder associated with unusual shifts in
mood, and thus regulated by the limbic system. Indeed, this
brings one to the relative argument of how thyroid auto-
antibodies are able to transgress the seemingly-impervious
blood-brain barrier (BBB) to bind cerebral targets in condi-
tions such as bipolar disorder associated with Hashimoto’s
and Grave’s disease. Curiously, there does appear to be mul-
tiple modes of egress beyond the BBB. Studies have shown
that during neurological diseases such as HIV-associated de-
mentia, multiple sclerosis, Alzheimer’s disease and bipolar
disorder, the integrity of the protective BBB can be altered,
thus, enhancing its permeability with consequential migration
of leukocytes and other circulating compounds into the brain
(Lou et al. 1997; Minagar et al. 2002; Patel and Frey 2015).
This influx of leukocytes triggers signal transduction cascades
leading to the loss of tight-junction proteins within the highly
specialised cerebral endothelium of the BBB (Bolton et al.
1998). Similarly in normal brain, the BBB is generally
thought to limit entry of endogenous IgG from plasma as well
as exogenously-administered monoclonal antibodies (Rojko
and Price-Schiavi 2008). However, Terasaki and Ohtsuki
(2005) reported that the BBB can be overcome by endogenous
IgG and other larger hydrophilic molecules by undergoing
brain-blood efflux (Terasaki and Ohtsuki 2005). Further evi-
dence of how the BBB can be overcome occurs when mole-
cules that are highly expressed by brain capillary endothelial
cell membranes, such as transferrin, are targeted by specific
monoclonal antibodies (Pardridge et al. 1991). In addition, St-
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Amour et al. (2013) have reported that up to 0.1% of
peripherally-administered IgG does reach the brain parenchy-
ma inmice (St-Amour et al. 2013). Lastly, antibodiesmay also
access the CNS by first migrating into the cerebrospinal fluid,
followed by progression through the ventricular circulation
and then finally into CNS parenchymal regions (Saunders
et al. 2012; Berer et al. 2011). Thus, it does appear that BBB
disturbance can occur during various neuro-pathological con-
ditions, and supports our present postulate that circulating
auto-antibodies gain ingress into the CNS and binds thyroid-
like factors in limbic areas, and thus exacerbate development
of symptoms of bipolar disorder.
Conclusion
The present study provides the first evidence for the distribu-
tion of thyroid-specific protein antigens in normal adult hu-
man brain limbic regions. In addition, there exists no previous
evidence, until now, of any quantitative comparison of these
thyroid factors in limbic regions. Whereas our previous pilot
study had used semi-quantitative analysis to show TSH-R/TG
localisation in various human brain regions, the present study
focuses our attention specifically on limbic structures and
utilised image analysis digitalisation and quantification.
Given the data accumulated in the present study, the amount
of thyroid protein cannot be related to function, and our ob-
servations relate only to the presence of limbic thyroid pro-
teins. Whilst quantitative analysis and statistical comparisons
are not extrapolated within the scope of the present study, it
does serve to provide baseline localisation values for future
comparative studies within neuro-immuno-pyschiatric disor-
ders. Thus, the cumulative results of the present study and the
previous pilot project provide a general distribution of
thyroid-like proteins that may be involved in neuro-
physiology as well as the distinct possibility of affecting
neuro-psycho-pharmacology in mood disorders.
We intend to further evolve this investigation to confirm
the expression of TSH-R mRNA in limbic structures of nor-
mal human brain and bipolar cerebral tissue, by molecular
determinations. There also exists the possibility of in vitro
neuro-stimulation of limbic tissue by TSH in order to measure
cyclic adenosine monophosphate (cAMP) production and
ligand-binding as a function of TSH-R activation.
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